WO2007107565A1 - Benzimidazoles which have activity at m1 receptor and their uses in medicine - Google Patents

Benzimidazoles which have activity at m1 receptor and their uses in medicine Download PDF

Info

Publication number
WO2007107565A1
WO2007107565A1 PCT/EP2007/052638 EP2007052638W WO2007107565A1 WO 2007107565 A1 WO2007107565 A1 WO 2007107565A1 EP 2007052638 W EP2007052638 W EP 2007052638W WO 2007107565 A1 WO2007107565 A1 WO 2007107565A1
Authority
WO
WIPO (PCT)
Prior art keywords
piperidinyl
cyclohexyl
frans
dihydro
benzimidazol
Prior art date
Application number
PCT/EP2007/052638
Other languages
French (fr)
Inventor
David Gwyn Cooper
Ian Thomson Forbes
Vincenzo Garzya
Jian Jin
Yann Louchart
Graham Walker
Paul Adrian Wyman
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP07727115.3A priority Critical patent/EP2004182B1/en
Priority to MX2008012160A priority patent/MX2008012160A/en
Priority to US12/293,625 priority patent/US20100280071A1/en
Priority to JP2009500852A priority patent/JP5256187B2/en
Priority to CN2007800188235A priority patent/CN101448495B/en
Priority to BRPI0708999-6A priority patent/BRPI0708999A2/en
Priority to AU2007228716A priority patent/AU2007228716A1/en
Priority to EA200870360A priority patent/EA200870360A1/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to CA002646896A priority patent/CA2646896A1/en
Publication of WO2007107565A1 publication Critical patent/WO2007107565A1/en
Priority to IL194206A priority patent/IL194206A0/en
Priority to NO20084048A priority patent/NO20084048L/en
Priority to US13/282,610 priority patent/US20120041028A1/en
Priority to US13/584,956 priority patent/US20120316202A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • cycloalkyl refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms.
  • Cs- ⁇ cycloalkyl means a non-aromatic carbocyclic ring containing at least three, and at most six, ring carbon atoms.
  • Examples of "cycloalkyl” as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • R 6 is selected from hydrogen, halogen, Ci -3 alkyl, Ci -3 alkyl substituted with one or two fluorine atoms, C 3-4 cycloalkyl, Ci -3 alkylsulfonyl, Ci -3 alkoxy, and Ci -3 alkoxy substituted with one, two or three fluorine atoms.
  • R 6 is selected from hydrogen, cyano, fluoro, bromo, methyl, ethyl, methoxy, trifluoromethoxy, methylsulfonyl, trifluoromethyl and cyclopropyl. In one embodiment of the invention, R 6 is selected from fluoro, chloro, bromo, methyl, ethyl, isopropyl, methoxy, trifluoromethoxy and trifluoromethyl. In a further embodiment of the invention, R 6 is selected from chloro, bromo, methyl, ethyl, isopropyl, methoxy, trifluoromethoxy and trifluoromethyl. For example, R 6 is methyl.
  • R is C 2-6 alkynyl. In one embodiment, R is C 2 - 4 alkynyl. In one embodiment, R is propynyl.
  • R is selected from Ci -3 alkyl, and C 3-6 cycloalkylCi. 3 alkyl, any alkyl or cycloalkyl group (for example any alkyl group) being optionally substituted with one or more fluorine atoms.
  • R is selected from methyl, ethyl, propyl, isopropyl and cyclopropylmethyl. In one embodiment, R is selected from methyl, ethyl, propyl and isopropyl.
  • Q is selected from hydrogen and Ci -3 alkyl. In a further embodiment, Q is selected from hydrogen, methyl, ethyl and propyl. In one embodiment, Q represents hydrogen or methyl. In one embodiment, Q is hydrogen. In one embodiment the salt or solvate of the compound of formula (I) is a pharmaceutically acceptable salt or solvate. In one embodiment, the invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • salts of formula (I) should be pharmaceutically acceptable.
  • Suitable salts will be apparent to those skilled in the art and include for example mono- or di- basic salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric, sulfamic phosphoric, hydroiodic, phosphoric or metaphosphoric acid; and with organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, formic, propionic, glycolic, gluconic, maleic, succinic, (1 S)- (-)-IO-camphorsulphonic, (1S)-(+)-10-camphorsulphonic, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic
  • non-pharmaceutically acceptable salts e.g. oxalates
  • oxalates may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention.
  • the compounds of the present invention may be in the form of their free base or pharmaceutically acceptable salts thereof, particularly the monohydrochloride, monoformate or monotrifluoroacetate salts.
  • Certain of the compounds of formula (I) may form acid addition salts with less than one (for example, 0.5 equivalent of a dibasic acid) or one or more equivalents of an acid.
  • the present invention includes within its scope all possible stoichiometric and non- stoichiometric forms thereof.
  • trans form may be drawn in the following different ways, although both represent the same isomeric form:
  • the compounds of formula (I) are cis isomers.
  • the salt of a compound listed above is a pharmaceutically acceptable salt.
  • Examples of the present invention includes:
  • Suitable prodrugs for compounds of the invention include : esters, carbonate esters, hemi-esters, phosphate esters, nitro esters, sulfate esters, sulfoxides, amides, carbamates, azo-compounds, phosphamides, glycosides, ethers, acetals and ketals.
  • R 6 is a group R 6 as previously defined, or a group convertible to R 6
  • R' is a group R as previously defined, or a group convertible to R.
  • the reaction is carried out under conditions suitable for reductive alkylation.
  • the reductive alkylation reaction is typically carried out using sodium triacetoxyborohydride in dichloroethane, optionally in the presence of triethylamine, and optionally in the presence of titanium tetraisopropoxide.
  • sodium cyanoborohydride can be used as the reducing reagent in solvents such as methanol or ethanol, or the reductive alkylation can be effected under catalytic hydrogenation conditions using a palladium catalyst.
  • the compounds (II) and (III) can be condensed under dehydrating conditions e.g. molecular sieves or magnesium sulfate, and the resultant imine or enamine reduced using for example sodium borohydride or by catalytic hydrogenation.
  • This reaction can generate a mixture of cis and trans isomers which can be separated by chromatography or crystallisation.
  • a modification of general process (A1 ) is required where Q is C 1 -5 alkyl.
  • a compound of formula (II) can be reacted with a compound of formula (III) in the presence of a source of cyanide, e.g. acetone cyanohydrin, to form the cyano intermediate (XXXX) which can be reacted with an alkyl Grignard reagent QMgX to form compounds of formula (I) in which Q is C 1-6 alkyl.
  • a source of cyanide e.g. acetone cyanohydrin
  • R 6 is a group R 6 as previously defined, or a group convertible to R 6
  • R' is a group R as previously defined, or a group convertible to R
  • Q is Ci_6 alkyl
  • X is bromo or iodo or chloro.
  • This reaction can generate a mixture of cis and trans isomers which can be separated by chromatography or crystallisation.
  • the invention provides a general process (B) for preparing compounds of formula (I) which process comprises:
  • R 6 is a group R 6 as previously defined, or a group convertible to R 6
  • R' is a group R as previously defined, or a group convertible to R
  • Q is as previously defined
  • X and Y both represent leaving groups.
  • X and Y can be the same or different and examples are Cl, PhO, EtO, imidazole.
  • X and Y are both Cl, i.e. phosgene
  • this reagent can be generated in situ e.g. from diphosgene or triphosgene.
  • reaction is carried out using standard methodology e.g. reacting the diamine (IV) with the reagent (V) in an inert solvent for example dichloromethane or toluene, optionally in the presence of a base such as triethylamine or potassium carbonate, and optionally with heating.
  • an inert solvent for example dichloromethane or toluene
  • a base such as triethylamine or potassium carbonate
  • compounds of formula (IV) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the reaction with (V) can be achieved by chromatography or crystallisation.
  • the invention provides a general process (C) for preparing compounds of formula (I) which process comprises:
  • R 6 is a group R 6 as previously defined, or a group convertible to R 6
  • R' is a group R as previously defined, or a group convertible to R
  • Q is as previously defined
  • Z is a leaving group such as bromo, iodo, chloro or triflate.
  • the cyclisation reaction can be carried out using a variety of palladium or copper reagents as described in the literature (JACS, 2003, 125, 6653, Tet. Lett., 2004, 45, 8535, or JACS, 2002, 124, 7421.)
  • compounds of formula (Vl) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the intramolecular cyclisation can be achieved by chromatography or crystallisation.
  • the invention provides a general process (D) for preparing compounds of formula (I) which process comprises:
  • R 6 is a group R 6 as previously defined, or a group convertible to R 6
  • R' is a group R as previously defined, or a group convertible to R
  • Q is as previously defined
  • R a is a C 1-5 alkyl group.
  • condensation and cyclisation reactions can be carried out under reaction conditions similar to those described in the literature for an analogous process (see eg US 3161645) (for example heating in an inert solvent such as xylene) followed by reduction of the piperidine double bond using for example catalytic hydrogenation over palladium or Raney nickel.
  • compounds of formula (IX) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the intramolecular cyclisation can be achieved by chromatography or crystallisation.
  • the invention provides a general process (E) for preparing compounds of formula (I) which process comprises:
  • Curtius rearrangement is typically carried out by mixing the two reactants in an inert solvent such as toluene, optionally with heating.
  • an inert solvent such as toluene
  • compounds of formula (X) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the intramolecular cyclisation can be achieved by chromatography or crystallisation.
  • the invention provides a general process (F) for preparing compounds of formula (I) which process comprises:
  • R 6 is a group R 6 as previously defined, or a group convertible to R 6
  • R' is a group R as previously defined, or a group convertible to R
  • Q is as previously defined
  • Z is hydroxy or a leaving group such as chloro, bromo or iodo, or alkyl/aryl sulfonate.
  • the benzimidazolone intermediate (Xl) can be deprotonated using a base such as sodium hydride in an inert solvent such as dimethylformamide, and then treated with the alkylating reagent (XII), optionally with heating.
  • compounds of formula (X) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the intramolecular cyclisation can be achieved by chromatography or crystallisation.
  • R 6 when R 6 is a halogen, it can be converted to an alkoxy, trifluoromethyl or methylsulphonyl group by copper catalysed reaction, using an alcohol, methyl fluorosulfonyl(difluoro)acetate or sodium methanesulphinate respectively. It may also be converted to an alkyl group with an organometallic reagent, for example an alkylstannane.
  • organometallic reagent for example an alkylstannane.
  • R 6 when R 6 is hydroxy, it may be converted to alkoxy by reaction with an alkyl halide or sulfonate, or to trifluoromethoxy by conversion to the xanthate followed by oxidation in the presence of fluoride ion.
  • R 6 when R 6 is methyl, it may be converted to trifluoromethyl by chlorination or bromination followed by displacement of the introduced halogens with fluoride.
  • R' is benzyl
  • the benzyl group can be removed using standard methodology, e.g. catalytic hydrogenation over palladium on carbon, to provide the alcohol.
  • Alkylation of the resultant alcohol using a strong base e.g. sodium hydride and a C- ⁇ -6 alkylating agent e.g. methyl iodide or ethyl iodide or propyl iodide, will afford the desired product. It will be appreciated that protection of any NH functionality present in the molecule may be necessary.
  • R when R is methyl, the methyl group can be removed by treatment with a dealkylating agent such as boron tribromide to afford the alcohol intermediate, which can be alkylated in a similar manner to that described above.
  • a dealkylating agent such as boron tribromide
  • the alcohol intermediate can be converted to R is trifluoromethyl by conversion to the xanthate followed by oxidation in the presence of fluoride ion.
  • the anthranilic acid or ester starting materials (XVII) are commercially available or can be made by standard methodology.
  • the Curtius rearrangement can be effected using the conditions described under process E.
  • Hydrogenation of the double bond and deprotection of the piperidine nitrogen can be accomplished separately or concomitantly dependent on the precise nature of the protecting group P, to afford the desired product (II).
  • Compounds of formula (VIII) are commercially available or can be prepared by standard methodology.
  • Compounds of formula (XX) are commercially available or can be prepared by standard methodology.
  • the compounds of formula (III) can be prepared by standard literature methodology.
  • Compounds of formula (V) are commercially available e.g. carbonyl diimidazole, phosgene, phosgene solution in toluene, diphosgene, triphosgene, phenyl chloroformate, diethyl carbonate.
  • Phosgene equivalents include carbonyl diimidazole, diphosgene, triphosgene, phenyl chloroformate
  • Palladium and copper catalysts (VII) are commercially available or can be prepared as described in the literature (see references in Process C).
  • the cis isomer of compound (XXVII) can be prepared by a similar procedure from the appropriate cis amine (XLIII).
  • the trans isomer (LIV) can be isolated by conversion of the mixture to the acid chloride, for example with thionyl chloride, followed by selective hydrolysis of the products by treatment with weak aqueous base such as sodium hydrogen carbonate solution.
  • the acid can be converted to the isocyanate (LV) by Curtius rearrangement at elevated temperature of an intermediate azide prepared using for example diphenylphosphoryl azide, then the isocyanate hydrolysed to amine (LVI) under acidic conditions.
  • M 1 receptor agonists are said to be useful to ameliorate positive and cognitive symptoms of psychotic disorders such as schizophrenia, schizo-affective disorders, schizophreniform diseases, psychotic depression, mania, acute mania, paranoid and delusional disorders, and cognitive impairment including memory disorders such as Alzheimer's disease without peripheral cholinergic side effects mediated predominantly through M 2 and M 3 receptors.
  • M 1 receptor agonists may also be suitable for combination with other typical and atypical antipsychotics and other actives such as mood stabilisers, antidepressants, anxiolytics, drugs for extrapyrimidal side effects and cognitive enhancers, to provide improved treatment of psychotic disorders.
  • the invention provides a compound of formula (I) as hereinbefore described or a salt or solvate thereof for use in therapy.
  • the invention provides a compound of formula (I) or a salt or solvate thereof for use in the treatment of a condition which requires agonism of a muscarinic M 1 receptor.
  • the term psychotic disorder includes Schizophrenia including the subtypes Paranoid Type (295.30), Disorganised Type (295.10), Catatonic Type (295.20), Undifferentiated Type (295.90) and Residual Type (295.60); Schizophreniform Disorder (295.40); Schizoaffective Disorder (295.70) including the subtypes Bipolar Type and Depressive Type; Delusional Disorder (297.1 ) including the subtypes Erotomanic Type, Grandiose Type, Jealous Type, Persecutory Type, Somatic Type, Mixed Type and Unspecified Type; Brief Psychotic Disorder (298.8); Shared Psychotic Disorder (297.3); Psychotic Disorder Due to a General Medical Condition including the subtypes With Delusions and With Hallucinations; Substance-Induced Psychotic Disorder including the subtypes With Delusions (293.81 ) and With Hallucinations (293.82); and Psychotic Disorder Not Otherwise Specified (298.9);
  • Depression and mood disorders including Major Depressive Episode, Manic Episode, Mixed Episode and Hypomanic Episode; Depressive Disorders including Major Depressive Disorder, Dysthymic Disorder (300.4), Depressive Disorder Not Otherwise Specified (311 ); Bipolar Disorders including Bipolar I Disorder, Bipolar Il Disorder (Recurrent Major Depressive Episodes with Hypomanic Episodes) (296.89), Cyclothymic Disorder (301.13) and Bipolar Disorder Not Otherwise Specified (296.80); Other Mood Disorders including Mood Disorder Due to a General Medical Condition (293.83) which includes the subtypes With Depressive Features, With Major Depressive-like Episode, With Manic Features and With Mixed Features), Substance-Induced Mood Disorder (including the subtypes With Depressive Features, With Manic Features and With Mixed Features) and Mood Disorder Not Otherwise Specified (296.90);
  • Anxiety disorders including Social Anxiety Disorder, Panic Attack, Agoraphobia, Panic Disorder, Agoraphobia Without History of Panic Disorder (300.22), Specific Phobia (300.29) including the subtypes Animal Type, Natural Environment Type, Blood-Injection- Injury Type, Situational Type and Other Type), Social Phobia (300.23), Obsessive- Compulsive Disorder (300.3), Posttraumatic Stress Disorder (309.81 ), Acute Stress Disorder (308.3), Generalized Anxiety Disorder (300.02), Anxiety Disorder Due to a General Medical Condition (293.84), Substance-Induced Anxiety Disorder and Anxiety Disorder Not Otherwise Specified (300.00);
  • Substance-related disorders including Substance Use Disorders such as Substance Dependence, Substance Craving and Substance Abuse; Substance-Induced Disorders such as Substance Intoxication, Substance Withdrawal, Substance-Induced Delirium, Substance-Induced Persisting Dementia, Substance-Induced Persisting Amnestic Disorder, Substance-Induced Psychotic Disorder, Substance-Induced Mood Disorder, Substance-Induced Anxiety Disorder, Substance-Induced sexual Dysfunction, Substance- Induced Sleep Disorder and Hallucinogen Persisting Perception Disorder (Flashbacks); Alcohol-Related Disorders such as Alcohol Dependence (303.90), Alcohol Abuse (305.00), Alcohol Intoxication (303.00), Alcohol Withdrawal (291.81 ), Alcohol Intoxication Delirium, Alcohol Withdrawal Delirium, Alcohol-Induced Persisting Dementia, Alcohol- Induced Persisting Amnestic Disorder, Alcohol-Induced Psychotic Disorder,
  • Sleep disorders including primary sleep disorders such as Dyssomnias such as Primary Insomnia (307.42), Primary Hypersomnia (307.44), Narcolepsy (347), Breathing-Related Sleep Disorders (780.59), Circadian Rhythm Sleep Disorder (307.45) and Dyssomnia Not Otherwise Specified (307.47); primary sleep disorders such as Parasomnias such as Nightmare Disorder (307.47), Sleep Terror Disorder (307.46), Sleepwalking Disorder (307.46) and Parasomnia Not Otherwise Specified (307.47); Sleep Disorders Related to Another Mental Disorder such as Insomnia Related to Another Mental Disorder (307.42) and Hypersomnia Related to Another Mental Disorder (307.44); Sleep Disorder Due to a General Medical Condition; and Substance-Induced Sleep Disorder including the subtypes Insomnia Type, Hypersomnia Type, Parasomnia Type and Mixed Type;
  • Eating disorders such as Anorexia Nervosa (307.1 ) including the subtypes Restricting Type and Binge-Eating/Purging Type; Bulimia Nervosa (307.51 ) including the subtypes Purging Type and Nonpurging Type; Obesity; Compulsive Eating Disorder; and Eating Disorder Not Otherwise Specified (307.50);
  • Attention-Deficit /Hyperactivity Disorder including the subtypes Attention-Deficit /Hyperactivity Disorder Combined Type (314.01 ), Attention-Deficit
  • Behaviour Disorders such as Conduct Disorder including the subtypes childhood-onset type (321.81 ), Adolescent-Onset Type (312.82) and Unspecified Onset (312.89),
  • Tic Disorders such as Tourette's Disorder (307.23); Personality Disorders including the subtypes Paranoid Personality Disorder (301.0), Schizoid Personality Disorder (301.20), Schizotypal Personality Disorder (301 ,22), Antisocial Personality Disorder (301.7), Borderline Personality Disorder (301 ,83), Histrionic Personality Disorder (301.50), Narcissistic Personality Disorder (301 ,81 ), Avoidant Personality Disorder (301.82), Dependent Personality Disorder (301.6), Obsessive-Compulsive Personality Disorder (301.4) and Personality Disorder Not Otherwise Specified (301.9); and
  • Sexual dysfunctions including sexual Desire Disorders such as Hypoactive Sexual Desire Disorder (302.71 ), and sexual Aversion Disorder (302.79); sexual arousal disorders such as Female sexual Arousal Disorder (302.72) and Male Erectile Disorder (302.72); orgasmic disorders such as Female Orgasmic Disorder (302.73), Male Orgasmic Disorder (302.74) and Premature Ejaculation (302.75); sexual pain disorder such as Dyspareunia (302.76) and Vaginismus (306.51 ); Sexual Dysfunction Not Otherwise Specified (302.70); paraphilias such as Exhibitionism (302.4), Fetishism (302.81 ), Frotteurism (302.89), Pedophilia (302.2), Sexual Masochism (302.83), sexual Sadism (302.84), Transvestic Fetishism (302.3), Voyeurism (302.82) and Paraphilia Not Otherwise Specified (302.9); gender identity disorders such as Gender Identity Disorder in Children (302.6) and Gender Identity Disorder in Adolescents or Adults (302.85); and
  • the compounds of formula (I) may also be useful for the enhancement of cognition, including both the treatment of cognitive impairment on its own and the treatment of cognition impairment in other diseases such as schizophrenia, bipolar disorder, depression, other psychiatric disorders and psychotic conditions associated with cognitive impairment.
  • the term cognitive impairment includes, for example, impairment of cognitive functions including attention, orientation, learning disorders, memory (i.e. memory disorders, amnesia, amnesic disorders, transient global amnesia syndrome and age-associated memory impairment) and language function; cognitive impairment as a result of stroke, Alzheimer's disease, Huntington's disease, Pick disease, Aids-related dementia or other dementia states such as Multiinfarct dementia, alcoholic dementia, hypotiroidism-related dementia, and dementia associated to other degenerative disorders such as cerebellar atrophy and amyotropic lateral sclerosis; other acute or sub-acute conditions that may cause cognitive decline such as delirium or depression (pseudodementia states) trauma, head trauma, age related cognitive decline, stroke, neurodegeneration, drug-induced states, neurotoxic agents, mild cognitive impairment, age related cognitive impairment, autism related cognitive impairment,
  • cognitive impairment including attention, orientation, learning disorders, memory (i.e. memory disorders, amnesia, amnesic disorders, transient global amnesia syndrome and age-
  • Down's syndrome cognitive deficit related to psychosis, and post-electroconvulsive treatment related cognitive disorders; and dyskinetic disorders such as Parkinson's disease, neuroleptic-induced parkinsonism, and tardive dyskinesias.
  • the therapy of the present invention may also be used as a memory and/or cognition enhancer in healthy humans with no cognitive and/or memory deficit.
  • the invention provides a compound of formula (I) as hereinbefore described or a salt or solvate thereof for use in the treatment of a psychotic disorder. In one embodiment, the invention provides a compound of formula (I) as hereinbefore described or a salt or solvate thereof for use in the treatment of schizophrenia.
  • the invention also provides a compound of formula (I) as hereinbefore described or a salt or solvate thereof for use in the treatment of cognitive impairment.
  • the invention provides the use of a compound of formula (I) as hereinbefore described or a salt or solvate thereof in the manufacture of a medicament for the treatment of a condition which requires agonism of a muscarinic M 1 receptor.
  • the invention provides the use of a compound of formula (I) as hereinbefore described or a salt or solvate thereof in the manufacture of a medicament for the treatment of a psychotic disorder.
  • the invention provides the use of a compound of formula (I) as hereinbefore described or a salt or solvate thereof in the manufacture of a medicament for the treatment of schizophrenia.
  • the invention also provides the use of a compound of formula (I) as hereinbefore described or a salt or solvate thereof in the manufacture of a medicament for the treatment of cognitive impairment.
  • the invention provides a method of treating a condition which requires agonism of a muscarinic M 1 receptor, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a salt or solvate thereof.
  • the mammal is a human.
  • the invention provides a method of treating a psychotic disorder which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a salt or solvate thereof.
  • the invention provides a method of treating schizophrenia, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a salt or solvate thereof.
  • the mammal is a human.
  • the invention also provides a method of treating cognitive impairment, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a salt or solvate thereof.
  • the mammal is a human.
  • the compounds of formula (I) and their salts and solvates thereof may alsbo be suitable for combination with other actives, such as typical and atypical antipsychotics, mood stabilisers, antidepressants, anxiolytics, drugs for extrapyrimidal side effects and cognitive enhancers to provide improved treatment of psychotic disorders.
  • actives such as typical and atypical antipsychotics, mood stabilisers, antidepressants, anxiolytics, drugs for extrapyrimidal side effects and cognitive enhancers to provide improved treatment of psychotic disorders.
  • adjunctive administration is meant the coterminous or overlapping administration of each of the components in the form of separate pharmaceutical compositions or devices.
  • This regime of therapeutic administration of two or more therapeutic agents is referred to generally by those skilled in the art and herein as adjunctive therapeutic administration; it is also known as add-on therapeutic administration.
  • Any and all treatment regimes in which a patient receives separate but coterminous or overlapping therapeutic administration of the compounds of formula (I) or a salt or solvate thereof and at least one antipsychotic agent, a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects or a cognitive enhancer are within the scope of the current invention.
  • a patient is typically stabilised on a therapeutic administration of one or more of the components for a period of time and then receives administration of another component.
  • the compounds of formula (I) or a salt or solvate thereof may be administered as adjunctive therapeutic treatment to patients who are receiving administration of at least one antipsychotic agent, a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects or a cognitive enhancer, but the scope of the invention also includes the adjunctive therapeutic administration of at least one antipsychotic agent, a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects or a cognitive enhancer to patients who are receiving administration of compounds of formula (I) or a salt or solvate thereof.
  • the combination therapies of the invention may also be administered simultaneously.
  • simultaneous administration is meant a treatment regime wherein the individual components are administered together, either in the form of a single pharmaceutical composition or device comprising or containing both components, or as separate compositions or devices, each comprising one of the components, administered simultaneously.
  • Such combinations of the separate individual components for simultaneous combination may be provided in the form of a kit-of-parts.
  • the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of compounds of formula (I) or a salt or solvate thereof to a patient receiving therapeutic administration of at least one antipsychotic agent.
  • the invention provides the use of compounds of formula (I) or a salt or solvate thereof in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent.
  • the invention further provides compounds of formula (I) or a salt or solvate thereof for use for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent.
  • the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of at least one antipsychotic agent to a patient receiving therapeutic administration of compounds of formula (I) or a salt or solvate thereof.
  • the invention provides the use of at least one antipsychotic agent in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I) or a salt or solvate thereof.
  • the invention further provides at least one antipsychotic agent for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I) or a salt or solvate thereof.
  • the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of compounds of formula (I) or a salt or solvate thereof in combination with at least one antipsychotic agent.
  • the invention further provides the use of a combination of compounds of formula (I) or a salt or solvate thereof and at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psychotic disorder.
  • the invention further provides the use of compounds of formula (I) or a salt thereof in the manufacture of a medicament for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder.
  • the invention further provides compounds of formula (I) or a salt thereof for use for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder.
  • the invention further provides the use of at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) or a salt thereof in the treatment of a psychotic disorder.
  • the invention provides a kit-of-parts for use in the treatment of a psychotic disorder comprising a first dosage form comprising compounds of formula (I) or a salt or solvate thereof and one or more further dosage forms each comprising a antipsychotic agent for simultaneous therapeutic administration.
  • the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of a compound of the present invention to a patient receiving therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
  • the invention provides the use of a compound of the present invention in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
  • the invention also provides the use of a compound of the present invention in adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
  • the invention further provides the use of a compound of the present invention for use for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
  • the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer to a patient receiving therapeutic administration of a compound of the present invention.
  • the invention provides the use of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of a compound of the present invention.
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of a compound of the present invention.
  • the invention also provides the use of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of a compound of the present invention
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
  • the invention further provides the use of a combination of a compound of the present invention and an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psychotic disorder.
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psychotic disorder.
  • the invention further provides the use of a combination of a compound of the present invention and an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for simultaneous therapeutic administration in the treatment of a psychotic disorder.
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for simultaneous therapeutic administration in the treatment of a psychotic disorder.
  • the invention further provides the use of a compound of the present invention in the manufacture of a medicament for simultaneous therapeutic administration with an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the treatment of a psychotic disorder.
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the treatment of a psychotic disorder.
  • the invention further provides the use of a compound of the present invention for simultaneous therapeutic administration with an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the treatment of a psychotic disorder.
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the treatment of a psychotic disorder.
  • the invention further provides a compound of the present invention for use for simultaneous therapeutic administration with an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the treatment of a psychotic disorder.
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the treatment of a psychotic disorder.
  • the invention further provides the use of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the manufacture of a medicament for simultaneous therapeutic administration with a compound of the present invention in the treatment of a psychotic disorder.
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the manufacture of a medicament for simultaneous therapeutic administration with a compound of the present invention in the treatment of a psychotic disorder.
  • the invention further provides the use of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for simultaneous therapeutic administration with a compound of the present invention in the treatment of a psychotic disorder.
  • an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for simultaneous therapeutic administration with a compound of the present invention in the treatment of a psychotic disorder.
  • the invention provides a kit-of-parts for use in the treatment of a psychotic disorder comprising a first dosage form comprising a compound of the present invention and one or more further dosage forms each comprising an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for simultaneous therapeutic administration.
  • the patient is a human.
  • antipsychotic drugs examples include, but are not limited to: sodium channel blockers; mixed 5HT/dopamine receptor antagonists; mGluR ⁇ positive modulators; D3 antagonists; 5HT6 angatonists; nicotinic alpha-7 modulators; glycine transporter GIyTI inhibitors; D2 partial agonist/D3 antanogist/H3 antagonists; AMPA modulators; NK3 antagonists such as osanetant and talnetant; an atypical antipsychotic, for example clozapine, olanzapine, risperidone, quetiapine, aripirazole, ziprasidone and amisulpride; butyrophenones, such as haloperidol, pimozide, and droperidol; phenothiazines, such as chlorpromazine, thioridazine, mesoridazine, trifluoperazine, perphenazine,
  • tradenames and suppliers of selected antipsychotic drugs that may be suitable for use in the present invention are as follows : clozapine (available under the tradename CLOZARIL®, from Mylan, Zenith Goldline, UDL, Novartis); olanzapine (available under the tradename ZYPREXA®, from Lilly ; ziprasidone (available under the tradename GEODON®, from Pfizer); risperidone (available under the tradename RISPERDAL®, from Janssen); quetiapine fumarate (available under the tradename SEROQUEL®, from AstraZeneca); sertindole (available under the tradename SERLECT®); amisulpride (available under the tradename SOLION®, from Sanofi- Synthelabo); haloperidol (available under the tradename HALDOL®, from Ortho-McNeil); haloperidol decanoate (available under the tradename HALDOL decanoate®);
  • antipsychotic drugs include promazine (available under the tradename SPARINE®), triflurpromazine (available under the tradename VESPRIN®), chlorprothixene (available under the tradename TARACTAN®), droperidol (available under the tradename INAPSINE®), acetophenazine (available under the tradename TINDAL®;), prochlorperazine (available under the tradename COMPAZINE®), methotrimeprazine (available under the tradename NOZINAN®), pipotiazine (available under the tradename PIPOTRIL®), iloperidone, pimozide and flupenthixol.
  • promazine available under the tradename SPARINE®
  • triflurpromazine available under the tradename VESPRIN®
  • chlorprothixene available under the tradename TARACTAN®
  • droperidol available under the tradename INAPSINE®
  • acetophenazine available under the tradename TINDAL®
  • suitable antipsychotic agents include olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone, talnetant and osanetant.
  • Mood stabilisers which may be used in the therapy of the present invention include lithium, sodium valproate/valproic acid/divalproex, carbamazepine, lamotrigine, gabapentin, topiramate, oxcarbazepine and tiagabine.
  • Antidepressant drugs which may be used in the therapy of the present invention include serotonin antagonists, CRF-1 antagonists, Cox-2 inhibitor/SSRI dual antagonists; dopamine/noradrenaline/serotonin triple reuptake inhibitors; NK1 antagonists; NK1 and NK2 dual antagonists; NK1/SSRI dual antagonists; NK2 antagonists; serotonin agonists (such as rauwolscine, yohimbine and metoclopramide); serotonin reuptake inhibitors (such as citalopram, escitalopram, fluoxetine, fluvoxamine, femoxetine, indalpine, zimeldine, paroxetine and sertraline); dual serotonin/noradrenaline reuptake inhibitors (such as venlafaxine, reboxetine, duloxetine and milnacipran); Noradrenaline reuptake inhibitors (such as reboxetine);
  • Anxiolytics which may be used in the therapy of the present invention include V1 b antagonists, 5HT7 antagonists and benzodiazepines such as alprazolam and lorazepam.
  • Drugs for extrapyramidal side effects which may be used in the therapy of the present invention include anticholinergics (such as benztropine, biperiden, procyclidine and trihexyphenidyl), antihistamines (such as diphenhydramine) and dopaminergics (such as amantadine).
  • anticholinergics such as benztropine, biperiden, procyclidine and trihexyphenidyl
  • antihistamines such as diphenhydramine
  • dopaminergics such as amantadine
  • Cognitive enhancers which may be used in the therapy of the present invention include example cholinesterase inhibitors (such as tacrine, donepezil, rivastigmine and galantamine), H3 antagonists and muscarinic M1 agonists (such as cevimeline).
  • cholinesterase inhibitors such as tacrine, donepezil, rivastigmine and galantamine
  • H3 antagonists such as muscarinic M1 agonists (such as cevimeline).
  • the active ingredient for use in combination with a compound of the present invention is an atypical antipsychotic, for example clozapine, olanzapine, risperidone, quetiapine, aripirazole, ziprasidone or amisulpride.
  • the active ingredient for use in combination with a compound of the present invention is a typical antipsychotic, for example chlorpromazine, thioridazine, mesoridazine, fluphenazine, perphenazine, prochlorperazine, trifluoperazine, thiothixine, haloperidol, thiflurpromazine, pimozide, droperidol, chlorprothixene, molindone or loxapine.
  • a typical antipsychotic for example chlorpromazine, thioridazine, mesoridazine, fluphenazine, perphenazine, prochlorperazine, trifluoperazine, thiothixine, haloperidol, thiflurpromazine, pimozide, droperidol, chlorprothixene, molindone or loxapine.
  • the active ingredient for use in combination with a compound of the present invention is a mood stabiliser, for example lithium, sodium valproate/valproic acid/divalproex, carbamazepine, lamotrigine, gabapentin, topiramate, oxcarbazepine or tiagabine.
  • a mood stabiliser for example lithium, sodium valproate/valproic acid/divalproex, carbamazepine, lamotrigine, gabapentin, topiramate, oxcarbazepine or tiagabine.
  • the active ingredient for use in combination with a compound of the present invention is an antidepressant, for example a serotonin agonist (such as rauwolscine, yohimbine or metoclopramide); a serotonin reuptake inhibitor (such as citalopram, escitalopram, fluoxetine, fluvoxamine, femoxetine, indalpine, zimeldine, paroxetine or sertraline); a dual serotonin/noradrenaline reuptake inhibitor (such as venlafaxine, reboxetine, duloxetine or milnacipran); a noradrenaline reuptake inhibitors (such as reboxetine); a tricyclic antidepressants (such as amitriptyline, clomipramine, imipramine, maprotiline, nortriptyline or trimipramine); a monoamine oxidase inhibitor (such as isocarboxazide), a
  • the active ingredient for use in combination with a compound of the present invention is an anxiolytic, for example a benzodiazepine such as alprazolam or lorazepam.
  • the compounds of the present invention are usually administered as a standard pharmaceutical composition.
  • the present invention therefore provides in a further aspect a pharmaceutical composition comprising a compound of formula (I) as hereinbefore described or a salt or solvate thereof and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition can be for use in the treatment of any of the conditions described herein.
  • the compounds of formula (I) may be administered by any convenient method, for example by oral, parenteral (e.g. intravenous), buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.
  • the compounds of formula (I) as hereinbefore described and their salts or solvates which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or salt or solvate in a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
  • a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
  • the formulation may also contain a suspending agent, preservative, flavouring or colouring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • Typical parenteral compositions consist of a solution or suspension of the compound or salt or solvate in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
  • compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders.
  • Aerosol formulations typically comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device.
  • the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted.
  • the dosage form comprises an aerosol dispenser
  • a propellant which can be a compressed gas such as compressed air or an organic propellant such as a fluorochloro- hydrocarbon.
  • the aerosol dosage forms can also take the form of a pump-atomiser.
  • compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
  • a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
  • compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
  • compositions suitable for transdermal administration include ointments, gels and patches.
  • the composition may be in unit dose form such as a tablet, capsule or ampoule.
  • Each dosage unit for oral administration contains, for example, from 1 to 250 mg (and for parenteral administration contains, for example, from 0.1 to 25 mg) of a compound of the formula (I) or a salt thereof calculated as the free base.
  • the antipsychotic agent component or components used in the adjunctive therapy of the present invention may also be administered in their basic or acidic forms as appropriate or, where appropriate, in the form of a salt or other derivative. All solvates and all alternative physical forms of the antipsychotic agent or agents or their salts or derivatives as described herein, including but not limited to alternative crystalline forms, amorphous forms and polymorphs, are also within the scope of this invention.
  • the forms and derivatives are, for example, those which are approved for therapeutic administration as monotherapies, including those mentioned above, but all references to antipsychotic agents herein include all salts or other derivatives thereof, and all solvates and alternative physical forms thereof.
  • compounds of formula (I) or salts or solvates and the antipsychotic agent or agents or their salts, derivatives or solvates may each be administered in pure form, but each of the components will, for example, be formulated into any suitable pharmaceutically acceptable and effective composition which provides effective levels of the respective component in the body.
  • suitable pharmaceutical compositions for each component is within the skill of the art, and may be the same form or different forms for each of the components.
  • Suitable formulations include, but are not limited to tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions.
  • compounds of formula (I) or their salts or solvates and the antipsychotic agent or agents and their salts, derivatives or solvates may be administered together in pure form, but the combined components will, for example, be formulated into any suitable pharmaceutically acceptable and effective composition which provides effective levels of each of the components in the body.
  • suitable pharmaceutically acceptable and effective composition which provides effective levels of each of the components in the body.
  • the choice of the most appropriate pharmaceutical compositions for the combined components is within the skill of the art.
  • Suitable formulations include, but are not limited to tablets, sub-lingual tablets, buccal compositions, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions.
  • compositions of each of the components, or of the combination of the components is, for example, in the form of a unit dose.
  • treatment includes prophylaxis, where this is appropriate for the relevant condition(s).
  • FLIPR experiments on M 1 receptor to determine agonist/antagonist potency Assay A Compounds of the invention were characterized in a functional assay to determine their ability to activate the intracellular calcium pathway in CHO cells with stable expression of human muscarinic receptors using FLIPR (Fluorometric Imaging Plate Reader) technology. Briefly, CHO-M1 cells were plated (20,000/well) and allowed to grow overnight at 37 degrees. Media was removed and 3OuL loading buffer (HBSS with 2OmM HEPES, pH 7.4) containing FLIPR Calcium 3 dye (Molecular Devices Co., Sunnyvale, CA) was added according to manufacturer's instructions.
  • 3OuL loading buffer HBSS with 2OmM HEPES, pH 7.4
  • Results were imported into ActivityBase data analysis suite (ID Business Solution Inc., Parsippany, NJ) where the curves were analysed by non-linear curve fitting and the resulting pEC 5 o/plC 5 o were calculated.
  • the intrinsic activities of agonist compounds were calculated as percentage of maximum FLIPR response induced by acetylcholine (ie using acetylcholine at EC-ioo as the control).
  • CHO-M1 cells were plated (15,000/well) and allowed to grow overnight at 37 degrees. Media was removed and 3OuL loading buffer (HBSS with 2.5mM probenicid, 2uM Fluo-4, 50OuM Brilliant Black, pH 7.4) was added. After incubation at 37 degrees for 90 minutes, 1 OuL of the assay buffer (HBSS with 2.5 mM probenecid, pH 7.4) containing test compounds was added to each well on the FLIPR instrument. Calcium response was monitored to determine agonism.
  • 3OuL loading buffer HBSS with 2.5mM probenicid, 2uM Fluo-4, 50OuM Brilliant Black, pH 7.4
  • the intrinsic activities of agonist compounds were calculated as percentage of maximum FLIPR response induced by acetylcholine added as control on the same compound plates, and converted to a fraction between 0 and 1 (ie calculated using a 100% max response from a fitted acetylcholine standard curve, containing multiple concentrations, as control).
  • the example compounds below were tested in one or both of the above assays and were found to have a pECso value of > 6.0 at the muscarinic M 1 receptor, and intrinsic activity > 50%.
  • Receptors and Channels 10 99- 109) in 2x10e 5 /ml_ cell suspension with 0.1 % virus/cell ratio (v/v).
  • the virus to cell ratio was determined in separate experiments by functional titration to be most appropriate to measure intrinsic activities of partial agonists. After mixing with virus in suspension, cells were then plated (10,000/well) and allowed to grow overnight at 37 degrees. FLIPR experiment was then carried out next day using the same protocol as described above for CHO-M1 cells. Results were imported into ActivityBase data analysis suite where the curves were analysed by non-linear curve fitting and the resulting pEC50 values were calculated.
  • the intrinsic activities of agonist compounds were calculated as percentage of maximum FLIPR response induced by acetylcholine added as control on the same compound plates, and converted to a fraction between 0 and 1 (ie calculated using a 100%max response from a fitted acetylcholine standard curve, containing multiple concentrations, as control).
  • M1 agonist compounds were characterized in FLIPR experiments on CHO cells with transient expression of human muscarinic M1 receptors. Briefly, CHO cells were transduced with M1 BacMam virus (Ames, R S; Fornwald, J A; Nuthulaganti, P; Trill, J J; Foley, J J; Buckley, P T; Kost, T A; Wu, Z and Romanos, M A. (2004) Use of BacMam recombinant baculoviruses to support G protein-coupled receptor drug discovery. Receptors and Channels 10 (3-4): 99- 109) at a multiplicity of infection of 6.
  • M1 BacMam virus Ames, R S; Fornwald, J A; Nuthulaganti, P; Trill, J J; Foley, J J; Buckley, P T; Kost, T A; Wu, Z and Romanos, M A. (2004) Use of BacMam recombinant baculoviruses to support G protein-coupled receptor drug
  • the virus to cell ratio was determined in separate experiments by functional titration to be most appropriate to measure intrinsic activities of partial agonists. After mixing with virus in suspension, cells were then plated (15,000/well) and allowed to grow overnight at 37 degrees. Alternatively, cells were then frozen in 1 ml vials at a concentration of 4.8x10e7 cells/ml in 90% dialysed Foetal Bovine Serum, 10% DimethylSulphoxide at -140 degrees. Cells could then be thawed on the day prior to assay, plated (15,000/well) and allowed to grow overnight at 37 degrees.
  • the FLIPR experiment was carried out on the day following plating using the same protocol as described above for CHO-M 1 cells. Results were imported into ActivityBase data analysis suite where the curves were analysed by non-linear curve fitting and the resulting pEC50 values were calculated. The intrinsic activities of agonist compounds were calculated as percentage of maximum FLIPR response induced by acetylcholine added as control on the same compound plates, and converted to a fraction between 0 and 1 (ie calculated using a 100% max response from a fitted acetylcholine standard curve, containing multiple concentrations, as control).
  • Assay B To determine selectivity of compounds of the invention against other muscarinic receptor subtypes, compounds were characterized in FLIPR experiments in CHO cells with stable expression of human muscarinic receptors, M2, M3, M4 or M5. In the case of M2 and M4 receptors, chimeric G-protein Gqi5 was also co-expressed to couple receptors to the calcium signaling pathway. Briefly, cells were plated (15,000/well) and allowed to grow overnight at 37 degrees. The FLIPR experiment was then carried out on the next day using the same protocol as described above for CHO-M1 cells. Results were imported into ActivityBase data analysis suite where the curves were analysed by non-linear curve fitting and the resulting pEC50/fpKi values were calculated.
  • the example compounds below were tested in one or both of the above assays and were found to be selective for the M1 receptor over M2, M3, M4 and M5 receptors, with typical selectivity (ratio of pEC50's) of >10-fold, and in certain cases > 100-fold.
  • the crude was eluted on SCX cartridge, firstly with dichloromethane to remove impurities and then with 2M NH 3 in methanol for collect the isomer mixture, plus a small amount of starting material.
  • This mixture was chromatographed on a silica column (10Og for 3.4g of crude: 5% to 5% 3CV, 5% to 20% 10CV, 20% to 20% 2CV of 0.4M NH 3 in methanol/dichloromethane) to afford 2.1g of the title compound mixture (36% yield).
  • Potassium cyanide (320mg; 5 mmol) was added to a mixture of 1 ,1-dimethylethyl 4- piperidinylcarbamate (1.Og), 4-(methyloxy)cyclohexanone (D3; 640mg; 5 mmol), and 2.5M hydrochloric acid (2.0ml; 5 mmol). After 2h at room temperature the mixture was partitioned between water and dichloromethane. Drying and evaporation gave the title compound as a mixture of cis and trans isomers, 1.1g.
  • Methyl magnesium bromide (5.0ml of 3M solution in diethyl ether) was added to a solution of c/s/frans-1 ,1-dimethylethyl [1-(1-cyano-4-methoxycyclohexyl)-4-piperidinyl]carbamate (D32, mixture of isomers) (1.1 g; 3.3 mmol) in tetrahydrofuran (25ml). After 2h at room temperature the solution was partitioned between an aqueous solution of Rochelle salt and dichloromethane. Drying, evaporation and chromatography (5Og silica, 0 to 10% methanol in dichloromethane) gave the title compound as a mixture of cis and trans isomers, 400mg.
  • the extract was dried, concentrated under vacuum and the residue loaded onto a SCX cartridge (2Og), which was eluted with dichloromethane followed by methanol to remove non-basic contaminants, then with 2M NH 3 /methanol to remove the product.
  • the product solution was concentrated under vacuum and the residue chromatographed on Biotage KP-NHTM-silica column (100g) eluting with 0-20% ethyl acetate/hexane to obtain the title compound as the fastest eluting isomer. This was obtained as an orange oil (186mg, 38%).
  • N-Ethoxycarbonylphthalimide (100g; 0.46 mol) was added to a mixture of trans-4- hydroxycyclohexylamine hydrochloride (69g; 0.46 mol), potassium carbonate (158g;
  • Acetaldehyde (10ml; 0.17mol) in acetonitrile (50ml) was added over 30 minutes to a solution of frans-N-(4-tert-butyldimethylsilyloxycyclohexyl)phthalimide (D41 ; 50.Og; 0.14mol), bismuth tribromide (6.7g; 0.015mol), triethylsilane (27ml; 0.18mol) in acetonitrile (500ml) stirred at ice bath temperature and the mixture was allowed to warm to room temperature overnight. The mixture was filtered and the resulting grey solid and filtrate were worked up separately.
  • lodomethane (65ml; LOOmol) was added in portions to a solution of 1-ethyl-4-piperidone (100g; 0.79mol) in acetone (1 L) at 20-30 0 C (internal, ice cooling). After stirring for 3h more the title compound was obtained by filtration, and washing with acetone (189g).
  • Chloro(1 ,1-dimethylethyl)dimethylsilane (115g; 0.76mol) was added in portions over 1 hour to a solution of ethyl 4-hydroxycyclohexanecarboxylate (118g; 0.68mol), imidazole
  • the resulting yellow solution was heated at 5O 0 C for 2.5hrs, then cooled to O 0 C and treated with iodomethane (3 eq., 0.3 mol, 19 ml). The mixture was allowed to warm to room temperature and stir overnight. The mixture was cooled to 1O 0 C, treated with 10% citric acid solution (200ml), and then solvent evaporated to half volume concentrated under vacuum. The residual mixture was diluted with water (200ml) and extracted with Et 2 O (2x). The combined extracts were washed with water (150ml x 2), dried (Na 2 SO 4 ), filtered and concentrated under vacuum to leave the title compound as a yellow oil, 16.2 g, 87%, a mixture of cis:trans isomers.
  • a three-necked flask was equipped with a Dean-Stark trap and an argon-connected condenser.
  • the flask was charged with 1 ,1-dimethylethyl 4-piperidinylcarbamate (1.1 eq., 7 mmol, 1.4 g), 4-(propyloxy)cyclohexanone (D19, 1 eq., 6.4 mmol, 1 g), 1 ,2,3-triazole (1.2 eq., 7.7 mmol, 0.53 g) and 50 ml of dry toluene.
  • Ethyl-4-amino-i-piperidine-carboxylate (16.0 g, 92 mmol) was added to a stirred suspension of 3-chloro-4-nitrobenzotrifluoride (19.0 g, 84 mmol), sodium carbonate (8.9 g, 84 mmol) and potassium iodide (0.14 g, 0.84 mmol) in dimethylformamide (200 ml_).
  • the mixture was heated to 90 0 C, stirred for 15 hours and then allowed to cool.
  • the reaction mixture was diluted with water (200ml) and ethyl acetate (200ml). The aqueous phase was separated and the organic phase was extracted with water (2 x 200ml).
  • the resulting yellow solution was heated at 5O 0 C for 2 hrs, then cooled to O 0 C and treated with iodomethane (3 eq., 12 ml). The mixture was allowed to warm to room temperature and was stirred for 2 hrs. The mixture was partitioned between citric acid (10% aqueous solution) and Et 2 O, the two phases were separated and the aqueous was extracted with Et 2 O (2x). Organics were combined, dried (Na 2 SO 4 ), filtered and concentrated under vacuum to leave a yellow solid (9.8g) a mixture of cisitrans isomers.
  • the mixture was refluxed at 8O 0 C for 2 hours.
  • the mixture was cooled to room temperature and poured onto 1 M NaOH (70 ml); the aqueous solution was extracted with
  • Raney Nickel (0.25ml_, 10% sol. in H 2 O) was added to a vigorously stirred solution of N- (5-fluoro-2-nitrophenyl)-1-[frans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinamine
  • a microwave vessel was charged with 2-fluoro-4-ethoxy-1 -nitrobenzene (D158, 0.3g), 1- [trans-i -methyl-4-(methoxy)cyclohexyl]-4-piperidinamine dihydrochloride (diHCI salt of D153, 0.3g), dimethylformamide (4ml) and diisopropylethylamine (1.0ml) and heated at 200 0 C for 20 minutes in a microwave reactor. The cooled reaction was evaporated, dissolved in methanol and loaded onto a SCX cartridge which was eluted with methanol then 2M methanolic ammonia.
  • a microwave vessel was charged with 2-fluoro-4-ethoxy-1 -nitrobenzene (D158, 0.3g), 1- [frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinamine dihydrochloride (D58, 0.312g), dimethylformamide (4ml) and diisopropylethylamine (1.0ml) and heated at 200 0 C for 20 minutes in a microwave reactor. The cooled reaction was evaporated, dissolved in methanol and loaded onto a SCX cartridge, which was eluted with methanol then 2M methanolic ammonia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of formula (I), salts and solvates are provided: formula (I), wherein Q, R and R6 are as defined in the claims. Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

Description

BENZIMIDAZOLES WHICH HAVE ACTIVITY AT Ml RECEPTOR AND THEIR USES IN MEDICINE
This invention relates to novel compounds, pharmaceutical compositions containing them and their use in therapy, in particular as antipsychotic agents.
Muscarinic acetylcholine receptors are members of the G protein coupled receptor superfamily which mediate the actions of the neurotransmitter acetylcholine in both the central and peripheral nervous system. Five muscarinic receptor subtypes have been cloned, M1 to M5. The muscarinic M1 receptor is predominantly expressed in the cerebral cortex and hippocampus, although it is also expressed in the periphery e.g. exocrine glands.
Muscarinic receptors in the central nervous system, especially M1, play a critical role in mediating higher cognitive processing. Diseases associated with cognitive impairments, such as Alzheimer's disease, are accompanied by loss of cholinergic neurons in the basal forebrain. Furthermore, in animal models, blockade or lesion of central cholinergic pathways results in profound cognitive deficits.
Cholinergic replacement therapy has largely been based on the use of acetylcholinesterase inhibitors to prevent the breakdown of endogenous acetylcholine. These compounds have shown efficacy versus symptomatic cognitive decline in the clinic, but give rise to side effects resulting from stimulation of peripheral muscarinic receptors including disturbed gastrointestinal motility and nausea.
The dopamine hypothesis of schizophrenia suggests that excess dopaminergic stimulation is responsible for the positive symptoms of the disease, hence the utility of dopamine receptor antagonists to reduce psychotic symptoms. However, conventional dopamine receptor antagonists can cause extrapyramidal side effects (EPS) in patients, including tremor and tardive dyskinesias.
M1 receptor agonists have been sought for the symptomatic treatment of cognitive decline. More recently, a number of groups have shown that muscarinic receptor agonists display an atypical antipsychotic-like profile in a range of pre-clinical paradigms. The muscarinic agonist, xanomeline, reverses a number of dopamine driven behaviours, including amphetamine induced locomotion in rats, apomorphine induced climbing in mice, dopamine agonist driven turning in unilateral 6-OH-DA lesioned rats and amphetamine- induced motor unrest in monkeys (without EPS liability). It also has been shown to inhibit A10, but not A9, dopamine cell firing and conditioned avoidance and induces c-fos expression in prefrontal cortex and nucleus accumbens, but not in striatum in rats. These data are all suggestive of an atypical antipsychotic-like profile. Xanomeline has also been shown to reduce psychotic symptoms such as suspiciousness, hallucinations and delusions in Alzheimer's patients. However, the relatively non-selective nature of the compound gives rise to dose-limiting peripheral cholinergic side effects.
Certain M1 receptor agonists are known, for example in PCT/GB2006/003585. We have now found a novel group of compounds which are M1 receptor agonists.
In a first aspect therefore, the invention provides a compound of formula (I) or a salt or solvate thereof:
Figure imgf000003_0001
(I) wherein:
• R6 is selected from hydrogen, cyano, halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkylsulfonyl, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C-i-βalkoxy, and C1^aIkOXy substituted with one or more fluorine atoms;
• R is selected from C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-6alkyl and C2-6alkynyl, any alkyl or cycloalkyl group being optionally substituted by one or more fluorine atoms; and • Q is hydrogen or C1-6alkyl.
The present invention also provides a compound of formula (Ia):
Figure imgf000003_0002
(Ia) wherein: R6 is selected from hydrogen, halogen, d-βalkyl, Chalky! substituted with one or more fluorine atoms, Cs-βcycloalkyl, Cs-βcycloalkyl substituted with one or more fluorine atoms, Ci-6alkoxy and Ci-6alkoxy substituted with one or more fluorine atoms; R is selected from d-βalkyl, Cs-βcycloalkyl, Cs-βcycloalkylCi-βalkyl, any alkyl or cycloalkyl group being optionally substituted with one or more fluorine atoms; and Q is hydrogen or Ci-6alkyl; or a pharmaceutically acceptable salt or solvate thereof.
As used herein, the term "alkyl" refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms. For example,
Figure imgf000004_0001
means a straight or branched alkyl containing at least 1 , and at most 6, carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isobutyl, isopropyl, t-butyl and 1 ,1-dimethylpropyl.
As used herein, the term "alkoxy" refers to a straight or branched alkoxy group containing the specified number of carbon atoms. For example, C-i-βalkoxy means a straight or branched alkoxy group containing at least 1 , and at most 6, carbon atoms. Examples of "alkoxy" as used herein include, but are not limited to, methoxy, ethoxy, propoxy, prop-2- oxy, butoxy, but-2-oxy, 1-methylethyl-oxy, 2-methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy or hexyloxy.
As used herein, the term "cycloalkyl" refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms. For example, Cs-βcycloalkyl means a non-aromatic carbocyclic ring containing at least three, and at most six, ring carbon atoms. Examples of "cycloalkyl" as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
As used herein, the term "alkynyl" refers to a linear or branched hydrocarbon group containing one or more carbon-carbon triple bonds and the specified number of carbon atoms. For example, C2-6alkynyl means a linear or branched hydrocarbon group containing one or more carbon-carbon triple bonds and at least two, and at most six, carbon atoms. Examples of "alkynyl" as used herein include, but are not limited to, include ethynyl, propynyl, butynyl, pentynyl and hexynyl.
As used herein, the term "halogen" (or the abbreviated form "halo") refers to the elements fluorine (which may be abbreviated to "fluoro" or "F"), chlorine (which may be abbreviated to "chloro" or "Cl"), bromine (which may be abbreviated to "bromo" or "Br") and iodine (which may be abbreviated to "iodo" or "I"). Examples of halogens are fluorine, chlorine and bromine.
As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include water, methanol, ethanol and acetic acid. The solvent used may be water and the solvate may also be referred to as a hydrate.
As used herein, the term "substituted" refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated. For example, there may be 1 , 2, 3 or 4 substituents on a given substituted group. For example, if R6 is a
Figure imgf000005_0001
group, it may be substituted by 1 , 2, 3 or 4 fluoro groups; and if R6 is a Ci-6alkoxy group, it may be substituted by 1 , 2, 3 or 4 fluoro groups. For example, R6 may be a
Figure imgf000005_0002
group substituted by 3 fluoro groups; and R6 may be a Ci- 6alkoxy group substituted by 3 fluoro groups. For example, R6 may be CF3. Similarly, if R is a Ci-6alkyl group substituted by one or more fluoro groups, it may be substituted by 1 , 2, 3 or 4 fluoro groups; and if R is a C3-6cycloalkyl group, it may be substituted by 1 , 2, 3 or 4 fluoro groups. For example, R may be a
Figure imgf000005_0003
group substituted by 3 fluoro groups; and R may be a C3-6cycloalkyl group substituted by 3 fluoro groups. For example, R may be CF3 or CH2F.
In one embodiment of the invention, R6 is selected from hydrogen, halogen, Ci-6alkyl, Ci- 6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, d-βalkylsulfonyl, Ci- βalkoxy, and
Figure imgf000005_0004
substituted with one or more fluorine atoms. .
In one embodiment, R6 is cyano.
In one embodiment of the invention, R6 is selected from hydrogen, cyano, halogen, Ci- βalkyl, substituted with one, two or three fluorine atoms, C3-6cycloalkyl, Ci- 6alkylsulfonyl, d-βalkoxy, and
Figure imgf000005_0005
substituted with one, two or three fluorine atoms.
In one embodiment, R6 is selected from hydrogen, halogen, Ci-3alkyl, Ci-3alkyl substituted with one or more fluorine atoms, C3-4cycloalkyl, Ci-3alkylsulfonyl, Ci-3alkoxy, and Ci- 3alkoxy substituted with one or more fluorine atoms.
In one embodiment, R6 is selected from hydrogen, halogen, Ci-3alkyl, Ci-3alkyl substituted with one or two fluorine atoms, C3-4cycloalkyl, Ci-3alkylsulfonyl, Ci-3alkoxy, and Ci-3alkoxy substituted with one, two or three fluorine atoms.
In one embodiment of the invention, R6 is selected from halogen, Ci-6alkyl, Ci-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms,
Figure imgf000005_0006
and
Figure imgf000005_0007
substituted with one or more fluorine atoms.
In one embodiment of the invention, R6 is selected from hydrogen, cyano, fluoro, bromo, methyl, ethyl, methoxy, trifluoromethoxy, methylsulfonyl, trifluoromethyl and cyclopropyl. In one embodiment of the invention, R6 is selected from fluoro, chloro, bromo, methyl, ethyl, isopropyl, methoxy, trifluoromethoxy and trifluoromethyl. In a further embodiment of the invention, R6 is selected from chloro, bromo, methyl, ethyl, isopropyl, methoxy, trifluoromethoxy and trifluoromethyl. For example, R6 is methyl.
In one embodiment, R is selected from d-βalkyl, C3-6cycloalkyl, and Cs-βcycloalkylCi-βalkyl, any alkyl or cycloalkyl group being optionally substituted by one, two or three fluorine atoms.
In one embodiment, R is selected from Ci_3alkyl, C3-6cycloalkyl, Cs-βcycloalkyld-salkyl and C2^alkynyl, any alkyl or cycloalkyl group being optionally substituted by one, two or three fluorine atoms.
In one embodiment, R is C2-6alkynyl. In one embodiment, R is C2-4alkynyl. In one embodiment, R is propynyl.
In a further embodiment of the invention, R is selected from Ci-3alkyl, and C3-6cycloalkylCi. 3alkyl, any alkyl or cycloalkyl group (for example any alkyl group) being optionally substituted with one or more fluorine atoms.
In a further embodiment, R is selected from methyl, ethyl, propyl, isopropyl and cyclopropylmethyl. In one embodiment, R is selected from methyl, ethyl, propyl and isopropyl.
In one embodiment of the invention, R is selected from d-βalkyl, C3-6cycloalkyl, C3- 6cycloalkylCi-6alkyl, any alkyl group being optionally substituted with one or more fluorine atoms.
In one embodiment of the invention, R is selected from Ci-6alkyl, C3-6cycloalkyl, C3- 6cycloalkylCi-6alkyl and C2-4alkynyl, any alkyl or cycloalkyl group being optionally substituted by one, two or three fluorine atoms.
In a further embodiment, R is selected from methyl, ethyl, propyl, isopropyl, CF3, cyclopropylmethyl, propynyl and cyclobutyl.
In an embodiment of the invention, Q is selected from hydrogen and Ci-3alkyl. In a further embodiment, Q is selected from hydrogen, methyl, ethyl and propyl. In one embodiment, Q represents hydrogen or methyl. In one embodiment, Q is hydrogen. In one embodiment the salt or solvate of the compound of formula (I) is a pharmaceutically acceptable salt or solvate. In one embodiment, the invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.
It will be appreciated that for use in medicine the salts of formula (I) should be pharmaceutically acceptable. Suitable salts will be apparent to those skilled in the art and include for example mono- or di- basic salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric, sulfamic phosphoric, hydroiodic, phosphoric or metaphosphoric acid; and with organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, formic, propionic, glycolic, gluconic, maleic, succinic, (1 S)- (-)-IO-camphorsulphonic, (1S)-(+)-10-camphorsulphonic, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, stearic, sulfinilic, alginic, galacturonic and arylsulfonic, for example naphthalene-1 ,5- disulphonic, naphthalene-1 ,3-disulphonic, benzenesulfonic, and p-toluenesulfonic, acids. Other non-pharmaceutically acceptable salts e.g. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention. The compounds of the present invention may be in the form of their free base or pharmaceutically acceptable salts thereof, particularly the monohydrochloride, monoformate or monotrifluoroacetate salts.
Certain of the compounds of formula (I) may form acid addition salts with less than one (for example, 0.5 equivalent of a dibasic acid) or one or more equivalents of an acid. The present invention includes within its scope all possible stoichiometric and non- stoichiometric forms thereof.
It will be appreciated that compounds of formula (I) can exist in cis or trans isomeric forms (the OR group on the cyclohexane ring in relation to the piperidine substituent).
Cis form:
Figure imgf000007_0001
It will be appreciated that the trans form may be drawn in the following different ways, although both represent the same isomeric form:
Figure imgf000008_0001
The individual isomers {cis and trans) and mixtures of these are included within the scope of the present invention. The isomers may be separated one from the other by the usual methods or by methods detailed for the example compounds below. Any given isomer may also be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof.
In one embodiment, the compounds of formula (I) are trans isomers.
In another embodiment, the compounds of formula (I) are cis isomers.
Mixtures of cis- and trans- compounds, or compounds in which the cis/trans conformation have not been determined, are drawn herein as shown below:
Figure imgf000008_0002
Compounds according to the invention include those specifically exemplified in the
Examples section and named hereinafter including, without limitation:- cis-6-Methyl-1-[1-(c/s-4-methoxycyclohexyl)-4-piperidinyl]-1 ,3-dihydro-2/-/-benzimidazol-2- one trans-6-Methyl-1-[1-(c/s-4-methoxycyclohexyl)-4-piperidinyl]-1 ,3-dihydro-2/-/-benzimidazol-
2-one
1 -{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-methyl-1 ,3-dihydro-2H-benzimidazol-2- one
1 -{1 -[c/s-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-methyl-1 ,3-dihydro-2H-benzimidazol-2- one
6-Methyl-1 -{1 -[c/s-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H-benzimidazol-2- one 6-Methyl-1 -{1 -[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/-benzimidazol- 2-one
6-Methyl-1-(1-{frans-4-[(1-methylethyl)oxy]cyclohexyl}-4-piperidinyl)-1 ,3-dihydro-2/-/- benzimidazol-2-one 6-Methyl-1 -{1 -[c/s-1 -methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
6-Methyl-1 -{1 -[frans-1 -methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
6-Methyl-1-(1-{c/s-4-[(1-methylethyl)oxy]cyclohexyl}-4-piperidinyl)-1 ,3-dihydro-2/-/- benzimidazol-2-one or a salt or solvate thereof, for example the hydrochloride salt, the trifluoroacetate salt or the formate salt.
In one embodiment, the salt of a compound listed above is a pharmaceutically acceptable salt.
Examples of the present invention includes:
I . 6-Methyl-1-[1-(c/s-4-methoxycyclohexyl)-4-piperidinyl]-1 ,3-dihydro-2H-benzimidazol-2- one 2. 6-Methyl-1-[1-(frans-4-methoxycyclohexyl)-4-piperidinyl]-1 ,3-dihydro-2H-benzimidazol- 2-one
3. 1 -{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-methyl-1 ,3-dihydro-2H- benzimidazol-2-one
4. 1 -{1 -[c/s-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-methyl-1 ,3-dihydro-2H-benzimidazol- 2-one
5. 6-Methyl-1 -{1 -[c/s-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
6. 6-Methyl-1 -{1 -[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one 7. 6-Methyl-1 -(1 -{frans-4-[(1 -methylethyl)oxy]cyclohexyl}-4-piperidinyl)-1 ,3-dihydro-2H- benzimidazol-2-one
8. 6-Methyl-1 -{1 -[c/s-1 -methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
9. 6-Methyl-1 -{1 -[frans-1 -methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
10. 6-Methyl-1-(1-{c/s-4-[(1-methylethyl)oxy]cyclohexyl}-4-piperidinyl)-1 ,3-dihydro-2/-/- benzimidazol-2-one
I 1. cis -(1 -[4-(Ethoxyl)cyclohexyl]-4-piperidinyl)-1 ,3-dihydro-2H-benzimidazol-2-one 12. trans 1-(1-[4-(Ethoxyl)cyclohexyl]-4-piperidinyl)-1 ,3-dihydro-2H-benzimidazol-2-one 13. 1 -{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-fluoro-1 ,3-dihydro-2H- benzimidazol-2-one 14. 6-Bromo-1-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one
15. 1 -{1 -[c/s-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-(trifluoromethyl)-1 ,3-dihydro-2H- benzimidazol-2-one 16. 6-Ethyl-1-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/-benzimidazol- 2-one
17. 6-Cyclopropyl-1-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one
18. 1 -{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-(methyloxy)-1 ,3-dihydro-2H- benzimidazol-2-one
19. ^-^{^^-(EthoxyJcyclohexyl^-pipeπdinylJ-δ-t^rifluoromethylJoxyl-I .S-dihydro^H- benzimidazol-2-one
20. frans-1-{1-[4-(Ethoxy)cyclohexyl]-4-piperidinyl}-6-[(trifluoromethyl)oxy]-1 ,3-dihydro-2H- benzimidazol-2-one 21. 6-Methyl-1 -[1 -(4-trifluoromethoxycyclohexyl)-4-piperidinyl]-1 ,3-dihydro-2H- benzimidazol-2-one
22. 1 -(1 -{c/s-4-[(Cyclopropylmethyl)oxy]cyclohexyl}-4-piperidinyl)-6-methyl-1 ,3-dihydro-2H- benzimidazol-2-one
23. 1 -(1 -{frans-4-[(Cyclopropylmethyl)oxy]cyclohexyl}-4-piperidinyl)-6-methyl-1 ,3-dihydro- 2/-/-benzimidazol-2-one
24. frans-6-Methyl-1-[1-(4-cyclopropyloxycyclohexyl)-4-piperidinyl]-1 ,3-dihydro-2/-/- benzimidazol-2-one
25. cis -1-(1-[4-(Propyloxy)cyclohexyl]-4-piperidinyl)-1 ,3-dihydro-2H-benzimidazol-2-one
26. frans-1 -(^^-(PropyloxyJcyclohexyO^-piperidinylJ-I .S-dihydro^H-benzimidazol^-one 27. 6-Bromo-1 -{1 -[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
28. 6-Ethyl-1-{1-[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one
29. 6-Cyclopropyl-1-{1-[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one
30. ^-^{^^-(PropyloxyJcyclohexyll^-piperidinylJ-δ-^trifluoromethylJoxyl-I .S-dihydro- 2/-/-benzimidazol-2-one
31. frans-1-{1-[4-(Propyloxy)cyclohexyl]-4-piperidinyl}-6-[(trifluoromethyl)oxy]-1 ,3-dihydro- 2/-/-benzimidazol-2-one 32. ^{^[^-^(EthyloxyJ-i-methylcyclohexyll^-piperidinylJ-e-methyl-I .S-dihydro^H- benzimidazol-2-one
33. 1-{1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-6-methyl-1 ,3-dihydro-2/-/- benzimidazol-2-one
34. 6-Methyl-1-{1-[c/s-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one
35. 6-Methyl-1 -{1 -[frans-1 -methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one 36. frans-6-Methyl-1-[1-(1-ethyl-4-propoxycyclohexyl)-4-piperidinyl]-1 ,3-dihydro-2/-/- benzimidazol-2-one
37. 3-{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-2-oxo-2,3-dihydro-1 H-benzimidazole- 5-carbonitrile 38. 3-{1-[frans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-2-oxo-2, 3-dihydro-1 H- benzimidazole-5-carbonitrile
39. 1 -{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-(methylsulfonyl)-1 ,3-dihydro-2H- benzimidazol-2-one
40. 6-Methyl-1 -{1 -[c/s-4-(2-propyn-1 -yloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
41. 6-Methyl-1 -{1 -[frans-4-(2-propyn-1 -yloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
42. 1-{1-[frans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-6-fluoro-1 ,3-dihydro-2/-/- benzimidazol-2-one 43. 6-Fluoro-1 -{1 -[frans-1 -methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
44. 6-Chloro-1 -{1 -[frans-1 -methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
45. 6-(Ethyloxy)-1-{1-[frans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro- 2/-/-benzimidazol-2-one
46. 6-(Ethyloxy)-1-{1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one
47. 6-Chloro-1-{1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one and salts and solvates thereof, for example the hydrochloride salt, the trifluoroacetate salt or the formate salt.
It will be appreciated by those skilled in the art that certain protected derivatives of compounds of formula (I), which may be made prior to a final deprotection stage, may not possess pharmacological activity as such, but may, in certain instances, be administered orally or parenterally and thereafter metabolised in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". Further, certain compounds of the invention may act as prodrugs of other compounds of the invention. All protected derivatives and prodrugs of compounds of the invention are included within the scope of the invention. Examples of suitable protecting groups for the compounds of the present invention are described in Drugs of Today, Volume 19, Number 9, 1983, pp 499 - 538 and in Topics in Chemistry, Chapter 31 , pp 306 - 316 and in "Design of Prodrugs" by H. Bundgaard, Elsevier, 1985, Chapter 1 (the disclosures in which documents are incorporated herein by reference). It will further be appreciated by those skilled in the art, that certain moieties, known to those skilled in the art as "pro-moieties", for example as described by H. Bundgaard in "Design of Prodrugs" (the disclosure in which document is incorporated herein by reference) may be placed on appropriate functionalities when such functionalities are present within compounds of the invention. Suitable prodrugs for compounds of the invention include : esters, carbonate esters, hemi-esters, phosphate esters, nitro esters, sulfate esters, sulfoxides, amides, carbamates, azo-compounds, phosphamides, glycosides, ethers, acetals and ketals.
In a further aspect, the invention provides a general process (A1 ) for preparing compounds of formula (I) in which Q =H, which process comprises:
coupling a compound of formula (II):
Figure imgf000012_0001
with a compound of formula (III)
Figure imgf000012_0002
wherein R6 is a group R6 as previously defined, or a group convertible to R6, and R' is a group R as previously defined, or a group convertible to R.
The reaction is carried out under conditions suitable for reductive alkylation. The reductive alkylation reaction is typically carried out using sodium triacetoxyborohydride in dichloroethane, optionally in the presence of triethylamine, and optionally in the presence of titanium tetraisopropoxide. Alternatively sodium cyanoborohydride can be used as the reducing reagent in solvents such as methanol or ethanol, or the reductive alkylation can be effected under catalytic hydrogenation conditions using a palladium catalyst. In a further variation, the compounds (II) and (III) can be condensed under dehydrating conditions e.g. molecular sieves or magnesium sulfate, and the resultant imine or enamine reduced using for example sodium borohydride or by catalytic hydrogenation.
This reaction can generate a mixture of cis and trans isomers which can be separated by chromatography or crystallisation.
A modification of general process (A1 ) is required where Q is C1-5 alkyl. Thus, in general process (A2), a compound of formula (II) can be reacted with a compound of formula (III) in the presence of a source of cyanide, e.g. acetone cyanohydrin, to form the cyano intermediate (XXXX) which can be reacted with an alkyl Grignard reagent QMgX to form compounds of formula (I) in which Q is C1-6 alkyl.
Figure imgf000013_0001
(XXXX)
wherein R6 is a group R6 as previously defined, or a group convertible to R6, and R' is a group R as previously defined, or a group convertible to R, Q is Ci_6 alkyl, and X is bromo or iodo or chloro.
This reaction can generate a mixture of cis and trans isomers which can be separated by chromatography or crystallisation.
In a further aspect, the invention provides a general process (B) for preparing compounds of formula (I) which process comprises:
coupling a compound of formula
Figure imgf000013_0002
with a compound of formula (V)
O
A. (V)
wherein R6 is a group R6 as previously defined, or a group convertible to R6, R' is a group R as previously defined, or a group convertible to R, Q is as previously defined, and X and Y both represent leaving groups. X and Y can be the same or different and examples are Cl, PhO, EtO, imidazole. When X and Y are both Cl, i.e. phosgene, this reagent can be generated in situ e.g. from diphosgene or triphosgene.
The above reaction is carried out using standard methodology e.g. reacting the diamine (IV) with the reagent (V) in an inert solvent for example dichloromethane or toluene, optionally in the presence of a base such as triethylamine or potassium carbonate, and optionally with heating.
It will be appreciated that compounds of formula (IV) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the reaction with (V) can be achieved by chromatography or crystallisation.
In a further aspect, the invention provides a general process (C) for preparing compounds of formula (I) which process comprises:
treatment of a compound of
Figure imgf000014_0001
with a palladium or copper catalyst (VII) to effect an intramolecular cyclisation; wherein R6 is a group R6 as previously defined, or a group convertible to R6, R' is a group R as previously defined, or a group convertible to R, Q is as previously defined, and Z is a leaving group such as bromo, iodo, chloro or triflate.
The cyclisation reaction can be carried out using a variety of palladium or copper reagents as described in the literature (JACS, 2003, 125, 6653, Tet. Lett., 2004, 45, 8535, or JACS, 2002, 124, 7421.)
It will be appreciated that compounds of formula (Vl) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the intramolecular cyclisation can be achieved by chromatography or crystallisation.
In a further aspect, the invention provides a general process (D) for preparing compounds of formula (I) which process comprises:
coupling a compound of for
Figure imgf000014_0002
with a compound of formula (IX)
Figure imgf000015_0001
wherein R6 is a group R6 as previously defined, or a group convertible to R6, R' is a group R as previously defined, or a group convertible to R, Q is as previously defined, and Ra is a C1-5 alkyl group.
The condensation and cyclisation reactions can be carried out under reaction conditions similar to those described in the literature for an analogous process (see eg US 3161645) (for example heating in an inert solvent such as xylene) followed by reduction of the piperidine double bond using for example catalytic hydrogenation over palladium or Raney nickel.
It will be appreciated that compounds of formula (IX) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the intramolecular cyclisation can be achieved by chromatography or crystallisation.
In a further aspect, the invention provides a general process (E) for preparing compounds of formula (I) which process comprises:
reaction of a compound of formul
Figure imgf000015_0002
wherein R6 is a group R6 as previously defined, or a group convertible to R6, R' is a group R as previously defined, or a group convertible to R, and Q is as previously defined; with diphenylphosphoryl azide or other reagent/combination of reagents to effect the Curtius rearrangement of compound (X), followed by intramolecular cyclisation.
The Curtius rearrangement is typically carried out by mixing the two reactants in an inert solvent such as toluene, optionally with heating. It will be appreciated that compounds of formula (X) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the intramolecular cyclisation can be achieved by chromatography or crystallisation.
In a further aspect, the invention provides a general process (F) for preparing compounds of formula (I) which process comprises:
coupling a compound of formula (Xl):
Figure imgf000016_0001
with a compound of formula (XII)
Figure imgf000016_0002
wherein R6 is a group R6 as previously defined, or a group convertible to R6, R' is a group R as previously defined, or a group convertible to R, Q is as previously defined, and Z is hydroxy or a leaving group such as chloro, bromo or iodo, or alkyl/aryl sulfonate.
The alkylation reaction can be carried out under classical alkylation (Z = a leaving group) or Mitsunobu reaction (Z = OH) conditions. Using classical alkylation conditions, the benzimidazolone intermediate (Xl) can be deprotonated using a base such as sodium hydride in an inert solvent such as dimethylformamide, and then treated with the alkylating reagent (XII), optionally with heating. The Mitsunobu reaction with (XII) Z = OH can be carried out using standard conditions e.g. triphenylphosphine and diethylazodicarboxylate in an inert solvent such as dichloromethane or tetrahydrofuran at room temperature.
It will be appreciated that compounds of formula (X) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the intramolecular cyclisation can be achieved by chromatography or crystallisation.
Conversion of R6 to R6 or interconversions of R6 may be accomplished as indicated below.
For example, when R6 is a halogen, it can be converted to an alkoxy, trifluoromethyl or methylsulphonyl group by copper catalysed reaction, using an alcohol, methyl fluorosulfonyl(difluoro)acetate or sodium methanesulphinate respectively. It may also be converted to an alkyl group with an organometallic reagent, for example an alkylstannane.
As another example, when R6 is hydroxy, it may be converted to alkoxy by reaction with an alkyl halide or sulfonate, or to trifluoromethoxy by conversion to the xanthate followed by oxidation in the presence of fluoride ion.
As a further example, when R6 is methyl, it may be converted to trifluoromethyl by chlorination or bromination followed by displacement of the introduced halogens with fluoride.
Conversion of R to R or interconversions of R may be accomplished as indicated below.
For example when R' is benzyl, the benzyl group can be removed using standard methodology, e.g. catalytic hydrogenation over palladium on carbon, to provide the alcohol. Alkylation of the resultant alcohol using a strong base e.g. sodium hydride and a C-ι-6 alkylating agent e.g. methyl iodide or ethyl iodide or propyl iodide, will afford the desired product. It will be appreciated that protection of any NH functionality present in the molecule may be necessary.
As another example, when R is methyl, the methyl group can be removed by treatment with a dealkylating agent such as boron tribromide to afford the alcohol intermediate, which can be alkylated in a similar manner to that described above. Alternatively the alcohol intermediate can be converted to R is trifluoromethyl by conversion to the xanthate followed by oxidation in the presence of fluoride ion.
Compounds of formula (II) are generally known in the literature or can be prepared by a range of different processes for example:
(a) displacement of an ortho-fluoro or ortho-chloro nitrobenzene intermediate (XIII) with the amine (XIV), wherein R6 is a group R6 as previously defined, or a group convertible to R6, and P represents a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, ethoxycarbonyl, benzyloxycarbonyl, to give (XXIII), followed by reduction of the nitro group, cyclisation using phosgene or a phosgene equivalent, and deprotection of the piperidine nitrogen using standard literature conditions (Scheme 1 ).
Scheme 1.
Figure imgf000018_0001
(H)
Compounds of formula (XIII) are commercially available or can be prepared by standard methodology. The compound (XIV) in which P = Boc is commercially available
(b) metal catalysed cyclisation of an intermediate (XV) followed by deprotection of the piperidine nitrogen, wherein R6 is a group R6 as previously defined, or a group convertible to R6, P represents a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, benzyloxycarbonyl, and Z represents a leaving group such as bromo, iodo, chloro or triflate. Reaction conditions for the metal catalysed cyclisation are summarised in Process C. The urea (XV) can be prepared using any of the classical methods for urea formation as illustrated in Scheme 2. The starting materials for this process are commercially available or can be prepared using standard methodology.
Scheme 2.
Figure imgf000019_0001
Figure imgf000019_0002
(c) Curtius rearrangement of an intermediate (XVI), wherein R6 is a group R6 as previously defined, or a group convertible to R6, P represents a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, benzyloxycarbonyl, and Rb represents H or a Ci-S alkyl group e.g. methyl or ethyl, followed by intramolecular cyclisation and deprotection of the piperidine nitrogen (Scheme 3). The anthranilic acid or ester starting materials (XVII) are commercially available or can be made by standard methodology. The piperidone starting material (P = Boc or benzyl) is commercially available. The Curtius rearrangement can be effected using the conditions described under process E.
Scheme 3.
Figure imgf000020_0001
Figure imgf000020_0003
Figure imgf000020_0002
(H) (XVl)
(d) Condensation of an orthophenylenediamine (VIII) with a 3-alkoxycarbonyl-4- piperidone (XX), wherein R6 is a group R6 as previously defined, or a group convertible to R6, P represents a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, benzyloxycarbonyl and Rb is a Ci-5 alkyl group (Scheme 4), by heating in an inert solvent at elevated temperature, to afford the tetrahydropyridine intermediate (XXI). Hydrogenation of the double bond and deprotection of the piperidine nitrogen can be accomplished separately or concomitantly dependent on the precise nature of the protecting group P, to afford the desired product (II). Compounds of formula (VIII) are commercially available or can be prepared by standard methodology. Compounds of formula (XX) are commercially available or can be prepared by standard methodology.
Scheme 4.
Figure imgf000020_0004
(e) Reductive alkylation of an ortho nitroaniline (XXII) with an N-protected 4-piperidone (XVIII), wherein R6 is a group R6 as previously defined, or a group convertible to R6, and P represents a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, benzyloxycarbonyl, using for example sodium triacetoxyborohydride to give the intermediate (XXIII). Reduction of the nitro group, followed by cyclisation and deprotection as described hereinbefore provides the desired product (II) (Scheme 5). Compounds of formula (XXII) and (XVIII) are commercially available or can be prepared by standard methodology
Scheme 5.
Figure imgf000021_0001
(f) metal catalysed reaction between the amine (XIV) and a suitably substituted nitrobenzene compound (XXIV) wherein R6 is a group R6 as previously defined, or a group convertible to R6, P represents a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, benzyloxycarbonyl, and Z represents a leaving group such as bromo, iodo, chloro or triflate (Scheme 6). This process generates intermediates of formula (XXIII) and subsequent reactions are similar to that for Scheme 5. Compounds of formula (XXIV) are commercially available or can be prepared by known methodology. The compound (XIV) in which P = Boc is commercially available
Scheme 6.
Figure imgf000022_0001
(g) metal catalysed reaction between the amine (XIV) and the protected aniline (XXV), wherein R6 is a group R6 as previously defined, or a group convertible to R6, P and P' independently represent a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, benzyloxycarbonyl, and Z represents a leaving group such as bromo, iodo, chloro or triflate, to give the intermediate (XXVI) (Scheme 7). Deprotection of the aniline followed by the same reaction sequence as in Scheme 6 affords the desired intermediate (II). Compounds of formula (XXV) are commercially available or can be prepared by known methodology e.g. halogenation ortho to the optionally protected aniline group. The compound (XIV) in which P = Boc is commercially available
Scheme 7.
Figure imgf000022_0002
The compounds of formula (III) can be prepared by standard literature methodology.
Compounds of formula (IV) can be prepared by a number of different processes e.g.
(h) displacement of an ortho-fluoro or ortho-chloro nitrobenzene intermediate (XIII) with the amine (XXVII) wherein R6 is a group R6 as previously defined, or a group convertible to R6, R' is a group R as previously defined, or a group convertible to R, and Q is as previously defined, to afford compound (XXVIII) followed by reduction of the nitro group using standard conditions e.g. hydrogenation over palladium or Raney nickel (Scheme 8). Compounds of formula (XIII) are commercially available or can be prepared by standard methodology. It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
Scheme 8.
Figure imgf000023_0001
(i) metal catalysed reaction of the amine (XXVII) with the ortho substituted nitrobenzene (XXIX), wherein R6 is a group R6 as previously defined, or a group convertible to R6, R' is a group R as previously defined, or a group convertible to R, and Q is as previously defined, to afford compound (XXVIII) (Scheme 9) followed by the same reactions as illustrated in Scheme 8. Compounds of formula (XXIX) are commercially available or can be prepared by standard methodology. It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
Scheme 9.
Figure imgf000024_0001
Figure imgf000024_0003
(XXVIl)
(XXIX)
Figure imgf000024_0002
(j) metal catalysed reaction of the amine (XXVII) with the protected aniline derivative (XXV), wherein wherein R6 is a group R6 as previously defined, or a group convertible to R6, R' is a group R as previously defined, or a group convertible to R, and Q is as previously defined, and P' represents a nitrogen protecting group such as acetyl, trifluoroacetyl, Boc, phthalimide, to afford compound (XXXI) (Scheme 10) followed by deprotection of the aniline group. Compounds of formula (XXV) are commercially available or can be prepared by standard methodology. It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
Scheme 10.
Figure imgf000024_0004
(k) Reductive alkylation of an ortho nitroaniline (XXII) with the piperidone (XXXII) wherein R6 is a group R6 as previously defined, or a group convertible to R6, R' is a group R as previously defined, or a group convertible to R, and Q is as previously defined, using for example sodium triacetoxyborohydride in dichloroethane to give the intermediate (XXVIII) (Scheme 11 ). Reduction of the nitro group using, for example, palladium on carbon or Raney nickel affords the desired intermediate (IV). It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
Scheme 11.
Figure imgf000025_0001
Compounds of formula (V) are commercially available e.g. carbonyl diimidazole, phosgene, phosgene solution in toluene, diphosgene, triphosgene, phenyl chloroformate, diethyl carbonate.
Compounds of formula (Vl) can be prepared by a variety of processes e.g. urea formation can be achieved as shown in Scheme 12 by
• combining the two amines (XXXIV) and (XXVII) with phosgene or a phosgene equivalent using standard conditions Phosgene equivalents include carbonyl diimidazole, diphosgene, triphosgene, phenyl chloroformate
• reacting the amine (XXVII) with the isocyanate (XXXV)
• reacting the amine (XXXIV) with the isocyanate (XXXVI) Both isocyanates can be prepared from the corresponding amines using standard methodology for isocyanate formation.
It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
Scheme 12.
phosgene equivalent
Figure imgf000026_0001
(XXXIV)
Figure imgf000026_0003
Figure imgf000026_0002
(XXXV) (XXVII)
Figure imgf000026_0004
(XXXIV) (XXXVI)
Palladium and copper catalysts (VII) are commercially available or can be prepared as described in the literature (see references in Process C).
Compounds of formula (VIII) are commercially available or can be prepared by known literature routes e.g. reduction of a mono or dinitrobenzene precursor.
Compounds of formula (IX) can be prepared by reductive alkylation of the 3- alkoxycarbonyl-4-piperidone with cyclohexanone (III).
Compounds of formula (X) can be prepared as shown in Scheme 13. Reductive alkylation of an anthranilic acid or ester (XVII) with the ketone (XXXII), followed if appropriate by hydrolysis of the ester group. It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
Scheme 13.
Figure imgf000027_0001
(X)
Compounds of formula (Xl) are commercially available or can be prepared by literature processes.
Compounds of formula (XII) where Q = H can be prepared as shown in Scheme 14, by reductive alkylation of (XXXVII) where Z' represents Z or a group convertible to Z with the ketone (III). Conversion of a Z' hydroxy group to Z = chloro or bromo can be accomplished using standard methodology e.g. treatment with thionyl chloride or triphenylphosphine/carbon tetrabromide. It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
Scheme 14.
Figure imgf000027_0002
(XXXVII)
(XII)
The compound (XXVII) where Q = H can be prepared as shown in Scheme 15. Reductive alkylation of the commercially available amine (XXXVIII) with cyclohexanone (III) using for example sodium triacetoxyborohydride in dichloroethane provides the intermediate (XXXIX) which is deprotected using HCI in ethanol or trifluoroacetic acid to afford the primary amine (XXVII). It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
Scheme 15.
Figure imgf000027_0003
(XXXVIII) (XXXIX) (XXVIl) The compound (XXVII) where Q = alkyl can be prepared as in process A2, followed by deprotection.
Alternatively the compound (XXVII) where Q = H can be prepared as shown in Scheme 16. Reductive amination of cyclohexanone (III) using for example ammonia solution under catalytic hydrogenation conditions provides intermediate amine (XL), which can be converted into piperidinone (XLII) by reaction with quaternary piperidine salt (XLI). Reductive amination, for example using ammonia and catalytic hydrogenation, affords primary amine (XXVII). It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
Scheme 16.
Figure imgf000028_0001
(lll) <XL) (XLl) (XL,,) <XXV")
Selective preparation of the cis and trans isomers of compound (XXVII) where Q =H can be carried out via the process which is illustrated in scheme 17 for the trans isomer. The commercially available amine (XLIII) is initially N-protected for example by incorporation in a phthalimide ring to give (XLIV), then the hydroxyl function converted into a silyl protected group, for example tert-butyldimethylsilyl, to give (XLV), which upon treatment with the appropriate aldehyde or ketone in presence of triethylsilane and bismuth tribromide affords (XLVI), which after deprotection gives intermediate amine (XLVII). Conversion of amine (XLVII) to the piperidinone (XLVIII) by reaction with quaternary piperidine salt (XLI) followed by reductive amination, for example using ammonia and catalytic hydrogenation, affords primary amine (XXVII).
Scheme 17.
Figure imgf000029_0001
The cis isomer of compound (XXVII) can be prepared by a similar procedure from the appropriate cis amine (XLIII).
A selective preparation of the trans isomer of compound (XXVII) where Q = Me is shown in scheme 18. A suitable ester of 4-hydroxycyclohexane carboxylic acid such as methyl or ethyl (XLIX) is protected as a silyl ether, for example tert-butyldimethylsilyl, to give (L), which on treatment with the appropriate aldehyde or ketone in presence of triethylsilane and bismuth tribromide affords ether (Ll). Hydrolysis to acid (LII) followed by alkylation using a base such as lithium diisopropylamide with iodomethane affords mixture of cis and trans 1-methylcyclohexane carboxylic acid (LIIII). The trans isomer (LIV) can be isolated by conversion of the mixture to the acid chloride, for example with thionyl chloride, followed by selective hydrolysis of the products by treatment with weak aqueous base such as sodium hydrogen carbonate solution. The acid can be converted to the isocyanate (LV) by Curtius rearrangement at elevated temperature of an intermediate azide prepared using for example diphenylphosphoryl azide, then the isocyanate hydrolysed to amine (LVI) under acidic conditions. Conversion of amine (LVI) to the piperidinone (LVII) by reaction with quaternary piperidine salt (XLI) followed by reductive amination, for example using ammonia and catalytic hydrogenation, affords primary amine (XXVII).
Scheme 18.
Figure imgf000030_0001
Figure imgf000030_0002
Figure imgf000030_0005
Figure imgf000030_0003
(LVI) (XXVII)
Figure imgf000030_0004
The cis isomer of (XXVII) where Q = Me can be obtained as shown in scheme 19. The mixture of acids (LIII) is converted to a mixture of isocyantes (LVIII) via Curtius rearrangement of an intermediate azide at elevated temperature prepared using for example diphenylphosphoryl azide. The cis isomer (LIX) can be isolated from this mixture by chromatographic separation, then converted through to amine (XXVII) using a similar procedure to that as shown for the trans isomer in scheme 17 through intermediates (LX) and (LXI).
Scheme 19.
Figure imgf000031_0001
(LIII) (LVIII) (LIX)
Figure imgf000031_0002
Compounds of the present invention are M1 receptor agonists. Selective M1 receptor agonists are said to be useful to ameliorate positive and cognitive symptoms of psychotic disorders such as schizophrenia, schizo-affective disorders, schizophreniform diseases, psychotic depression, mania, acute mania, paranoid and delusional disorders, and cognitive impairment including memory disorders such as Alzheimer's disease without peripheral cholinergic side effects mediated predominantly through M2 and M3 receptors. M1 receptor agonists may also be suitable for combination with other typical and atypical antipsychotics and other actives such as mood stabilisers, antidepressants, anxiolytics, drugs for extrapyrimidal side effects and cognitive enhancers, to provide improved treatment of psychotic disorders.
Thus in a further aspect, the invention provides a compound of formula (I) as hereinbefore described or a salt or solvate thereof for use in therapy.
In another aspect, the invention provides a compound of formula (I) or a salt or solvate thereof for use in the treatment of a condition which requires agonism of a muscarinic M1 receptor.
The terms describing the indications used herein are classified in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, published by the American Psychiatric Association (DSM-IV) and/or the International Classification of Diseases, 10th Edition (ICD-10). The various subtypes of the disorders mentioned herein are contemplated as part of the present invention. Numbers in brackets after the listed diseases below refer to the classification code in DSM-IV. Within the context of the present invention, the term psychotic disorder includes Schizophrenia including the subtypes Paranoid Type (295.30), Disorganised Type (295.10), Catatonic Type (295.20), Undifferentiated Type (295.90) and Residual Type (295.60); Schizophreniform Disorder (295.40); Schizoaffective Disorder (295.70) including the subtypes Bipolar Type and Depressive Type; Delusional Disorder (297.1 ) including the subtypes Erotomanic Type, Grandiose Type, Jealous Type, Persecutory Type, Somatic Type, Mixed Type and Unspecified Type; Brief Psychotic Disorder (298.8); Shared Psychotic Disorder (297.3); Psychotic Disorder Due to a General Medical Condition including the subtypes With Delusions and With Hallucinations; Substance-Induced Psychotic Disorder including the subtypes With Delusions (293.81 ) and With Hallucinations (293.82); and Psychotic Disorder Not Otherwise Specified (298.9);
Other conditions the treatment of which require agonism of a muscarinic M1 receptor include:
Depression and mood disorders including Major Depressive Episode, Manic Episode, Mixed Episode and Hypomanic Episode; Depressive Disorders including Major Depressive Disorder, Dysthymic Disorder (300.4), Depressive Disorder Not Otherwise Specified (311 ); Bipolar Disorders including Bipolar I Disorder, Bipolar Il Disorder (Recurrent Major Depressive Episodes with Hypomanic Episodes) (296.89), Cyclothymic Disorder (301.13) and Bipolar Disorder Not Otherwise Specified (296.80); Other Mood Disorders including Mood Disorder Due to a General Medical Condition (293.83) which includes the subtypes With Depressive Features, With Major Depressive-like Episode, With Manic Features and With Mixed Features), Substance-Induced Mood Disorder (including the subtypes With Depressive Features, With Manic Features and With Mixed Features) and Mood Disorder Not Otherwise Specified (296.90);
Anxiety disorders including Social Anxiety Disorder, Panic Attack, Agoraphobia, Panic Disorder, Agoraphobia Without History of Panic Disorder (300.22), Specific Phobia (300.29) including the subtypes Animal Type, Natural Environment Type, Blood-Injection- Injury Type, Situational Type and Other Type), Social Phobia (300.23), Obsessive- Compulsive Disorder (300.3), Posttraumatic Stress Disorder (309.81 ), Acute Stress Disorder (308.3), Generalized Anxiety Disorder (300.02), Anxiety Disorder Due to a General Medical Condition (293.84), Substance-Induced Anxiety Disorder and Anxiety Disorder Not Otherwise Specified (300.00);
Substance-related disorders including Substance Use Disorders such as Substance Dependence, Substance Craving and Substance Abuse; Substance-Induced Disorders such as Substance Intoxication, Substance Withdrawal, Substance-Induced Delirium, Substance-Induced Persisting Dementia, Substance-Induced Persisting Amnestic Disorder, Substance-Induced Psychotic Disorder, Substance-Induced Mood Disorder, Substance-Induced Anxiety Disorder, Substance-Induced Sexual Dysfunction, Substance- Induced Sleep Disorder and Hallucinogen Persisting Perception Disorder (Flashbacks); Alcohol-Related Disorders such as Alcohol Dependence (303.90), Alcohol Abuse (305.00), Alcohol Intoxication (303.00), Alcohol Withdrawal (291.81 ), Alcohol Intoxication Delirium, Alcohol Withdrawal Delirium, Alcohol-Induced Persisting Dementia, Alcohol- Induced Persisting Amnestic Disorder, Alcohol-Induced Psychotic Disorder, Alcohol- Induced Mood Disorder, Alcohol-Induced Anxiety Disorder, Alcohol-Induced Sexual Dysfunction, Alcohol-Induced Sleep Disorder and Alcohol-Related Disorder Not Otherwise Specified (291.9); Amphetamine (or Amphetamine-I_ike)-Related Disorders such as Amphetamine Dependence (304.40), Amphetamine Abuse (305.70), Amphetamine Intoxication (292.89), Amphetamine Withdrawal (292.0), Amphetamine Intoxication Delirium, Amphetamine Induced Psychotic Disorder, Amphetamine-Induced Mood Disorder, Amphetamine-Induced Anxiety Disorder, Amphetamine-Induced Sexual Dysfunction, Amphetamine-Induced Sleep Disorder and Amphetamine-Related Disorder Not Otherwise Specified (292.9); Caffeine Related Disorders such as Caffeine Intoxication (305.90), Caffeine-Induced Anxiety Disorder, Caffeine-Induced Sleep Disorder and Caffeine-Related Disorder Not Otherwise Specified (292.9); Cannabis-Related Disorders such as Cannabis Dependence (304.30), Cannabis Abuse (305.20), Cannabis Intoxication (292.89), Cannabis Intoxication Delirium, Cannabis-lnduced Psychotic Disorder, Cannabis-lnduced Anxiety Disorder and Cannabis-Related Disorder Not Otherwise Specified (292.9); Cocaine-Related Disorders such as Cocaine Dependence (304.20), Cocaine Abuse (305.60), Cocaine Intoxication (292.89), Cocaine Withdrawal (292.0), Cocaine Intoxication Delirium, Cocaine-Induced Psychotic Disorder, Cocaine-Induced Mood Disorder, Cocaine-Induced Anxiety Disorder, Cocaine-Induced Sexual Dysfunction, Cocaine-Induced Sleep Disorder and Cocaine-Related Disorder Not Otherwise Specified (292.9); Hallucinogen-Related Disorders such as Hallucinogen Dependence (304.50), Hallucinogen Abuse (305.30), Hallucinogen Intoxication (292.89), Hallucinogen Persisting Perception Disorder (Flashbacks) (292.89), Hallucinogen Intoxication Delirium, Hallucinogen-Induced Psychotic Disorder, Hallucinogen-Induced Mood Disorder, Hallucinogen-Induced Anxiety Disorder and Hallucinogen-Related Disorder Not Otherwise Specified (292.9); Inhalant-Related Disorders such as Inhalant Dependence (304.60), Inhalant Abuse (305.90), Inhalant Intoxication (292.89), Inhalant Intoxication Delirium, Inhalant-Induced Persisting Dementia, Inhalant-Induced Psychotic Disorder, Inhalant- Induced Mood Disorder, Inhalant-Induced Anxiety Disorder and Inhalant-Related Disorder Not Otherwise Specified (292.9); Nicotine-Related Disorders such as Nicotine Dependence (305.1 ), Nicotine Withdrawal (292.0) and Nicotine-Related Disorder Not Otherwise Specified (292.9); Opioid-Related Disorders such as Opioid Dependence (304.00), Opioid Abuse (305.50), Opioid Intoxication (292.89), Opioid Withdrawal (292.0), Opioid Intoxication Delirium, Opioid-lnduced Psychotic Disorder, Opioid-lnduced Mood Disorder, Opioid-lnduced Sexual Dysfunction, Opioid-lnduced Sleep Disorder and Opioid- Related Disorder Not Otherwise Specified (292.9); Phencyclidine (or Phencyclidine-Like)- Related Disorders such as Phencyclidine Dependence (304.60), Phencyclidine Abuse (305.90), Phencyclidine Intoxication (292.89), Phencyclidine Intoxication Delirium, Phencyclidine-lnduced Psychotic Disorder, Phencyclidine-lnduced Mood Disorder, Phencyclidine-lnduced Anxiety Disorder and Phencyclidine-Related Disorder Not Otherwise Specified (292.9); Sedative-, Hypnotic-, or Anxiolytic-Related Disorders such as Sedative, Hypnotic, or Anxiolytic Dependence (304.10), Sedative, Hypnotic, or Anxiolytic Abuse (305.40), Sedative, Hypnotic, or Anxiolytic Intoxication (292.89), Sedative, Hypnotic, or Anxiolytic Withdrawal (292.0), Sedative, Hypnotic, or Anxiolytic Intoxication Delirium, Sedative, Hypnotic, or Anxiolytic Withdrawal Delirium, Sedative-, Hypnotic-, or Anxiolytic-Persisting Dementia, Sedative-, Hypnotic-, or Anxiolytic- Persisting Amnestic Disorder, Sedative-, Hypnotic-, or Anxiolytic-lnduced Psychotic Disorder, Sedative-, Hypnotic-, or Anxiolytic-lnduced Mood Disorder, Sedative-, Hypnotic-, or Anxiolytic- lnduced Anxiety Disorder Sedative-, Hypnotic-, or Anxiolytic-lnduced Sexual Dysfunction, Sedative-, Hypnotic-, or Anxiolytic-lnduced Sleep Disorder and Sedative-, Hypnotic-, or Anxiolytic-Related Disorder Not Otherwise Specified (292.9); Polysubstance-Related Disorder such as Polysubstance Dependence (304.80); and Other (or Unknown) Substance-Related Disorders such as Anabolic Steroids, Nitrate Inhalants and Nitrous Oxide;
Sleep disorders including primary sleep disorders such as Dyssomnias such as Primary Insomnia (307.42), Primary Hypersomnia (307.44), Narcolepsy (347), Breathing-Related Sleep Disorders (780.59), Circadian Rhythm Sleep Disorder (307.45) and Dyssomnia Not Otherwise Specified (307.47); primary sleep disorders such as Parasomnias such as Nightmare Disorder (307.47), Sleep Terror Disorder (307.46), Sleepwalking Disorder (307.46) and Parasomnia Not Otherwise Specified (307.47); Sleep Disorders Related to Another Mental Disorder such as Insomnia Related to Another Mental Disorder (307.42) and Hypersomnia Related to Another Mental Disorder (307.44); Sleep Disorder Due to a General Medical Condition; and Substance-Induced Sleep Disorder including the subtypes Insomnia Type, Hypersomnia Type, Parasomnia Type and Mixed Type;
Eating disorders such as Anorexia Nervosa (307.1 ) including the subtypes Restricting Type and Binge-Eating/Purging Type; Bulimia Nervosa (307.51 ) including the subtypes Purging Type and Nonpurging Type; Obesity; Compulsive Eating Disorder; and Eating Disorder Not Otherwise Specified (307.50);
Autistic Disorder (299.00); Attention-Deficit /Hyperactivity Disorder including the subtypes Attention-Deficit /Hyperactivity Disorder Combined Type (314.01 ), Attention-Deficit
/Hyperactivity Disorder Predominantly Inattentive Type (314.00), Attention-Deficit
/Hyperactivity Disorder Hyperactive-Impulse Type (314.01 ) and Attention-Deficit
/Hyperactivity Disorder Not Otherwise Specified (314.9); Hyperkinetic Disorder; Disruptive
Behaviour Disorders such as Conduct Disorder including the subtypes childhood-onset type (321.81 ), Adolescent-Onset Type (312.82) and Unspecified Onset (312.89),
Oppositional Defiant Disorder (313.81 ) and Disruptive Behaviour Disorder Not Otherwise
Specified; and Tic Disorders such as Tourette's Disorder (307.23); Personality Disorders including the subtypes Paranoid Personality Disorder (301.0), Schizoid Personality Disorder (301.20), Schizotypal Personality Disorder (301 ,22), Antisocial Personality Disorder (301.7), Borderline Personality Disorder (301 ,83), Histrionic Personality Disorder (301.50), Narcissistic Personality Disorder (301 ,81 ), Avoidant Personality Disorder (301.82), Dependent Personality Disorder (301.6), Obsessive-Compulsive Personality Disorder (301.4) and Personality Disorder Not Otherwise Specified (301.9); and
Sexual dysfunctions including Sexual Desire Disorders such as Hypoactive Sexual Desire Disorder (302.71 ), and Sexual Aversion Disorder (302.79); sexual arousal disorders such as Female Sexual Arousal Disorder (302.72) and Male Erectile Disorder (302.72); orgasmic disorders such as Female Orgasmic Disorder (302.73), Male Orgasmic Disorder (302.74) and Premature Ejaculation (302.75); sexual pain disorder such as Dyspareunia (302.76) and Vaginismus (306.51 ); Sexual Dysfunction Not Otherwise Specified (302.70); paraphilias such as Exhibitionism (302.4), Fetishism (302.81 ), Frotteurism (302.89), Pedophilia (302.2), Sexual Masochism (302.83), Sexual Sadism (302.84), Transvestic Fetishism (302.3), Voyeurism (302.82) and Paraphilia Not Otherwise Specified (302.9); gender identity disorders such as Gender Identity Disorder in Children (302.6) and Gender Identity Disorder in Adolescents or Adults (302.85); and Sexual Disorder Not Otherwise Specified (302.9).
The compounds of formula (I) may also be useful for the enhancement of cognition, including both the treatment of cognitive impairment on its own and the treatment of cognition impairment in other diseases such as schizophrenia, bipolar disorder, depression, other psychiatric disorders and psychotic conditions associated with cognitive impairment.
Within the context of the present invention, the term cognitive impairment includes, for example, impairment of cognitive functions including attention, orientation, learning disorders, memory (i.e. memory disorders, amnesia, amnesic disorders, transient global amnesia syndrome and age-associated memory impairment) and language function; cognitive impairment as a result of stroke, Alzheimer's disease, Huntington's disease, Pick disease, Aids-related dementia or other dementia states such as Multiinfarct dementia, alcoholic dementia, hypotiroidism-related dementia, and dementia associated to other degenerative disorders such as cerebellar atrophy and amyotropic lateral sclerosis; other acute or sub-acute conditions that may cause cognitive decline such as delirium or depression (pseudodementia states) trauma, head trauma, age related cognitive decline, stroke, neurodegeneration, drug-induced states, neurotoxic agents, mild cognitive impairment, age related cognitive impairment, autism related cognitive impairment,
Down's syndrome, cognitive deficit related to psychosis, and post-electroconvulsive treatment related cognitive disorders; and dyskinetic disorders such as Parkinson's disease, neuroleptic-induced parkinsonism, and tardive dyskinesias.
The therapy of the present invention may also be used as a memory and/or cognition enhancer in healthy humans with no cognitive and/or memory deficit.
In another aspect, the invention provides a compound of formula (I) as hereinbefore described or a salt or solvate thereof for use in the treatment of a psychotic disorder. In one embodiment, the invention provides a compound of formula (I) as hereinbefore described or a salt or solvate thereof for use in the treatment of schizophrenia.
The invention also provides a compound of formula (I) as hereinbefore described or a salt or solvate thereof for use in the treatment of cognitive impairment.
In another aspect, the invention provides the use of a compound of formula (I) as hereinbefore described or a salt or solvate thereof in the manufacture of a medicament for the treatment of a condition which requires agonism of a muscarinic M1 receptor.
In another aspect, the invention provides the use of a compound of formula (I) as hereinbefore described or a salt or solvate thereof in the manufacture of a medicament for the treatment of a psychotic disorder. In one embodiment, the invention provides the use of a compound of formula (I) as hereinbefore described or a salt or solvate thereof in the manufacture of a medicament for the treatment of schizophrenia.
The invention also provides the use of a compound of formula (I) as hereinbefore described or a salt or solvate thereof in the manufacture of a medicament for the treatment of cognitive impairment.
In another aspect, the invention provides a method of treating a condition which requires agonism of a muscarinic M1 receptor, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a salt or solvate thereof. In one embodiment, the mammal is a human.
In another aspect, the invention provides a method of treating a psychotic disorder which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a salt or solvate thereof. In one embodiment, the invention provides a method of treating schizophrenia, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a salt or solvate thereof. In one embodiment, the mammal is a human. The invention also provides a method of treating cognitive impairment, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a salt or solvate thereof. In one embodiment, the mammal is a human.
The compounds of formula (I) and their salts and solvates thereof may alsbo be suitable for combination with other actives, such as typical and atypical antipsychotics, mood stabilisers, antidepressants, anxiolytics, drugs for extrapyrimidal side effects and cognitive enhancers to provide improved treatment of psychotic disorders.
The combination therapies of the invention are, for example, administered adjunctively. By adjunctive administration is meant the coterminous or overlapping administration of each of the components in the form of separate pharmaceutical compositions or devices. This regime of therapeutic administration of two or more therapeutic agents is referred to generally by those skilled in the art and herein as adjunctive therapeutic administration; it is also known as add-on therapeutic administration. Any and all treatment regimes in which a patient receives separate but coterminous or overlapping therapeutic administration of the compounds of formula (I) or a salt or solvate thereof and at least one antipsychotic agent, a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects or a cognitive enhancer are within the scope of the current invention. In one embodiment of adjunctive therapeutic administration as described herein, a patient is typically stabilised on a therapeutic administration of one or more of the components for a period of time and then receives administration of another component. The compounds of formula (I) or a salt or solvate thereof may be administered as adjunctive therapeutic treatment to patients who are receiving administration of at least one antipsychotic agent, a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects or a cognitive enhancer, but the scope of the invention also includes the adjunctive therapeutic administration of at least one antipsychotic agent, a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects or a cognitive enhancer to patients who are receiving administration of compounds of formula (I) or a salt or solvate thereof.
The combination therapies of the invention may also be administered simultaneously. By simultaneous administration is meant a treatment regime wherein the individual components are administered together, either in the form of a single pharmaceutical composition or device comprising or containing both components, or as separate compositions or devices, each comprising one of the components, administered simultaneously. Such combinations of the separate individual components for simultaneous combination may be provided in the form of a kit-of-parts.
In a further aspect therefore, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of compounds of formula (I) or a salt or solvate thereof to a patient receiving therapeutic administration of at least one antipsychotic agent. In a further aspect, the invention provides the use of compounds of formula (I) or a salt or solvate thereof in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent. The invention further provides compounds of formula (I) or a salt or solvate thereof for use for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent.
In a further aspect, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of at least one antipsychotic agent to a patient receiving therapeutic administration of compounds of formula (I) or a salt or solvate thereof. In a further aspect, the invention provides the use of at least one antipsychotic agent in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I) or a salt or solvate thereof. The invention further provides at least one antipsychotic agent for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I) or a salt or solvate thereof.
In a further aspect, the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of compounds of formula (I) or a salt or solvate thereof in combination with at least one antipsychotic agent. The invention further provides the use of a combination of compounds of formula (I) or a salt or solvate thereof and at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psychotic disorder. The invention further provides the use of compounds of formula (I) or a salt thereof in the manufacture of a medicament for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder. The invention further provides compounds of formula (I) or a salt thereof for use for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder. The invention further provides the use of at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) or a salt thereof in the treatment of a psychotic disorder.
In a further aspect, the invention provides a kit-of-parts for use in the treatment of a psychotic disorder comprising a first dosage form comprising compounds of formula (I) or a salt or solvate thereof and one or more further dosage forms each comprising a antipsychotic agent for simultaneous therapeutic administration.
In another aspect, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of a compound of the present invention to a patient receiving therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
In a further aspect, the invention provides the use of a compound of the present invention in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
The invention also provides the use of a compound of the present invention in adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
The invention further provides the use of a compound of the present invention for use for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
In a further aspect, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer to a patient receiving therapeutic administration of a compound of the present invention.
In a further aspect, the invention provides the use of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of a compound of the present invention.
The invention also provides the use of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of a compound of the present invention In a further aspect, the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of a compound of the present invention in combination with an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
The invention further provides the use of a combination of a compound of the present invention and an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psychotic disorder.
The invention further provides the use of a combination of a compound of the present invention and an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for simultaneous therapeutic administration in the treatment of a psychotic disorder.
The invention further provides the use of a compound of the present invention in the manufacture of a medicament for simultaneous therapeutic administration with an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the treatment of a psychotic disorder.
The invention further provides the use of a compound of the present invention for simultaneous therapeutic administration with an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the treatment of a psychotic disorder.
The invention further provides a compound of the present invention for use for simultaneous therapeutic administration with an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the treatment of a psychotic disorder.
The invention further provides the use of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the manufacture of a medicament for simultaneous therapeutic administration with a compound of the present invention in the treatment of a psychotic disorder.
The invention further provides the use of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for simultaneous therapeutic administration with a compound of the present invention in the treatment of a psychotic disorder.
In a further aspect, the invention provides a kit-of-parts for use in the treatment of a psychotic disorder comprising a first dosage form comprising a compound of the present invention and one or more further dosage forms each comprising an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for simultaneous therapeutic administration.
In one embodiment, the patient is a human.
Examples of antipsychotic drugs that may be useful in the present invention include, but are not limited to: sodium channel blockers; mixed 5HT/dopamine receptor antagonists; mGluRδ positive modulators; D3 antagonists; 5HT6 angatonists; nicotinic alpha-7 modulators; glycine transporter GIyTI inhibitors; D2 partial agonist/D3 antanogist/H3 antagonists; AMPA modulators; NK3 antagonists such as osanetant and talnetant; an atypical antipsychotic, for example clozapine, olanzapine, risperidone, quetiapine, aripirazole, ziprasidone and amisulpride; butyrophenones, such as haloperidol, pimozide, and droperidol; phenothiazines, such as chlorpromazine, thioridazine, mesoridazine, trifluoperazine, perphenazine, fluphenazine, thiflupromazine, prochlorperazine, and acetophenazine; thioxanthenes, such as thiothixene and chlorprothixene; thienobenzodiazepines; dibenzodiazepines; benzisoxazoles; dibenzothiazepines; imidazolidinones; benzisothiazolyl-piperazines; triazine such as lamotrigine; dibenzoxazepines, such as loxapine; dihydroindolones, such as molindone; aripiprazole; and derivatives thereof that have antipsychotic activity.
Examples of tradenames and suppliers of selected antipsychotic drugs that may be suitable for use in the present invention are as follows : clozapine (available under the tradename CLOZARIL®, from Mylan, Zenith Goldline, UDL, Novartis); olanzapine (available under the tradename ZYPREXA®, from Lilly ; ziprasidone (available under the tradename GEODON®, from Pfizer); risperidone (available under the tradename RISPERDAL®, from Janssen); quetiapine fumarate (available under the tradename SEROQUEL®, from AstraZeneca); sertindole (available under the tradename SERLECT®); amisulpride (available under the tradename SOLION®, from Sanofi- Synthelabo); haloperidol (available under the tradename HALDOL®, from Ortho-McNeil); haloperidol decanoate (available under the tradename HALDOL decanoate®); haloperidol lactate (available under the tradenames HALDOL® and INTENSOL®); chlorpromazine (available under the tradename THORAZINE®, from SmithKline Beecham (GSK); fluphenazine (available under the tradename PROLIXIN®, from Apothecon, Copley, Schering, Teva, and American Pharmaceutical Partners, Pasadena); fluphenazine decanoate (available under the tradename PROLIXIN decanoate®); fluphenazine enanthate (available under the tradename PROLIXIN®); fluphenazine hydrochloride (available under the tradename PROLIXIN®); thiothixene (available under the tradename NAVANE®;, from Pfizer); thiothixene hydrochloride (available under the tradename NAVANE®); trifluoperazine (10-[3-(4-methyl-1-piperazinyl)propyl]-2- (trifluoromethyl)phenothiazine dihydrochloride, available under the tradename STELAZINE®, from SmithKline Beckman; perphenazine (available under the tradename TRILAFON®; from Schering); perphenazine and amitriptyline hydrochloride (available under the tradename ETRAFON TRILAFON®); thioridazine (available under the tradename MELLARIL®; from Novartis, Roxane, HiTech, Teva, and Alpharma) ; molindone (available under the tradename MOBAN®, from Endo); molindone hydrochloride (available under the tradename MOBAN®); loxapine (available under the tradename LOXITANE®; from Watson); loxapine hydrochloride (available under the tradename LOXITANE®); and loxapine succinate (available under the tradename LOXITANE®). Furthermore, benperidol (Glianimon®), perazine (Taxilan®) or melperone (Eunerpan®)) may be used.
Other suitable antipsychotic drugs include promazine (available under the tradename SPARINE®), triflurpromazine (available under the tradename VESPRIN®), chlorprothixene (available under the tradename TARACTAN®), droperidol (available under the tradename INAPSINE®), acetophenazine (available under the tradename TINDAL®;), prochlorperazine (available under the tradename COMPAZINE®), methotrimeprazine (available under the tradename NOZINAN®), pipotiazine (available under the tradename PIPOTRIL®), iloperidone, pimozide and flupenthixol.
The antipsychotic drugs listed above by Tradename may also be available from other suppliers under a different Tradename.
In one further aspect of the invention, suitable antipsychotic agents include olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone, talnetant and osanetant.
Mood stabilisers which may be used in the therapy of the present invention include lithium, sodium valproate/valproic acid/divalproex, carbamazepine, lamotrigine, gabapentin, topiramate, oxcarbazepine and tiagabine.
Antidepressant drugs which may be used in the therapy of the present invention include serotonin antagonists, CRF-1 antagonists, Cox-2 inhibitor/SSRI dual antagonists; dopamine/noradrenaline/serotonin triple reuptake inhibitors; NK1 antagonists; NK1 and NK2 dual antagonists; NK1/SSRI dual antagonists; NK2 antagonists; serotonin agonists (such as rauwolscine, yohimbine and metoclopramide); serotonin reuptake inhibitors (such as citalopram, escitalopram, fluoxetine, fluvoxamine, femoxetine, indalpine, zimeldine, paroxetine and sertraline); dual serotonin/noradrenaline reuptake inhibitors (such as venlafaxine, reboxetine, duloxetine and milnacipran); Noradrenaline reuptake inhibitors (such as reboxetine); tricyclic antidepressants (such as amitriptyline, clomipramine, imipramine, maprotiline, nortriptyline and trimipramine); monoamine oxidase inhibitors (such as isocarboxazide, moclobemide, phenelzine and tranylcypromine); 5HT3 antagonists (such as example ondansetron and granisetron); and others (such as bupropion, amineptine, radafaxine, mianserin, mirtazapine, nefazodone and trazodone).
Anxiolytics which may be used in the therapy of the present invention include V1 b antagonists, 5HT7 antagonists and benzodiazepines such as alprazolam and lorazepam.
Drugs for extrapyramidal side effects which may be used in the therapy of the present invention include anticholinergics (such as benztropine, biperiden, procyclidine and trihexyphenidyl), antihistamines (such as diphenhydramine) and dopaminergics (such as amantadine).
Cognitive enhancers which may be used in the therapy of the present invention include example cholinesterase inhibitors (such as tacrine, donepezil, rivastigmine and galantamine), H3 antagonists and muscarinic M1 agonists (such as cevimeline).
In one embodiment, the active ingredient for use in combination with a compound of the present invention, is an atypical antipsychotic, for example clozapine, olanzapine, risperidone, quetiapine, aripirazole, ziprasidone or amisulpride.
In one embodiment, the active ingredient for use in combination with a compound of the present invention is a typical antipsychotic, for example chlorpromazine, thioridazine, mesoridazine, fluphenazine, perphenazine, prochlorperazine, trifluoperazine, thiothixine, haloperidol, thiflurpromazine, pimozide, droperidol, chlorprothixene, molindone or loxapine.
In another embodiment, the active ingredient for use in combination with a compound of the present invention is a mood stabiliser, for example lithium, sodium valproate/valproic acid/divalproex, carbamazepine, lamotrigine, gabapentin, topiramate, oxcarbazepine or tiagabine.
In another embodiment, the active ingredient for use in combination with a compound of the present invention is an antidepressant, for example a serotonin agonist (such as rauwolscine, yohimbine or metoclopramide); a serotonin reuptake inhibitor (such as citalopram, escitalopram, fluoxetine, fluvoxamine, femoxetine, indalpine, zimeldine, paroxetine or sertraline); a dual serotonin/noradrenaline reuptake inhibitor (such as venlafaxine, reboxetine, duloxetine or milnacipran); a noradrenaline reuptake inhibitors (such as reboxetine); a tricyclic antidepressants (such as amitriptyline, clomipramine, imipramine, maprotiline, nortriptyline or trimipramine); a monoamine oxidase inhibitor (such as isocarboxazide, moclobemide, phenelzine or tranylcypromine); or other (such as bupropion, amineptine, radafaxine, mianserin, mirtazapine, nefazodone or trazodone).
In another embodiment, the active ingredient for use in combination with a compound of the present invention is an anxiolytic, for example a benzodiazepine such as alprazolam or lorazepam.
For use in medicine, the compounds of the present invention are usually administered as a standard pharmaceutical composition. The present invention therefore provides in a further aspect a pharmaceutical composition comprising a compound of formula (I) as hereinbefore described or a salt or solvate thereof and a pharmaceutically acceptable carrier. The pharmaceutical composition can be for use in the treatment of any of the conditions described herein.
The compounds of formula (I) may be administered by any convenient method, for example by oral, parenteral (e.g. intravenous), buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.
The compounds of formula (I) as hereinbefore described and their salts or solvates which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or salt or solvate in a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring or colouring agent.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
Typical parenteral compositions consist of a solution or suspension of the compound or salt or solvate in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air or an organic propellant such as a fluorochloro- hydrocarbon. The aerosol dosage forms can also take the form of a pump-atomiser.
Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
Compositions suitable for transdermal administration include ointments, gels and patches. The composition may be in unit dose form such as a tablet, capsule or ampoule.
Each dosage unit for oral administration contains, for example, from 1 to 250 mg (and for parenteral administration contains, for example, from 0.1 to 25 mg) of a compound of the formula (I) or a salt thereof calculated as the free base.
The antipsychotic agent component or components used in the adjunctive therapy of the present invention may also be administered in their basic or acidic forms as appropriate or, where appropriate, in the form of a salt or other derivative. All solvates and all alternative physical forms of the antipsychotic agent or agents or their salts or derivatives as described herein, including but not limited to alternative crystalline forms, amorphous forms and polymorphs, are also within the scope of this invention. In the case of the antipsychotic agent or agents, the forms and derivatives are, for example, those which are approved for therapeutic administration as monotherapies, including those mentioned above, but all references to antipsychotic agents herein include all salts or other derivatives thereof, and all solvates and alternative physical forms thereof. For adjunctive therapeutic administration according to the invention, compounds of formula (I) or salts or solvates and the antipsychotic agent or agents or their salts, derivatives or solvates may each be administered in pure form, but each of the components will, for example, be formulated into any suitable pharmaceutically acceptable and effective composition which provides effective levels of the respective component in the body. The choice of the most appropriate pharmaceutical compositions for each component is within the skill of the art, and may be the same form or different forms for each of the components. Suitable formulations include, but are not limited to tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions.
For simultaneous administration as a combined composition of compounds of formula (I) and the antipsychotic agent or agents according to the invention, compounds of formula (I) or their salts or solvates and the antipsychotic agent or agents and their salts, derivatives or solvates may be administered together in pure form, but the combined components will, for example, be formulated into any suitable pharmaceutically acceptable and effective composition which provides effective levels of each of the components in the body. The choice of the most appropriate pharmaceutical compositions for the combined components is within the skill of the art. Suitable formulations include, but are not limited to tablets, sub-lingual tablets, buccal compositions, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions.
In order to obtain consistency of adjunctive administration, the compositions of each of the components, or of the combination of the components is, for example, in the form of a unit dose.
The term "treatment" includes prophylaxis, where this is appropriate for the relevant condition(s).
Biological Test Methods
FLIPR experiments on M1 receptor to determine agonist/antagonist potency Assay A Compounds of the invention were characterized in a functional assay to determine their ability to activate the intracellular calcium pathway in CHO cells with stable expression of human muscarinic receptors using FLIPR (Fluorometric Imaging Plate Reader) technology. Briefly, CHO-M1 cells were plated (20,000/well) and allowed to grow overnight at 37 degrees. Media was removed and 3OuL loading buffer (HBSS with 2OmM HEPES, pH 7.4) containing FLIPR Calcium 3 dye (Molecular Devices Co., Sunnyvale, CA) was added according to manufacturer's instructions. After incubation at 37 degrees for 45-60 minutes, 1OuL of the assay buffer (HBSS with 2OmM HEPES and 2.5 mM probenecid, pH 7.4) containing test compounds was added to each well on FLIPR instrument. Calcium response was monitored to determine agonism. Plates were then incubated for another 30 minutes before 1OuL of assay buffer containing acetylcholine was added at an ECβo, as the agonist challenge. Calcium response was then monitored again to determine compound's antagonism to acetylcholine. Concentration-response curves of both agonism and antagonism on M1 receptors were performed for each compound. Results were imported into ActivityBase data analysis suite (ID Business Solution Inc., Parsippany, NJ) where the curves were analysed by non-linear curve fitting and the resulting pEC5o/plC5o were calculated. The intrinsic activities of agonist compounds were calculated as percentage of maximum FLIPR response induced by acetylcholine (ie using acetylcholine at EC-ioo as the control).
Assay B
Compounds of the invention were characterized in a functional assay to determine their ability to activate the intracellular calcium pathway in CHO cells with stable expression of human muscarinic receptors using FLIPR (Fluorometric Imaging Plate Reader) technology. Briefly, CHO-M1 cells were plated (15,000/well) and allowed to grow overnight at 37 degrees. Media was removed and 3OuL loading buffer (HBSS with 2.5mM probenicid, 2uM Fluo-4, 50OuM Brilliant Black, pH 7.4) was added. After incubation at 37 degrees for 90 minutes, 1 OuL of the assay buffer (HBSS with 2.5 mM probenecid, pH 7.4) containing test compounds was added to each well on the FLIPR instrument. Calcium response was monitored to determine agonism. Plates were then incubated for another 30 minutes before 1OuL of assay buffer containing acetylcholine was added at an EC80, as the agonist challenge. Calcium response was then monitored again to determine compound's antagonism to acetylcholine. Concentration-response curves of both agonism and antagonism on M1 receptors were performed for each compound. Results were imported into ActivityBase data analysis suite (ID Business Solution Inc., Parsippany, NJ) where the curves were analysed by non-linear curve fitting and the resulting pEC50/fpKi were calculated. The intrinsic activities of agonist compounds were calculated as percentage of maximum FLIPR response induced by acetylcholine added as control on the same compound plates, and converted to a fraction between 0 and 1 (ie calculated using a 100% max response from a fitted acetylcholine standard curve, containing multiple concentrations, as control).
The example compounds below were tested in one or both of the above assays and were found to have a pECso value of > 6.0 at the muscarinic M1 receptor, and intrinsic activity > 50%.
FLIPR experiments on M1 receptor to determine agonist intrinsic activity Assay A
To determine the intrinsic activities of M1 agonist compounds, compounds of the invention were characterized in FLIPR experiments on U2OS cells with transient expression of human muscarinic M1 receptors. Briefly, U2OS cells were transduced with M1 BacMam virus (Ames, R S; Fornwald, J A; Nuthulaganti, P; Trill, J J; Foley, J J; Buckley, P T; Kost, T A; Wu, Z and Romanos, M A. (2004) Use of BacMam recombinant baculoviruses to support G protein-coupled receptor drug discovery. Receptors and Channels 10 (3-4): 99- 109) in 2x10e5/ml_ cell suspension with 0.1 % virus/cell ratio (v/v). The virus to cell ratio was determined in separate experiments by functional titration to be most appropriate to measure intrinsic activities of partial agonists. After mixing with virus in suspension, cells were then plated (10,000/well) and allowed to grow overnight at 37 degrees. FLIPR experiment was then carried out next day using the same protocol as described above for CHO-M1 cells. Results were imported into ActivityBase data analysis suite where the curves were analysed by non-linear curve fitting and the resulting pEC50 values were calculated. The intrinsic activities of agonist compounds were calculated as percentage of maximum FLIPR response induced by acetylcholine added as control on the same compound plates, and converted to a fraction between 0 and 1 (ie calculated using a 100%max response from a fitted acetylcholine standard curve, containing multiple concentrations, as control).
Assay B
To determine the intrinsic activities of M1 agonist compounds, compounds of the invention were characterized in FLIPR experiments on CHO cells with transient expression of human muscarinic M1 receptors. Briefly, CHO cells were transduced with M1 BacMam virus (Ames, R S; Fornwald, J A; Nuthulaganti, P; Trill, J J; Foley, J J; Buckley, P T; Kost, T A; Wu, Z and Romanos, M A. (2004) Use of BacMam recombinant baculoviruses to support G protein-coupled receptor drug discovery. Receptors and Channels 10 (3-4): 99- 109) at a multiplicity of infection of 6. The virus to cell ratio was determined in separate experiments by functional titration to be most appropriate to measure intrinsic activities of partial agonists. After mixing with virus in suspension, cells were then plated (15,000/well) and allowed to grow overnight at 37 degrees. Alternatively, cells were then frozen in 1 ml vials at a concentration of 4.8x10e7 cells/ml in 90% dialysed Foetal Bovine Serum, 10% DimethylSulphoxide at -140 degrees. Cells could then be thawed on the day prior to assay, plated (15,000/well) and allowed to grow overnight at 37 degrees.
The FLIPR experiment was carried out on the day following plating using the same protocol as described above for CHO-M 1 cells. Results were imported into ActivityBase data analysis suite where the curves were analysed by non-linear curve fitting and the resulting pEC50 values were calculated. The intrinsic activities of agonist compounds were calculated as percentage of maximum FLIPR response induced by acetylcholine added as control on the same compound plates, and converted to a fraction between 0 and 1 (ie calculated using a 100% max response from a fitted acetylcholine standard curve, containing multiple concentrations, as control).
The example compounds below were tested in one or both of the above assays, and were found to have a pECso value of > 6.0 at the muscarinic M1 receptor, and intrinsic activity of greater than or equal to 0.3. FLIPR experiments on M?^ receptor to determine receptor subtype selectivity Assay A
To determine selectivity of compounds of the invention against other muscarinic receptor subtypes, compounds were characterized in FLIPR experiments in CHO cells with stable expression of human muscarinic receptors, M2, M3, M4 or M5. In the case of M2 and M4 receptors, chimeric G-protein Gqi5 was also co-expressed to couple receptors to the calcium signaling pathway. Briefly, cells were plated (20,000/well) and allowed to grow overnight at 37 degrees. FLIPR experiment was then carried out next day using the same protocol as described above for CHO-M 1 cells. Results were imported into ActivityBase data analysis suite where the curves were analysed by non-linear curve fitting and the resulting pEC50/plC50 values were calculated.
Assay B To determine selectivity of compounds of the invention against other muscarinic receptor subtypes, compounds were characterized in FLIPR experiments in CHO cells with stable expression of human muscarinic receptors, M2, M3, M4 or M5. In the case of M2 and M4 receptors, chimeric G-protein Gqi5 was also co-expressed to couple receptors to the calcium signaling pathway. Briefly, cells were plated (15,000/well) and allowed to grow overnight at 37 degrees. The FLIPR experiment was then carried out on the next day using the same protocol as described above for CHO-M1 cells. Results were imported into ActivityBase data analysis suite where the curves were analysed by non-linear curve fitting and the resulting pEC50/fpKi values were calculated.
The example compounds below were tested in one or both of the above assays and were found to be selective for the M1 receptor over M2, M3, M4 and M5 receptors, with typical selectivity (ratio of pEC50's) of >10-fold, and in certain cases > 100-fold.
The invention is further illustrated by the following non-limiting examples. In the procedures that follow, after each starting material, reference to a Description by number is typically provided. This is provided merely for assistance to the skilled chemist. The starting material may not necessarily have been prepared from the batch referred to. SCX refers to a sulfonic acid ion exchange resin supplied by Varian.
All reactions were either done under argon or can be done under argon, unless stated otherwise (for example hydrogenation reactions).
Description 1. 1,4-Dioxaspiro[4.5]decan-8-ol (D1)
Figure imgf000050_0001
1 ,4-Dioxaspiro[4.5]decan-8-one (64 mmol, 10 g) was dissolved in ethanol (125 ml) and treated with NaBH4 (1.2eq., 76.8 mmol, 2.9 g), at O0C portionwise and the mixture was stirred at room temperature for 1 hour. Reaction was quenched with NaOH (25 ml, 2N aqueous solution). The aqueous solution was extracted with dichloromethane (2x). The organics were combined, dried over Na2SO4, filtered and the solvent was evaporated to afford the title compound, 8.3 g, 82%, as a colourless oil.
1H NMR δ (d6DMSO, 400 MHz) 1.44 (4H, m), 1.64 (4H, m), 3.54 (1 H, d broad), 3.82 (4H, m), 4.48 (1 H, d).
Description 2. 8-(Methyloxy)-1 ,4-dioxaspiro[4.5]decane (D2)
Figure imgf000050_0002
1 ,4-dioxaspiro[4.5]decan-8-ol (D1 , 52.5 mmol, 8.3g) was dissolved in dimethylformamide (100 ml) and NaH (2eq., 105 mmol, 4.2 g) was added at O0C portionwise. The mixture was stirred at O0C for 10 minutes and iodomethane (2 eq., 6.5 ml) was added at room temperature. The mixture was stirred at room temperature for 2 hours, then it was quenched with methanol, partitioned between ethyl acetate and water and the two phases were separated. The aqueous phase was extracted with ethyl acetate (2x), the combined organics were washed with brine, dried over Na2SO4, filtered and the solvent was evaporated to afford the crude compound. Chromatography (ethyl acetate/n-hexane) afforded title compound, 7.35 g, 80%, as a colourless oil. 1H NMR δ (d6DMSO, 400 MHz) 1.46 (2H, m),1.56 (2H, m), 1.64 (2H, m), 1.73 (2H, m), 3.21 (3H, s), 3.24 (1 H, m), 3.83 (4H, m)
Description 3. 4-(Methyloxy)cyclohexanone (D3)
Figure imgf000050_0003
8-(Methyloxy)-1 ,4-dioxaspiro[4.5]decane (D2, 62.2 mmol, 11.9g) was dissolved in 10 ml of tetrahydrofuran and HCI (50ml of 5M aqueous solution) was added at room temperature; the mixture was stirred at room temperature overnight. Tetrahydrofuran was then evaporated, mixture was basified to pH=10 and it was extracted with ethyl acetate (3x); the organic phases were combined and washed with brine, dried over Na2SO4, filtered and the solvent was evaporated to afford the title compound, 8.2g, complete conversion. 1H NMR δ (d6DMSO, 400 MHz) 1.92 (4H, m), 2.20 (2H, m), 2.35 (2H, m), 3.29 (3H, s), 3.53 (1 H1 m)
Description 4. cis/trans-Λ, 1-Dimethylethyl [1 -(4-methoxycyclohexyl)-4- piperidinyljcarbamate (D4)
BocNH— ( NVV-/ Wo
(D4)
A mixture of 4-methoxycyclohexanone (D3, 4.5g, 40mmol), dichloromethane (200ml), 1 ,1-dimethylethyl 4-piperidinylcarbamate (9.Og; 45mmol) and sodium triacetoxyborohydride (16.Og, 80mmol) was stirred at room temperature for 18h, then partitioned between dichloromethane and water at pH9. Drying, evaporation, and chromatography (5Og silica, 0-10% methanol in dichloromethane + NH3) gave the title compound as a mixture of cis and trans isomers, 7.Og.
Description 5. cis/trans-Λ -(4-Methoxycyclohexyl)-4-piperidinamine dihydrochloride (D5)
Figure imgf000051_0001
A mixture of cis/trans 1 ,1-dimethylethyl [1-(4-methoxycyclohexyl)-4-piperidinyl]carbamate (D4, 7.Og; 22mmol), dichloromethane (50ml) and 4M HCI in dioxane (25ml; l OOmmol) was maintained at room temperature for 4h. Evaporation gave the title compound, 6.3g.
Description 6. cis and frans-Λ/-(5-Methyl-2-nitrophenyl)-1 -(4-methoxycyclohexyl)-4- piperidinamine (D6a, D6b)
Figure imgf000051_0002
A stirred solution of 3-fluoro-4-nitrotoluene (0.87g) in dimethylformamide (25ml) at room temperature under argon was treated with diisopropylethylamine (2.9ml) and 1-[4- (methoxy)cyclohexyl]-4-piperidinamine dihydrochloride (D5, cis:trans mixture, 1.2g) and heated at 550C over a weekend. The cooled reaction was diluted with ethyl acetate and washed three times with water and once with brine, then dried, evaporated and chromatographed (Biotage KP-NH™-silica column eluting with 0-25% ethyl acetate/hexane) to give the cis (D6a, 300mg) and trans (D6b, 100mg) isomers of the title compound.
Description 7. c/s-5-Methyl-Λ/-[1 -(4-methoxycyclohexyl)-4-piperidinyl]-1,2- benzenediamine (D7)
Figure imgf000052_0001
A stirred suspension of cis Λ/-(5-methyl-2-nitrophenyl)-1-(4-methoxycyclohexyl)-4- piperidinamine (D6a, 300mg; 0.9mmol) in EtOH (20ml) at 5O0C was treated with Raney nickel (1.8ml of 50% aqueous suspension) followed by dropwise addition of hydrazine hydrate (0.45ml). The mixture was heated at the same temperature for 1 h, then filtered through Celite and the filtrate evaporated, and re-evaporated from first toluene and then diethyl ether, to afford the title compound, 320mg.
Description 8. frans-5-Methyl-Λ/-[1 -(4-methoxycyclohexyl)-4-piperidinyl]-1 ,2- benzenediamine (D8)
Figure imgf000052_0002
A stirred suspension of trans Λ/-(3-fluoro-5-methyl-2-nitrophenyl)-1-(4-methoxycyclohexyl)- 4-piperidinamine (D6b, 100mg, 0.3 mmol) in ethanol (6ml) at 5O0C was treated with Raney nickel (0.6ml of 10% aqueous suspension) followed by dropwise addition of hydrazine hydrate (0.15ml, 10eq). The mixture was heated at the same temperature for 1 h, then filtered through Kieselguhr and the filtrate evaporated and re-evaporated from toluene then Et2O to afford the title compound, 100mg.
Description 9. 8-(Ethyloxy)-1 ,4-dioxaspiro[4.5]decane (D9)
Figure imgf000053_0001
A stirred solution of 1 ,4-dioxaspiro[4.5]decan-8-ol (D1 , 4.Og, 0.025mol) in N- methylpyrrolidinone (35ml) at 1 O0C under argon was treated portionwise with NaH (1.1 g of 60% oil dispersion, 0.028mol) and maintained for 1 h, then iodoethane (2.6ml, 0.032mol) was added. The mixture was allowed to warm to room temperature and stir for 18h. Further NaH (0.5g of 60% oil dispersion; 0.012mol) was added and the mixture stirred for 0.5h, then more iodoethane (2.0ml; 0.025mol) was added and the mixture maintained at room temperature for 3h. The mixture was cautiously treated with ethanol (1 ml) to destroy excess NaH and then water (300ml) was added and the mixture extracted with hexane (2 x 200ml). The combined extract was washed with water (2 x 200ml), then dried (Na2SO4) and concentrated under vacuum to afford a colourless oil (4.7g) containing the title compound contaminated with mineral oil residues.
1HNMR δ (CDCI3, 400 MHz): 1.20 (3H, t), 1.50-1.60 (2H, m), 1.63-1.77 (2H, m), 1.77-1.90 (4H, m), 3.35-3.43 (1 H, m), 3.49 (2H, q), 3.90-4.00 (4H, m).
Description 10. 4-(Ethyloxy)cyclohexanone (D10)
Figure imgf000053_0002
A solution of 8-(ethyloxy)-1 ,4-dioxaspiro[4.5]decane (D9, 4.7g, 0.025mol) in tetrahydrofuran (10ml) at room temperature under argon was treated with 5M HCI acid
(40ml) and stirred for 18h, at which stage cone. HCI acid (5ml) was added and the mixture stirred at 4O0C for 3.5h to complete the reaction. The resulting mixture was diluted with water (75ml) and extracted with dichloromethane (2 x 80ml). The combined extract was dried (Na2SO4) and carefully concentrated under partial vacuum at <20°C to afford the title compound as a pale yellow oil (3.8g, ~90% purity).
1H NMR D(CDCI3, 400 MHz): 1.25 (3H, t), 1.90-2.00 (2H, m), 2.01-2.13 (2H, m), 2.20-2.32 (2H, m), 2.53-2.65 (2H, m), 3.55 (2H, q), 3.58-3.70 (1 H, m).
Description 11. 1,1-Dimethylethyl {1-[c/s-4-(ethyloxy)cyclohexyl]-4- piperidinyljcarbamate (D11a) and 1 ,1 -dimethylethyl {1-[frans-4- (ethyloxy)cyclohexyl]-4-piperidinyl}carbamate (D11 b)
Figure imgf000053_0003
D11 a D11 b A stirred solution of 4-(ethyloxy)cyclohexanone (D10, 3.5g, ≤0.025 mol) in dichloromethane (100ml) at room temperature under argon was treated with 1 ,1- dimethylethyl 4-piperidinylcarbamate (5.Og, 0.025 mol), followed by portionwise addition over 5 minutes of sodium triacetoxyborohydride (7.4g, 0.035mol), then the resulting mixture stirred well at room temperature for 2Oh. The reaction mixture was treated with methanol (8ml) and the resulting solution allowed to stand for 3 days at room temperature, then 5% Na2CC>3 solution (100ml) was added and the mixture extracted with dichloromethane (200ml). The extract was washed with brine, then dried (Na2SO4) and concentrated under vacuum. The residual yellow oil was dissolved in 60-80 petrol ether (100ml) and allowed to stand at room temperature overnight whereupon the crystals which had formed were filtered off, washed with petrol and dried to give 1.7g of -45:55 mixture of title compound trans isomer and starting 1 ,1-dimethylethyl 4- piperidinylcarbamate. Purification by column chromatography on silica gel eluting with 0- 5% methanol/dichloromethane afforded the pure title compound trans isomer (D11 b) as a white solid (930mg).
1H NMR δ (CDCI3, 400 MHz): 1.15-1.50 (6H, m), 1.18 (3H, t), 1.44 (9H, s), 1.82-2.00 (4H, m), 2.04-2.14 (2H, m), 2.20-2.32 (3H, m), 2.85 (2H, br d), 3.10-3.20 (1 H, m), 3.38-3.50 (1 H, m), 3.50 (2H, q), 4.40 (1 H, br d). Concentration under vacuum of the mother liquors from the crystallisation afforded 6g of a yellow oil containing the title compound cis isomer (D11 a) as -4:1 mixture with the trans isomer.
Description 12. 1-(frans-4-Ethoxycyclohexyl)piperidin-4-amine (D12)
Figure imgf000054_0001
Method A
1 ,1-Dimethylethyl {1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}carbamate (D11 b, 920mg, 4.299 mmol) was dissolved in dichloromethane (6ml) and treated with HCI (21 ml of a 4M solution in 1 ,4-dioxane) at room temperature. The mixture was stirred at room temperature for 1 hour and the solvent was evaporated. The crude was passed through an SCX cartridge to yield the free base title compound as a pale brown powder (865mg, 4.0 mmol, 89%). M+ + H = 227. Method B
A mixture of frans-1 -(4-ethoxycyclohexyl)-4-piperidone (D45, 13.2g), 2M ammonia in methanol (300ml) and 10% palladium on carbon paste (4g) was hydrogenated at 50psi at room temperature overnight, then more 10% palladium on carbon paste (1g) was added and hydrogenated at 50psi over a weekend, then filtered and evaporated to give the title compound (9.5g) as an oil.
Description 13. 1 -[frans-4-(Ethyloxy)cyclohexyl]-Λ/-(5-methyl-2-nitrophenyl)-4- piperidinamine (D13)
Figure imgf000055_0001
To a solution of 1-(frans-4-ethoxycyclohexyl)piperidin-4-amine (D12, 150mg, 0.70 mmol) in dry dimethylformamide (6 ml), diisopropylethylamine (0.1 1 ml, 1eq., 0.70 mmol) and 3- fluoro-4-nitrotoluene (103mg, 1eq., 0.70 mmol) were added at room temperature and the mixture was refluxed at 8O0C for 24 hours. The reaction showed to be incomplete by TLC. The reaction was then completed by microwave at 15O0C for a total of 30 minutes. The crude mixture was then cooled to room temperature and the crude was poured onto water; the aqueous solution was extracted with ethyl acetate (2x) and the organics were alternatively washed with brine and water (2x). The organics were combined, dried over Na2SO4, filtered and the solvent was evaporated to afford the crude product which was purified by chromatography (ethyl acetate/n-hexane) on a Biotage KP-NH™-silica column to yield the title compound as a yellow gum (118 mg, 50%). M+ + H = 362.
Description 14. (2-Amino-5-methylphenyl){1 -[frans-4-(ethyloxy)cyclohexyl]-4- piperidinyljamine (D14)
Figure imgf000056_0001
1 -[frans-4-(Ethyloxy)cyclohexyl]-Λ/-(5-methyl-2-nitrophenyl)-4-piperidinamine (D13,
1 18mg, 0.33 mmol) was dissolved in ethanol (3 ml) and an aqueous suspension of Raney Nickel (1 ml of a 50% suspension) was added at room temperature. The mixture was stirred for 30 minutes at room temperature before adding hydrazine monohydrate (0.15ml, 15eq., 5.0 mmol) over 30 minutes. The reaction was left overnight. The reaction mixture was filtered through celite and the solvent was evaporated to yield the title compound as a brown solid (1 10mg, 100%). M+ + H = 332.
Description 15. cis/trans-Λ -(4-Ethoxycyclohexyl)piperidin-4-amine dihydrochloride salt (D 15)
Figure imgf000056_0002
(D15)
cis/trans-1 ,1-Dimethylethyl {1-[4-(ethyloxy)cyclohexyl]-4-piperidinyl}carbamate (D1 1a, 2.6g, 8.0 mmol) was dissolved in dichloromethane (12 ml) and treated with HCI (35 ml of a 4M solution in 1 ,4-dioxane). The mixture was stirred at room temperature for 1 hour and the solvent was evaporated to yield the title compound as a mixture of the cis/trans isomers (2.17g, 9.631 mmol, 100%). M+ + H = 227.
Description 16. 1 -[c/s-^EthyloxyJcyclohexyll-Λ/^S-methyl^-nitrophenyl)^- piperidinamine (D16)
Figure imgf000057_0001
2-Fluoro-4-methyl-1 -nitrobenzene (300mg, 1 eq.), cis/trans 1-[4-(ethyloxy)cyclohexyl]-4- piperidinamine dihydrochloride (D15, 600mg, 1 eq., 2 mmol) and diisopropylethylamine (1 ml, 3eq.) were partially dissolved in dimethylformamide (2.5 ml) at room temperature and the mixture was heated to 2000C by microwave for 25 minutes. The crude mixture was then cooled to room temperature and poured onto water/brine; the aqueous solution was extracted with ethyl acetate (2x) and the organics were alternatively washed with brine and water (2x). The organics were combined, dried over Na2SO4, filtered and the solvent was evaporated to afford the crude product which was purified by chromatography on a Biotage KP-NH™-silica column to yield the title compound (cis isomer) (160 mg). M+ + H = 362.
Description 17. (2-Amino-5-methylphenyl){1 -[c/s-4-(ethyloxy)cyclohexyl]-4- piperidinyljamine (D17)
Figure imgf000057_0002
1-[c/s-4-(Ethyloxy)cyclohexyl]-Λ/-(5-methyl-2-nitrophenyl)-4-piperidinamine (D16, 160mg, 0.44 mmol) was dissolved in ethanol (3 ml) and an aqueous suspension of Raney Nickel (1 ml of a 50% suspension) was added at room temperature. The mixture was stirred for 30 minutes before adding hydrazine monohydrate (0.21 ml, 15eq., 6.6 mmol) over 30 minutes. The reaction was left overnight. The reaction mixture was filtered through celite and the solvent was evaporated to yield the title compound as a brown solid (147 mg, 100%). M+ + H = 332. Description 18. 8-(Propyloxy)-1,4-dioxaspiro[4.5]decane (D18)
Figure imgf000058_0001
A stirred solution of 1 ,4-dioxaspiro[4.5]decan-8-ol (D1 , 4g, 25.3mmol) and 1- bromopropane (2.78ml, 30.36mmol) in N-methylpyrrolidin-2-one (35ml) at 0°C under argon was treated with NaH (60%, 1.1 g) then warmed up to room temperature and stirred for 3h. 1-bromopropane (1 ml, 10.92mmol) was added and the reaction stirred overnight. Water was added and the mixture was extracted with hexane (20ml x 3). The organic fractions were collected, dried on MgSO4, then concentrated to leave the title compound as a colourless liquid (3.4g, 68% yield). 1 H NMR δ (CDCI3 400MHz): 0.8-0.9 (3H, t), 1.5-1.85 (10H, m), 3.4 (3H, m), 3.9 (4H, m).
Description 19. 4-(Propyloxy)cyclohexanone (D19)
Figure imgf000058_0002
A stirred solution of 8-(propyloxy)-1 ,4-dioxaspiro[4.5]decane (D18, 3.4g, 17mmol) in tetrahydrofuran (35ml) was treated with 5M HCI acid (35ml) and stirred overnight under argon at room temperature. The tetrahydrofuran was partially removed under vacuum, water (~20ml) was added and the solution was extracted with dichloromethane (~20ml x 3), and the extract dried on MgSO4 then concentrated under vacuum to leave the title compound as a pale yellow oil (2.7g, 98%yield). This crude was used for the next step without any further purification.
Description 20. cis/trans-Λ , 1-Dimethylethyl {1-[4-(propyloxy)cyclohexyl]-4- piperidinyljcarbamate (D20)
Figure imgf000059_0001
A stirred solution of 4-propoxycyclohexanone (D19, 2.7g, 0.017 mol) and 1 ,1- dimethylethyl 4-piperidinylcarbamate (3.6g, 0.017 mol) in dichloromethane (30ml) at room temperature under argon was treated with sodium triacetoxyborohydride (3.8g, 0.02 mol), then the resulting mixture stirred well at room temperature overnight. The mixture was treated with water and extracted with dichloromethane (30ml x3) and the organics were collected and dried on MgSO4 then concentrated under vacuum. The crude was eluted on SCX cartridge, firstly with dichloromethane to remove impurities and then with 2M NH3 in methanol for collect the isomer mixture, plus a small amount of starting material. This mixture was chromatographed on a silica column (10Og for 3.4g of crude: 5% to 5% 3CV, 5% to 20% 10CV, 20% to 20% 2CV of 0.4M NH3 in methanol/dichloromethane) to afford 2.1g of the title compound mixture (36% yield).
Description 21. cis/trans-Λ -[4-(Propyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D21)
Figure imgf000059_0002
2HCI (D21 )
A mixture of c/s/frans-1 , 1-dimethylethyl {1-[4-(propyloxy)cyclohexyl]-4- piperidinyl}carbamate (D20, 2.1 g; 6.17mmol) in diethyl ether (15ml) was treated with a 1 M HCI solution in diethyl ether (15ml) under argon at room temperature and stirred overnight. The mixture containing a white precipitate was collected by filtration then dried to afford the title mixture as a white solid (1.2g, 81 %yield).
Description 22. Λ/-(5-Methyl-2-nitrophenyl)-1 -[c/s-4-(propyloxy)cyclohexyl]-4- piperidinamine (D22a) and Λ/-(5-methyl-2-nitrophenyl)-1-[frans-4-
(propyloxy)cyclohexyl]-4-piperidinamine (D22b)
Figure imgf000060_0001
(D22a) (D22b)
A mixture of c/s/frans-1-[4-(propyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D21 , 1.2g, 3.8mmol), 3-fluoro-4-nitrotoluene (570mg, 3.8mmol) and diisopropylethylamine
(2.5ml 14.7mmol; 3eq) in dimethylformamide (20ml) was stirred and heated at 80°C overnight, under argon. The mixture was washed with water and extracted with dichloromethane. The organic layer was eluted through a SCX cartridge and the cis/trans mixture was collected by elution of 2M NH3 in methanol. Separation of isomers was obtained by chromatography on a Biotage KP-NH™-silica column (10Og for 1.4gr of crude: 0% to 20% ethyl acetate/hexane, 20CV). The chromatography was repeated twice affording 410mg of cis isomer and 340mg of trans isomer (55% yield).
Cis (D22a): 1H NMR δ (CDCI3 400MHz): 0.9 (3H, t), 1.2-1.35 (4H, m), 1.55-17 (4H, m), 1.9 (2H, m), 2.1 (4H, m), 2.35 (3H, s), 2.35 (1 H, m), 2.4 (2H, m), 2.9 (2H, m), 3.1-3.2 (1 H, m), 3.4 (2H, t), 3.55 (1 H, m), 6.4 (1 H, d), 6.6 (1 H, s), 8.05 (1 H, d), 8.2 (1 H, d).
MH+ 376 and 377.
Trans (D22b): 1H NMR δ (CDCI3 400MHz): 0.9 (3H, t), 1.4 (2H, m), 1.55-175 (8H, m), 2.0
(2H, m), 2.1 (2H, m), 2.3 (3H, s), 2.4 (1 H, m), 2.5 (2H, m), 2.9 (2H, m), 3.35 (2H, t), 3.5 (1 H, m), 3.55 (1 H, m), 6.4 (1 H, d), 6.6 (1 H, s), 8.05 (1 H, d), 8.2 (1 H, d).
MH+ 376 and 377.
Description 23. (2-Amino-5-methylphenyl){1 -[c/s-4-(propyloxy)cyclohexyl]-4- piperidinyljamine (D23)
Figure imgf000061_0001
A stirred solution of Λ/-(5-methyl-2-nitrophenyl)-1-[c/s-4-(propyloxy)cyclohexyl]-4- piperidinamine (D22a, 440mg, 1.17mmol) in ethanol (30ml) at room temperature under argon was treated with Raney nickel (~50mg) followed by a dropwise addition of hydrazine hydrate (2ml, 30.4mmol) and heated at 50°C for 3h. The solution was filtered through a Kieselguhr pad and then concentrated under vacuum to leave 400mg (98% yield) of the title compound as a pale yellow oil. MH+ 346 and 347.
Description 24. (2-Amino-5-methylphenyl){1 -[frans-4-(propyloxy)cyclohexyl]-4- piperidinyljamine (D24)
Figure imgf000061_0002
A stirred suspension of Λ/-(5-methyl-2-nitrophenyl)-1-[frans-4-(propyloxy)cyclohexyl]-4- piperidinamine (D22b, 340mg, 0.9mmol) in ethanol (20ml) at room temperature under argon was treated with Raney nickel (~30mg) followed by a dropwise addition of hydrazine hydrate (0.28ml, 9.5mmol) and heated at 50°C for 3h. The solution was filtered through a Kieselguhr pad and then concentrated under vacuum to leave 310mg (99% yield) of title compound as a pale yellow oil. MH+ 346 and 347.
Description 25. 8-[(1-Methylethyl)oxy]-1 ,4-dioxaspiro[4.5]decane (D25)
Figure imgf000062_0001
A mixture of 1 ,4-dioxaspiro[4.5]decan-8-ol (D1 , 5.Og, 0.032mol), 2-iodopropane (25ml) and silver (I) oxide (14g, O.OδOmol) at room temperature under argon was stirred in the dark for 6 days, followed by 6 days standing. The mixture was treated with diethyl ether
(40ml) and filtered through Kieselguhr washing well with diethyl ether. The filtrate was concentrated under vacuum and the residue dissolved in hexane (150ml), washed with water (150ml), then dried (Na2SO4) and concentrated under vacuum to afford a colourless oil (4.89g) containing approx. 80% of the title compound together with 4-[(1- methylethyl)oxy]cyclohexanone from ketal hydrolysis. This mixture was used in the next step without purification.
1H NMR δ (CDCI3, 400 MHz): 1.13 (6H, d), 1.5-1.59 (2H, m), 1.60-1.74 (2H, m), 1.75-1.88
(4H, m), 3.43-3.50 (1 H, m), 3.62-3.72 (1 H, m), 3.90-4.00 (4H, m).
Description 26. 4-[(1-Methylethyl)oxy]cyclohexanone (D26)
Figure imgf000062_0002
A solution of the mixture of 8-[(1-methylethyl)oxy]-1 ,4-dioxaspiro[4.5]decane and 4-[(1- methylethyl)oxy]cyclohexanone (~4:1 ) (D25 , 4.89g, ~0.025mol) in tetrahydrofuran (10ml) at room temperature under argon was treated with 5M HCI acid (50ml) and stirred well for 18h. The reaction mixture was treated with water (150ml) and extracted with dichloromethane (2 x 80ml). The combined extract was washed with brine, dried (Na2SO4) and concentrated under vacuum to afford the title compound as a colourless oil (3.9g, 100%).
1H NMR δ (CDCI3, 400 MHz): 1.19 (6H, d), 1.88-2.08 (4H, m), 2.22-2.32 (2H, m), 2.54- 2.65 (2H, m), 3.70-3.84 (2H, m).
Description 27. 1 ,1 -Dimethylethyl (1-{c/s-4-[(1-methylethyl)oxy]cyclohexyl}-4- piperidinyl)carbamate (D27a) and 1,1-dimethylethyl (1-{frans-4-[(1 - methylethyl)oxy]cyclohexyl}-4-piperidinyl)carbamate (D27b)
Figure imgf000062_0003
D27a D27b
A stirred solution of 4-[(1-methylethyl)oxy]cyclohexanone (D26, 3.9g, 0.025 mol) in dichloromethane (100ml) at room temperature under argon was treated with 1 ,1- dimethylethyl 4-piperidinylcarbamate (5.Og, 0.025 mol), followed by portionwise addition over 10 minutes of sodium triacetoxyborohydride (7.4g, 0.035mol). Further dichloromethane (50ml) was added to aid stirring which was continued at room temperature for 18h. The reaction mixture was carefully treated with methanol (5ml) and stirred for 20 minutes, then 2% Na2CO3 solution (200ml) was added and the mixture extracted with dichloromethane (2 x 150ml). The combined extract was washed with brine, then dried (Na2SO4) and concentrated under vacuum. The residual yellow oil (8.6g) was triturated with 60-80 petrol ether (80ml) which caused immediate crystallisation of a white solid. This was filtered off, washed with 60-80 petrol ether and dried, then recrystallised from 9:1 60-80 petrol ether/dichloromethane to afford the title compound trans isomer (D27b) as a white solid (0.85g).
1H NMR δ (CDCI3, 400 MHz): 1.12 (6H, d), 1.18-1.50 (6H, m), 1.44 (9H, s), 1.80-2.05 (6H, m), 2.20-2.32 (3H, m), 2.80-2.90 (2H, m), 3.15-3.26 (1 H, m), 3.38-3.50 (1 H, m), 3.64-3.73 (1 H, m), 4.37-4.47 (1 H, m).
Concentration under vacuum of the mother liquors from the first crystallisation afforded 7.3g of a yellow oil containing the title compound cis isomer (D27a) as -4:1 mixture with the trans isomer.
Description 28. 1 -{frans-4-[(1 -Methylethyl)oxy]cyclohexyl}-4-piperidinamine dihydrochloride (D28)
Figure imgf000063_0001
(D28)
A stirred solution of 1 ,1 -dimethylethyl (1-{frans-4-[(1-methylethyl)oxy]cyclohexyl}-4- piperidinyl)carbamate (D27b, 850mg, 2.5mmol) in dichloromethane (10ml) at room temperature under argon was treated with 4M HCI/dioxane (5ml; 20mmol) and maintained for 18h, then concentrated under vacuum. The residue was treated with diethyl ether (20ml), stirred for 5 minutes, then the solid filtered off, washed with diethyl ether and then dried to afford the title compound as a white solid (730mg, 93%).
1H NMR δ (d6DMSO, 400 MHz): 1.05 (6H, d), 1.08-1.22 (2H, m), 1.43-1.60 (2H, m), 1.93- 2.20 (8H, m), 2.98-3.15 (3H, m), 3.20-3.55 (5H, m), 3.62-3.72 (1 H, m), 8.46 & 8.60 (together 3H, 2 x brs), 10.84 & 10.95 (together 1 H, 2 x brs). Description 29. cis/trans-Λ -{4-[(1 -Methylethyl)oxy]cyclohexyl}-4-piperidinamine dihydrochloride (D29)
Figure imgf000064_0001
2HCI (D29)
A solution of cis/trans 1 ,1-dimethylethyl (1-{cis-4-[(1-methylethyl)oxy]cyclohexyl}-4- piperidinyl)carbamate (D27a, -4:1 cis:trans, 7.3g, 0.021 mol) in dichloromethane (50ml) at room temperature under argon was treated with 4M HCI/dioxane (30ml; 0.12mol) and stirred well for 18h. The mixture containing a white precipitate was concentrated under vacuum and the residue treated with diethyl ether (100ml), stirred well for 5 minutes, then the solid filtered off, washed with diethyl ether and dried to afford the title compound (-4:1 mixture of cis:trans isomers) as a white solid (4.46g, 67%).
Description 30. 1 -{frans-4-[(1 -Methylethyl)oxy]cyclohexyl}-Λ/-(5-methyl-2- nitrophenyl)-4-piperidinamine (D30)
Figure imgf000064_0002
A stirred mixture of 3-fluoro-4-nitrotoluene (155mg, I .Ommol), diisopropylethylamine (0.53ml, 3.0mmol) and 1-{frans-4-[(1-methylethyl)oxy]cyclohexyl}-4-piperidinamine dihydrochloride (D28, 250mg, O.δOmmol) in dimethylformamide (5ml) under argon was heated at 2000C for 10 minutes in a microwave reactor. The resulting mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution and extracted with dichloromethane. The extract was dried, concentrated under vacuum and the residue loaded onto a SCX cartridge (10g), which was washed with dichloromethane followed by methanol to remove non-basic contaminants, then with 2M NH3/methanol to remove the product. Further purification by chromatography on silica gel (2Og) eluting with 0-5% methanol/dichloromethane afforded the title compound as a dark orange solid (220mg, 74%). 1H NMR δ (CDCI3, 400 MHz): 1.14 (6H, d), 1.20-1.38 (4H, m), 1.58-1.72 (2H, m), 1.86- 1.96 (2H, m), 2.00-2.12 (4H, m), 2.27-2.37 (1 H, m), 2.33 (3H, s), 2.38-2.48 (2H, m), 2.83- 2.93 (2H, m), 3.19-3.29 (1 H, m), 3.50-3.60 (1 H, m), 3.65-3.77 (1 H, m), 6.43 (1 H, dd), 6.61 (1 H, s), 8.06 (1 H, d), 8.19 (1 H, d).
Description 31. (2-Amino-5-methylphenyl)(1-{frans-4-[(1- methylethyl)oxy]cyclohexyl}-4-piperidinyl)amine (D31 )
Figure imgf000065_0001
A stirred suspension of 1-{frans-4-[(1-methylethyl)oxy]cyclohexyl}-Λ/-(5-methyl-2- nitrophenyl)-4-piperidinamine (D30, 220mg, 0.59mmol) in ethanol (15ml) at room temperature under argon was treated with Raney nickel (~20mg) followed by dropwise addition of hydrazine hydrate (0.18ml, δ.Ommol). The mixture was maintained at room temperature for 3h, then filtered through Kieselguhr to remove the catalyst and the filtrate concentrated under vacuum to afford the title compound as a pale grey solid (187mg, 92%).
1H NMR δ (CDCI3, 400 MHz): 1.14 (6H, d), 1.18-1.37 (4H, m), 1.42-1.56 (2H, m), 1.87- 1.97 (2H, m), 1.98-2.12 (4H, m), 2.25 (3H, s), 2.27-2.42 (3H, m), 2.85-2.95 (2H, m), 3.00- 3.30 (4H, br m), 3.63-3.75 (1 H, m), 6.43-6.49 (2H, m), 6.62 (1 H, dd).
Description 32. cis/trans-Λ , 1-Dimethylethyl [1-(1-cyano-4-methoxycyclohexyl)-4- piperidinyljcarbamate (D32)
Figure imgf000065_0002
(D32)
Potassium cyanide (320mg; 5 mmol) was added to a mixture of 1 ,1-dimethylethyl 4- piperidinylcarbamate (1.Og), 4-(methyloxy)cyclohexanone (D3; 640mg; 5 mmol), and 2.5M hydrochloric acid (2.0ml; 5 mmol). After 2h at room temperature the mixture was partitioned between water and dichloromethane. Drying and evaporation gave the title compound as a mixture of cis and trans isomers, 1.1g.
Description 33. cis/trans-Λ, 1 -Dimethylethyl [1-(1-methyl-4-methoxycyclohexyl)-4- piperidinyljcarbamate (D33)
Figure imgf000066_0001
(D33)
Methyl magnesium bromide (5.0ml of 3M solution in diethyl ether) was added to a solution of c/s/frans-1 ,1-dimethylethyl [1-(1-cyano-4-methoxycyclohexyl)-4-piperidinyl]carbamate (D32, mixture of isomers) (1.1 g; 3.3 mmol) in tetrahydrofuran (25ml). After 2h at room temperature the solution was partitioned between an aqueous solution of Rochelle salt and dichloromethane. Drying, evaporation and chromatography (5Og silica, 0 to 10% methanol in dichloromethane) gave the title compound as a mixture of cis and trans isomers, 400mg.
Description 34. cis/trans-1 -[1 -Methyl-4-(methyloxy)cyclohexyl]-4-piperidinamine (D34)
Figure imgf000066_0002
(D34)
c/s/frans-1 , 1-Dimethylethyl {1-[1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}carbamate (D33, 360 mg, 1.1 mmol), was dissolved in dichloromethane (5 ml) and HCI (10 eq., 1 1 mmol, 2.8 ml of a 4M solution in 1 ,4-dioxane) was added at room temperature; the mixture was stirred at room temperature overnight. The solvent was subsequently evaporated to afford the crude product which was purified by SCX to afford the title compound, 200 mg, 60 %.
1H NMR δ (d6DMSO, 400 MHz) 0.750 (3H, d), 1.100(3H, m), 1.522 (9H, m), 1.838 (1 H, d), 1.973 (2H, m), 2.433 (1 H, m), 2.770 (2H, t), 3.121 (1 H, m), 3.195 (3H, d), 3.329 (1 H, s br).
Description 35. cis and frans-1-[1-Methyl-4-(methyloxy)cyclohexyl]-Λ/-(5-methyl-2- nitrophenyl)-4-piperidinamine (cis = D35a, trans = D35b)
Figure imgf000067_0001
(D35a) (D35b)
2-Fluoro-4-methyl-1-nitrobenzene (1 eq., 136 mg), cis/trans 1-[1-methyl-4- (methyloxy)cyclohexyl]-4-piperidinamine (D34, 1 eq., 200 mg, 0.88 mmol), Hunig's base diisopropylethylamine (1eq., 150 μl), were all dissolved in dimethylformamide (3 ml) at room temperature and the mixture was refluxed at 100 0C overnight. The crude mixture was then cooled to room temperature and poured onto brine; the aqueous solution was extracted with ethyl acetate (3x) and the organics were alternatively washed with brine and water. The organics were combined, dried over Na2SO4, filtered and the solvent was evaporated to afford the crude product which was purified by chromatography on silica column (methanol-NH3-dichloromethane) to yield the two separate isomers, (cis, D35a, 118 mg) and {trans, D35b, 61 mg), 56% total yield, M+ + H = 362.
Description 36. (2-Amino-5-methylphenyl){1-[c/s-1-methyl-4-(methyloxy)- cyclohexyl]-4-piperidinyl}amine (D36)
Figure imgf000067_0002
1-[c/s-1-Methyl-4-(methyloxy)cyclohexyl]-Λ/-(5-methyl-2-nitrophenyl)-4-piperidinamine
(D35a, 118 mg, 0.327 mmol,) was dissolved into ethanol (8ml) and Raney-Ni (0.3 ml of a 50% aqueous suspension) was added at room temperature; the mixture was heated to 5O0C and hydrazine hydrate (10 eq., 3.2 mmol, 0.1 ml) was added dropwise at 5O0C. Reaction was stirred at 5O0C until no more starting material was observed by TLC. The mixture was cooled to room temperature and filtered through celite; the solvent was subsequently evaporated to afford the title compound, 91 mg, 84%, M+ + H = 332.
Description 37. (2-Amino-5-methylphenyl){1 -[frans-1 -methyl-4-(methyloxy)- cyclohexyl]-4-piperidinyl}amine (D37)
Figure imgf000068_0001
1-[frans-1-Methyl-4-(methyloxy)cyclohexyl]-Λ/-(5-methyl-2-nitrophenyl)-4-piperidinamine (D35b, 60 mg, 0.166 mmol,) was dissolved into ethanol (4 ml) and Raney-Ni (0.2 ml of a 50% aqueous suspension) was added at room temperature; the mixture was heated to 5O0C and hydrazine hydrate (10 eq., 1.6 mmol, 0.05 ml) was added dropwise at 5O0C. Reaction was stirred at 5O0C until no more starting material was observed by TLC. The mixture was cooled to room temperature and filtered through celite; the solvent was subsequently evaporated to afford the title compound, 30 mg, 55%, M+ + H = 332.
Description 38. 1 -{c/s-4-[(1 -Methylethyl)oxy]cyclohexyl}-Λ/-(5-methyl-2-nitrophenyl)- 4-piperidinamine (D38)
Figure imgf000068_0002
A stirred mixture of 3-fluoro-4-nitrotoluene (250mg, 1.6mmol), diisopropylethylamine (0.86ml, 4.8mmol) and cis/trans-1-{4-[(1-methylethyl)oxy]cyclohexyl}-4-piperidinamine dihydrochloride (D29, ~4:1 cis/trans, 400mg, 1.3mmol) in dimethylformamide (8ml) under argon was heated at 2000C for 12 minutes in a microwave reactor. The resulting mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution and extracted with dichloromethane. The extract was dried, concentrated under vacuum and the residue loaded onto a SCX cartridge (2Og), which was eluted with dichloromethane followed by methanol to remove non-basic contaminants, then with 2M NH3/methanol to remove the product. The product solution was concentrated under vacuum and the residue chromatographed on Biotage KP-NH™-silica column (100g) eluting with 0-20% ethyl acetate/hexane to obtain the title compound as the fastest eluting isomer. This was obtained as an orange oil (186mg, 38%).
1HNMR δ (CDCI3, 400 MHz): 1.14 (6H, d), 1.33-1.46 (2H, m), 1.52-1.78 (6H, m), 1.80-1.96 (2H, m), 2.02-2.12 (2H, m), 2.28-2.40 (1 H, m), 2.33 (3H, s), 2.40-2.50 (2H, m), 2.82-2.93 (2H, m), 3.48-3.68 (3H, m), 6.42 (1 H, dd), 6.62 (1 H, s), 8.05 (1 H, d), 8.19 (1 H, d).
Description 39. (2-Amino-5-methylphenyl)(1 -{c/s-4-[(1 -methylethyl)oxy]-cyclohexyl}- 4-piperidinyl)amine (D39)
Figure imgf000069_0001
A stirred suspension of 1-{c/s-4-[(1-methylethyl)oxy]cyclohexyl}-Λ/-(5-methyl-2- nitrophenyl)-4-piperidinamine (D38, 186mg, 0.50mmol) in ethanol (15ml) at room temperature under argon was treated with Raney nickel (~20mg) followed by dropwise addition of hydrazine hydrate (0.15ml, δ.Ommol). The mixture was maintained at room temperature for 2h, then filtered through Kieselguhr to remove the catalyst and the filtrate concentrated under vacuum to afford the title compound as a grey oil (170mg, 99%). 1H NMR δ (CDCI3, 400 MHz): 1.13 (6H, d), 1.33-1.80 (8H, m), 1.85-1.96 (2H, m), 2.02- 2.12 (2H, m), 2.25 (3H, s), 2.29-2.42 (3H, m), 2.88-2.98 (2H, m), 3.05-3.40 (4H, br m), 3.53-3.70 (2H, m), 6.41-6.50 (2H, m), 6.61 (1 H, d).
Description 40. frans-N-(4-Hydroxycyclohexyl)phthalimide (D40)
Figure imgf000069_0002
N-Ethoxycarbonylphthalimide (100g; 0.46 mol) was added to a mixture of trans-4- hydroxycyclohexylamine hydrochloride (69g; 0.46 mol), potassium carbonate (158g;
1.15mol) and water (11) at room temperature. After stirring for 3h the title compound was isolated by filtration, washing with water then ethyl acetate, 95g.
Description 41. frans-N-(4-tert-Butyldimethylsilyloxycyclohexyl)phthalimide (D41)
Figure imgf000070_0001
)
Tert-butyldimethylsilyl chloride (6Og; 0.39mol) was added in portions to a mixture of trans N-(4-hydroxycyclohexyl)phthalimide (D40, 95g; 0.39mol), imidazole (55g; 0.78mol), and DMF (200ml) at 20-300C (internal, ice cooling). After stirring for 3h more at 400C the mixture was partitioned water/hexane. Drying and evaporation of the organic layer gave the title compound crystallised from pentane, 92g.
Description 42. frans-N-(4-Ethoxycyclohexyl)phthalimide (D42)
Figure imgf000070_0002
Acetaldehyde (10ml; 0.17mol) in acetonitrile (50ml) was added over 30 minutes to a solution of frans-N-(4-tert-butyldimethylsilyloxycyclohexyl)phthalimide (D41 ; 50.Og; 0.14mol), bismuth tribromide (6.7g; 0.015mol), triethylsilane (27ml; 0.18mol) in acetonitrile (500ml) stirred at ice bath temperature and the mixture was allowed to warm to room temperature overnight. The mixture was filtered and the resulting grey solid and filtrate were worked up separately. The filtrate was evaporated and treated with hexane to give the title compound as a white solid (16.35g). The grey solid washed with dichloromethane, the dichloromethane extract was evaporated and the residue was stirred with hexane (200ml) to give a second crop of the title compound as a white solid (17.47g).
Description 43. frans-4-Ethoxycyclohexylamine (D43)
Figure imgf000071_0001
(D43)
A solution of frans-N-(4-ethoxycyclohexyl)phthalimide (D42, 16.35g), hydrazine hydrate (12ml) in ethanol (300ml) and methanol (200ml) was stirred at reflux for 3 hours. The solvent was removed to give a slurry, which was treated with diethyl ether and filtered. The filtrate was evaporated to afford the title compound as a viscous oil contaminated with ether (8.16g).
Description 44. 1-Ethyl-1-methyl-4-oxopiperidinium iodide (D44)
Figure imgf000071_0002
lodomethane (65ml; LOOmol) was added in portions to a solution of 1-ethyl-4-piperidone (100g; 0.79mol) in acetone (1 L) at 20-300C (internal, ice cooling). After stirring for 3h more the title compound was obtained by filtration, and washing with acetone (189g).
Description 45. frans-1-(4-Ethoxycyclohexyl)-4-piperidone (D45)
Figure imgf000071_0003
A mixture of 1-ethyl-4-piperidone methiodide (D44, 27g), frans-4-ethoxycyclohexylamine (D43, 8.16g, 0.065mol), potassium carbonate (13.5g), water (100ml), and ethanol (200ml) was heated for 3 hours at 800C, then cooled overnight. The mixture was partitioned with aqueous sodium bicarbonate and dichloromethane. The dichloromethane layer was separated, washed with brine and solvent removed to give the title compound as a amber coloured oil (13.2g). Description 46. frans-N-(4-Propoxycyclohexyl)phthalimide (D46)
Figure imgf000072_0001
A solution of frans-N-(4-tert-butyldimethylsilyloxycyclohexyl)phthalimide (D41 , 45g) in acetonitrile (500ml) at room temperature was treated sequentially with triethylsilane (24ml), bismuth tribromide (6g), and (dropwise) propanal (1 1 ml) at 20-300C (internal, ice cooling). After 30min more the solution was partitioned aqueous sodium bicarbonate / ethyl acetate. Drying and evaporation of the organic layer gave the title compound crystallised from pentane, 2Og.
Description 47. frans-4-Propoxycyclohexylamine (D47)
Figure imgf000072_0002
NH2 (D47)
A mixture of frans-N-(4-propoxycyclohexyl)phthalimide (D46, 2Og), hydrazine hydrate (15ml), and ethanol (400ml) was heated at at 800C for 2h then cooled and filtered. The filtrate was evaporated and the resulting residue redissolved in diethyl ether, filtered and again evaporated to give the title compound, 1 1g.
Description 48. frans-1-(4-Propoxycyclohexyl)-4-piperidone (D48)
Figure imgf000072_0003
1 -Ethyl-4-piperidone methiodide (D44, 26g) was added to a refluxing mixture of trans-4- propoxycyclohexylamine (D47, 11g), , potassium carbonate (1g), water (75ml), and ethanol (150ml) over 30min, and the mixture was then heated for another 30min at 800C, then cooled, partitioned aqueous sodium bicarbonate / dichloromethane, and purified by chromatography (40+M Biotage silica column, 0 to 10% methanol in dichloromethane containing 0.2M ammonia) to give the title compound, 8g.
Description 49. frans-1-(4-Propoxycyclohexyl)-4-piperidinamine dihydrochloride (D49)
Figure imgf000073_0001
A mixture of frans-1 -(4-propoxycyclohexyl)-4-piperidone (D48, 7.5g), 2M ammonia in methanol (100ml), and 10% palladium on carbon paste (100mg) was hydrogenated at 50psi at room temperature for 18h then filtered and evaporated. The residue was converted to the dihydrochloride salt to give the title compound, crystallised from diethyl ether, 7.5g.
Description 50. c/s/frans-Ethyl 4-{[(1,1 - dimethylethyl)(dimethyl)silyl]oxy}cyclohexanecarboxylate (D50)
Figure imgf000073_0002
Chloro(1 ,1-dimethylethyl)dimethylsilane (115g; 0.76mol) was added in portions over 1 hour to a solution of ethyl 4-hydroxycyclohexanecarboxylate (118g; 0.68mol), imidazole
(103g; 1.52mol) and dimethylformamide (400ml) stirred under an atmosphere of argon. A small exotherm was observed resulting in the reaction mixture temperature increasing to
~40°C. The mixture was stirred at room temperature overnight then poured into 10% citric acid solution (2L) and extracted with diethyl ether (2 x 800ml). The ether extracts were washed with water, brine and then dried (Na2SO4) and the solvent was removed to give the title compound as a oil (198.4g) 1H NMR δ (CDCI3, 400 MHz): 0.01 (6H, m), 0.85 (9H, s), 1.2 (3H, m), 1.3-1.5 (2H, m), 1.6 (2H, m), 1.85-2 (3H, m), 2.15-2.3 (1 H, m) 3.5 (0.4H, m) 3.86 (1 H, m) 4.1 (1 H, m).
Description 51. c/s/frans-Ethyl 4-(ethyloxy)cyclohexanecarboxylate (D51)
Figure imgf000074_0001
cis/trans ethyl 4-{[(1 ,1-dimethylethyl)(dimethyl)silyl]oxy}cyclohexanecarboxylate (D50, 35g, 122 mmol) was dissolved in CH3CN (250 ml) and Et3SiH (1.2 eq., 146 mmol, 23ml), BiBr3 (4% mol, 4.9 mmol, 2.2 g) were added dropwise at room temperature followed by acetaldehyde (1.2 eq., 8.2 ml) that was slowly added at 250C. The mixture was stirred at room temperature for 1 hour. The mixture was subsequently poured onto an aqueous saturated solution of NaHCO3 and the mixture obtained was then extracted with EtOAc (3x). Organics were combined, washed with brine, dried over Na2SO4, filtered and the solvent was evaporated to afford the crude mixture that was purified by silica chromatography (Biotage 65i column, EtOAc-nhex) to afford the title compound, 21 g, 87%.
1H NMR δ (DMSO, 400 MHz): 1.1 (3H, m), 1.15 (3H, m), 1.492-3.212 (assume 10 H, set of broad signals and multiplets), 3.312 (2 H, m), 4.041 (2H, m).
Description 52. c/s/frans-4-(Ethyloxy)cyclohexanecarboxylic acid (D52)
Figure imgf000074_0002
c/s/frans-ethyl 4-(ethyloxy)cyclohexanecarboxylate (D51 , 21 g, 105 mmol) was dissolved in MeOH-THF (100 ml-100 ml) and NaOH (5 eq., 0.5 mol, 40 ml, 12.5N aqueous solution) was slowly added at room temperature. The mixture was stirred at room temperature overnight. The THF/MeOH was then evaporated and the crude was washed with Et2O. The aqueous phase was acidified and extracted with EtOAc (2x); organics were dried over Na2SO4, filtered and the solvent was evaporated to afford the title compound as a pale- yellow oil, 17.3 g, 96%.
1H NMR δ (DMSO, 400 MHz): 1.1 (3H, m), 1.3-3.201 (assume 10 H, set of broad signals and multiplets), 3.417 (2H, m), 12.1 (1 H, s broad).
Description 53. c/s/frans-4-(Ethyloxy)-1-methylcyclohexanecarboxylic acid (D53)
Figure imgf000075_0001
A stirred solution of diisopropylamine (2.3 eq., 0.231 mol, 33 ml) in dryTHF (400ml) at - 2O0C under argon was treated over 10 min with 2.5M n-butyllithium in hexane (2.3 eq., 93 ml; 0.231 mol), then allowed to warm to O0C and stir for 15 mins. The mixture was recooled to -1 O0C and treated over 10 min with a solution of cis/trans-4- (ethyloxy)cyclohexanecarboxylic acid (D52, 17.3g, 0.1 mol) in -50 ml of dry THF. The resulting yellow solution was heated at 5O0C for 2.5hrs, then cooled to O0C and treated with iodomethane (3 eq., 0.3 mol, 19 ml). The mixture was allowed to warm to room temperature and stir overnight. The mixture was cooled to 1O0C, treated with 10% citric acid solution (200ml), and then solvent evaporated to half volume concentrated under vacuum. The residual mixture was diluted with water (200ml) and extracted with Et2O (2x). The combined extracts were washed with water (150ml x 2), dried (Na2SO4), filtered and concentrated under vacuum to leave the title compound as a yellow oil, 16.2 g, 87%, a mixture of cis:trans isomers.
1H NMR δ (DMSO, 400 MHz): 1.086 (assume 8H, m), 1.510 (3H, m), 1.698 (1 H, m), 1.781 (1 H, m), 2.005 (1 H, m), 3.191 (1/2H, m), 3.392 (2H, m), 3.606 (1/2H, m), 12.2 (1 H, s br).
Description 54. frans-4-(Ethyloxy)-1 -methylcyclohexanecarboxylic acid (D54)
Figure imgf000075_0002
c/s/frans-4-(ethyloxy)-1-methylcyclohexanecarboxylic acid (D53, 16.2 g, 87.1 mmol) was dissolved in thionyl chloride (15 eq., 1.31 mol, ~95 ml) at at room temperature and it was subsequently reluxed at 850C for 4 hrs. The mixture was then allowed to cool to room temperature and the thionyl chloride was azeotropically evaporated with toluene. The residue was dissolved in THF (100ml), treated with a 5 % aqueous solution of Na2COs (500 ml) and stirred well at room temperature for 20 minutes. The aqueous residue washed with Et2O (2), then acidified and extracted with EtOAc (3x). The combined extracts were dried (Na2SO4), filtered and concentrated under vacuum to leave the title compound, 6.5 g, 40%
1H NMR δ (DMSO, 400 MHz): 1.076 (6H, m), 1.505 (6H, m), 1.693 (2H, m), 3.331 (1 H, m), 3.394 (2H1 q), 12.1 (1 H, s br).
Description 55. frans-4-(Ethyloxy)-1 -isocyanato-1 -methylcyclohexane (D55)
Figure imgf000076_0001
A stirred solution of frans-4-(ethyloxy)-1-methylcyclohexanecarboxylic acid (D54, 5.5g, 29.5mmol) in toluene (120ml) at room temperature under argon was treated with triethylamine (1.3 eq., 37.7 mmol, 5.3 ml) and diphenylphosphoryl azide (1eq., 29.5 mmol, 6.4 ml) and heated at 850C for 1 hr. The mixture was allowed to cool to room temperature, then treated with 1 M NaOH solution (300ml) and extracted with Et2O (3x). The combined extract was dried (Na2SO4), filtered and concentrated under vacuum to leave the title compound, 5 g, 94 %. 1H NMR δ (DMSO, 400 MHz): 1.092 (3H, t), 1.330 (3H, s), 1.487-1.691 (8H, m), 3.392 (2H, q), 3.477 (1 H, m).
Description 56. [frans-4-(Ethyloxy)-1 -methylcyclohexyl]amine mono hydrochloride (D56)
O ' NH,
HCl (D56)
A solution of frans-4-(ethyloxy)-1-isocyanato-1-methylcyclohexane (D55, 5.Og, 27.3 mmol) in THF (100ml) was treated with 5M aqueous HCI acid (5.5 eq., 150 mmol, 30 ml) and stirred at room temperature under argon overnight, then concentrated under vacuum. The residual semi-solid was triturated with Et2O to give a first batch of title compound as a white solid, 2.8 g. The mother liquors were evaporated, dissolved in THF again (50 ml) and treated with 5M aqueous HCI acid (15 ml) and the mixture stirred over a weekend at room temperature. The solvent was then evaporated and the solid obtained was dried in the oven at 5O0C before trituration with Et2O. This final trituration afforded further 646 mg of title compound.
1H NMR δ (DMSO, 400 MHz): 1.084 (3H, t), 1.256 (3H, s), 1.378 (2H, m), 1.619 (4H, m), 1.847 (2H, m), 3.243 (1 H, m), 3.424 (2H, q), 8.090 (3H, br s).
Description 57. 1 -[frans-4-(Ethyloxy)-1 -methylcyclohexyl]-4-piperidinone (D57)
Figure imgf000076_0002
A stirred solution of [frans-4-(ethyloxy)-1-methylcyclohexyl]amine mono hydrochloride (D56, 3.44 g, 17.8 mmol) in a mixture of ethanol (216 ml) and water (108 ml) at room temperature under argon was treated with potassium carbonate (1.1 eq., 19.6 mmol, 2.7g) followed by 1-ethyl-1-methyl-4-oxopiperidinium iodide (D44, 1 .5 eq., 26.7 mmol, 7.1g), then heated at 8O0C for 2 hours. The mixture was allowed to cool to room temperature then the aqueous residue was treated with sat. NaHCOs solution and extracted with dichloromethane (3x). The combined extracts were dried (Na2SO4) and concentrated under vacuum to leave the crude compound which was chromatographed on silica gel (Biotage 65i column) eluting with 0-10% MeOH/NH3/DCM to afford the title compound, 2.3 g, 54%.
1H NMR δ (DMSO, 400 MHz): 0.855 (3H, s), 1.099 (3H, t), 1 .421 (2H, m), 1 .544 (4H, m), 1.793 (2H, m), 2.297 (4H, t), 2.726 (4H, t), 3.377-3.430 (3H, t + m).
Description 58. 1 -[frans-4-(Ethyloxy)-1 -methylcyclohexylj^-piperidinamine dihydrochloride (D58)
Figure imgf000077_0001
2HCI (D58)
A solution of 1 -[frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinone (2.3g, 9.62 mmol) in 2M NHs/MeOH (200ml) was treated with 10% Pd/C (510 mg) and shaken under hydrogen atmosphere at 50psi initial pressure overnight at room temperature. The mixture was filtered through Kieselguhr to remove catalyst and the filtrate concentrated under vacuum to leave the free base of the title compound. This was treated with 10 ml of HCI (1 M solution of in Et2O) and stirred in MeOH (20 ml) for 10 min. Solvent was subsequently evaporated to afford the title compound as a white solid 2.8 g, complete conversion. 1H NMR δ (DMSO, 250 MHz, at 352.2K): 1 .091 (6H, m br), 1.336 (2H, m), 1.695-1 .865 (7H, m), 2.067 (2H, d br), 2.531 (1 H, br), 3.187-3.317 (assume 6H, set of broad signals and multiplets), 3.434 (2H, q), 8.496 (2H, s br).
Description 59. c/s-4-(Ethyloxy)-1 -isocyanato-1 -methylcyclohexane (D59)
Figure imgf000077_0002
A stirred solution of cis/frans-4-(ethoxy)-1 -methylcyclohexanecarboxylic acid (D53, 2.Og, 10.7mmol) in toluene (40ml) at room temperature under argon was treated with triethylamine (1 .95ml, 14.0mmol) and diphenylphosphoryl azide (2.3ml, 10.7mmol) and heated at 8O0C for 45 mins. The mixture was allowed to cool to room temperature, then treated with 1 M NaOH solution (50ml) and Et2O (50ml), shaken well and the organic solution separated, dried (Na2SO4) and concentrated under vacuum to leave a yellow oil (1.7g), which was chromatographed on silica gel (4Og) eluting with 0-10% EtOAc/hexane. This afforded the title compound as the lower rf component (215mg) along with mixed fractions containing both isomers. 1H NMR (cis isomer) δ (CDCI3, 400 MHz): 1.20 (3H, t), 1.32-1.50 (5H, m), 1.5-1.66 (2H, m), 1.78-1.96 (4H, m), 3.16-3.26 (1 H, m), 3.48-3.58 (2H, q )
Description 60. [c/s-4-(Ethyloxy)-1 -methylcyclohexyl]amine hydrochloride (D60)
Figure imgf000078_0001
A solution of c/s-4-(ethyloxy)-1-isocyanato-1-methylcyclohexane (D59, 215mg, 1.17mmol) in THF (5ml) was treated with 5M HCI acid (1 ml) and stirred at room temperature for 18hrs, then concentrated under vacuum and the residue azeotroped with toluene to remove traces of water. The residual colourless oil was dried under vacuum for 2 days. Trituration of the remaining semi-solid with Et2O (5ml) afforded the title compound as a white solid (213mg, 94%).
1H NMR δ (CDCI3, 400 MHz): 1.19 (3H, t), 1.50 (3H, s), 1.55-1.77 (4H, m), 1.79-1.91 (2H, m), 2.02-2.15 (2H, m), 3.34-3.40 (1 H, m), 3.47 (2H, q), 8.40 (3H, br s).
Description 61. 1 -[c/s-4-(Ethyloxy)-1 -methylcyclohexyl]-4-piperidinone (D61 )
Figure imgf000078_0002
A stirred solution of [c/s-4-(ethyloxy)-1-methylcyclohexyl]amine hydrochloride (D60, 200mg, 1.03mmol) in a mixture of ethanol (12ml) and water (6ml) at room temperature under argon was treated with potassium carbonate (156mg, 1.13mmol) followed by 1- ethyl-1-methyl-4-oxopiperidinium iodide (D44, 404mg, 1.50mmol), then heated at 8O0C for 1.5hrs. The mixture was allowed to cool, concentrated under vacuum to approx. 7ml, then treated with NaHCO3 solution (15ml) and extracted with dichloromethane (3x20ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave an brown oil (250mg), which was chromatographed on silica gel eluting with 0-5% MeOH/ dichloromethane to afford the title compound as a yellow oil (140mg, 57%). 1H NMR δ (CDCI3, 400 MHz): 0.89 (3H, s), 1.13-1.27 (2H, m), 1.20 (3H, t), 1.68-1.80 (4H, m), 1.95-2.05 (2H, m), 2.40-2.47 (4H, m), 2.76-2.83 (4H, m), 3.25-3.33 (1 H, m), 3.52 (2H, q)- Description 62. 1 -[c/s-4-(Ethyloxy)-1 -methylcyclohexyl]-4-piperidinamine (D62)
Figure imgf000079_0001
A solution of 1-[c/s-4-ethoxy-1-methylcyclohexyl]-4-piperidinone (D61 , 140mg, 0.585mmol) in 2M NH3/MeOH (12ml) was treated with 10% Pd/C paste (30mg) and shaken under hydrogen atmosphere at 50psi initial pressure for 2.5 days. The mixture was filtered through Kieselguhr to remove catalyst and the filtrate concentrated under vacuum to leave the title compound as a colourless oil (140mg, 100%). 1H NMR δ (CDCI3, 400 MHz): 0.84 (3H, s), 1.04-1.20 (2H, m), 1.20 (3H, t), 1.37-1.50 (2H, m), 1.58-1.72 (4H, m), 1.83-2.00 (4H, m), 2.05-2.20 (2H, m), 2.65-2.75 (1 H, m), 2.88 (2H, br d), 3.20-3.30 (1 H, m), 3.20-3.80 (assume 4H including 3.50 = 2H, q).
Description 63 c/s/frans-Ethyl 4-(propyloxy)cyclohexanecarboxylate (D63)
Figure imgf000079_0002
Propionaldehyde (6.4g) in acetonitrile (50ml) was added over 30 minutes to a solution of cis/trans ethyl 4-{[(1 ,1-dimethylethyl)(dimethyl)silyl]oxy}cyclohexanecarboxylate (D50, 25.2g), bismuth tribromide (4.4g), triethylsilane (17.5ml) in acetonitrile (300ml) and the mixture was stirred fro a further 1.5 hours. The solvent was partially removed then the residue was treated with ethyl acetate and saturated sodium bicarbonate solution. The organic layer was separated, washed with brine, dried with anhydrous sodium sulphate and the solvent was removed to give the title compound contaminated with silicone residues (39.1g).
Description 64. c/s/frans-4-(Propyloxy)cyclohexanecarboxylic acid (D64)
Figure imgf000079_0003
The product from Description 63 (39.1g), 40% w/w sodium hydroxide solution (150ml) tetrahydrofuran (200ml) and methanol (150ml) was stirred for approx. 72 hours. The solvent was partially removed then the resulting mixture was treated with ethyl acetate and water. The aqueous layer was separated, acidified with concentrated hydrochloric acid and extracted with diethyl ether. The ether layer was washed with brine, dried with anhydrous sodium sulphate and the solvent was removed to give the title compound as a oil (15.42g).
Description 65. cis/trans-Λ -Methyl-4-(propyloxy)cyclohexanecarboxylic acid (D65)
Figure imgf000080_0001
A stirred solution of diisopropylamine (24ml, 0.17mol) in THF (300ml) at -2O0C under argon was treated over 10 mins with 2.5M n-butyllithium in hexane (68ml, 0.17mol), then allowed to warm to O0C and stir for 15 mins. The mixture was recooled to -1 O0C and treated over 10 mins with a solution of 4-(propyloxy)cyclohexanecarboxylic acid (D64,
13.8g, 0.074mol) in THF. The resulting yellow solution was heated at 5O0C for 2.5hrs, then cooled to O0C and treated with iodomethane (13.8ml, 0.22mol). The mixture was allowed to warm to room temperature and stir for 20hrs when a yellow precipitate had formed. The mixture was cooled to 1 O0C, treated with 10% citric acid solution (200ml), then concentrated under vacuum to approx. 250ml volume. The residual mixture was diluted with water (200ml) and extracted with Et2O (3x250ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave a yellow oil (15.Og) which was approx. 60:40 mixture of cis:trans isomers.
Description 66. frans-1-Methyl-4-(propyloxy)cyclohexanecarboxylic acid (D66)
Figure imgf000080_0002
cis/trans-i -Methyl-4-(propyloxy)cyclohexanecarboxylic acid (D65, 13g, 0.070mol) was added to stirred thionyl chloride (50ml), 0.68mol) at 1 O0C and then allowed to warm to room temperature, followed by heating at 850C for 3 hrs. The mixture was concentrated under vacuum and the residue concentrated twice with toluene to remove excess thionyl chloride. The residue was dissolved in THF (100ml), treated with dil. NaHCO3 solution (250ml) and stirred well at room temperature for 24 hrs, followed by standing at room temperatue for 3 days. The mixture from the same stage of a smaller scale reaction on 2g of c/s/frans-1 -methyl-4-(propyloxy)cyclohexanecarboxylic acid was combined at this time. The combined mixture was concentrated under vacuum to approx. 300ml and the aqueous residue washed with Et2O (2x120ml), then acidified with 2M HCI acid and extracted with EtOAc (2x150ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave the title compound as a pale yellow solid (5.1g, 34%). 1H NMR δ (CDCI3, 400 MHz): 0.92 (3H, t), 1.24 (3H, s), 1.54-1.74 (8H, m), 1.78-1.88 (2H, m), 3.33-3.40 (3H, m). 1 H not discernible from spectrum.
Description 67. frans-1-lsocyanato-1 -methyl-4-(propyloxy)cyclohexane (D67)
Figure imgf000081_0001
A stirred solution of frans-1 -methyl-4-(propyloxy)cyclohexanecarboxylic acid (D66, 5.1g, 0.027mol) in toluene (120ml) at room temperature under argon was treated with triethylamine (4.9ml, 0.035mol) and diphenylphosphoryl azide (5.8ml, 0.027mol) and heated at 850C for 1 hr. The mixture was allowed to cool to room temperature, then treated with 1 M NaOH solution (200ml) and extracted with Et2O (2x150ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave the title compound as a yekllow oil (5.Og, 100%). 1H NMR δ (CDCI3, 400 MHz): 0.91 (3H, t), 1.36 (3H, s), 1.50-1.60 (4H, m), 1.65-1.80 (6H, m), 3.33 (2H, t), 3.46-3.52 (1 H, m).
Description 68. [frans-1 -Methyl-4-(propyloxy)cyclohexyl]amine hydrochloride (D68)
Figure imgf000081_0002
A solution of trans-1 -isocyanato-1-methyl-4-(propyloxy)cyclohexane (D67, 5.Og, 0.027mol) in THF (100ml) was treated with 5M HCI acid (25ml) and stirred at room temperature under argon for 20hrs, then concentrated under vacuum and the residue azeotroped with toluene to remove traces of water. The residual semi-solid was triturated with Et2O
(120ml) to give a solid, which was filtered off, washed with Et2O and dried at 5O0C under vacuum to afford the title compound as a white solid (4.5g, 85%).
1H NMR δ (CDCI3, 400 MHz): 0.91 (3H, t), 1.47 (3H, s), 1-45-1.70 (4H, m), 1.75-2.00 (6H, m), 3.52 (2H, t), 3.40-3.48 (1 H, m), 8.38 (3H, br s).
Description 69. 1 -[frans-1-Methyl-4-(propyloxy)cyclohexyl]-4-piperidinone (D69)
Figure imgf000081_0003
A stirred solution of [trans-i -methyl-4-(propyloxy)cyclohexyl]amine hydrochloride (D68, 4.5g, 0.022mol) in a mixture of ethanol (100ml) and water (60ml) at room temperature under argon was treated with potassium carbonate (3.31 g, 0.024mol) followed by 1-ethyl- 1-methyl-4-oxopiperidinium iodide (D44, 8.91g, 0.033mol), then heated at 8O0C for 2.5hrs. The mixture was allowed to cool, concentrated under vacuum to approx. 60ml, then the aqueous residue was treated with sat. NaHCO3 solution and extracted with DCM (3x80ml). The combined extract was dried (Na2SU4) and concentrated under vacuum to leave an orange oil (6.1 g), which was chromatographed on silica gel eluting with 0-10% MeOH/DCM to afford the title compound as a yellow oil (3.45g, 63%). 1H NMR δ (CDCI3, 400 MHz): 0.93 (3H, s + 3H, t), 1.48-1.72 (8H, m), 1.80-1.92 (2H, m), 2.41 (4H, t), 2.82 (4H, t), 3.35-3.45 (3H, t + m).
Description 70. 1 -[frans-1-Methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine (D70)
Figure imgf000082_0001
A solution of 1-[frans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinone (D69, 2.Og, 0.0079mol) in 2M NH3/MeOH (60ml) was treated with 10% Pd/C (150mg) and shaken under hydrogen atmosphere at 55psi initial pressure for 3.5 days at room temperature. The mixture was filtered through Kieselguhr to remove catalyst and the filtrate concentrated under vacuum to leave the title compound as a white solid (1.82g, 91 %). 1H NMR δ (CDCI3, 400 MHz): 0.91 (3H, t), 1.08 (3H, br s), 1.32-1.45 (2H, m), 1.5-1-60 (2H, m), 1.62-2.60 (assume 12H, set of broad signals), 2.70-3.10 (1 H, br), 34.10-3.25 (2H, br), 3.30-3.45 (3H, m), 3.40-4.40 (2H, v br).
Description 71. 1 -[frans-4-(Ethyloxy)cyclohexyl]-Λ/-(5-fluoro-2-nitrophenyl)-4- piperidinamine (D71)
Figure imgf000082_0002
) A stirred solution of 2, 4-difluoro-1 -nitrobenzene (100mg, 0.63mmol) in DMF (3ml) at room temperature under argon was treated with diisopropylethylamine (0.40ml, 2.2mmol) followed by 1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D12, 179mg, O.δOmmol) and maintained at room temperature for 20hrs, then heated at 5O0C for 7hrs. The mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution (10ml) and extracted with dichloromethane (2x15ml). The combined extract was dried (Na2SCM), concentrated under vacuum and the residue chromatographed on silica gel (1Og) eluting with 0-10% methanol/dichloromethane to give a yellow solid which was recrystallised from methanol to afford the title compound as an yellow solid (120mg, 55%). MH+ 366.
1H NMR δ (CDCI3, 400 MHz): 1.15-1.40 (7H, m), 1.60-1.72 (2H, m), 1.90-1.96 (2H, m), 2.05-2.18 (4H, m), 2.30-2.50 (3H, m), 2.85-2.93 (2H, m), 3.13-3.23 (1 H, m), 3.38-3.50 (1 H, m), 3.52 (2H, q), 6.31-6.40 (1 H, m), 6.48 (1 H, dd), 8.18-8.30 (2H, m).
Description 72. Λ/2-{1-[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-4-fluoro-1 ,2- benzenediamine (D72)
Figure imgf000083_0001
A stirred solution of 1-[frans-4-(ethyloxy)cyclohexyl]-Λ/-(5-fluoro-2-nitrophenyl)-4- piperidinamine (D71 , 120mg, 0.33mmol) in ethanol (15ml) at room temperature under argon was treated with Raney Nickel (~20mg) followed by hydrazine hydrate (0.10ml, 3.3mmol) and maintained for 2 hrs. The mixture was filtered through Kieselguhr to remove catalyst and the filtrate concentrated under vacuum to afford the title compound as a pale brown solid (11 Omg, 100%yield). MH+ 336.
1H NMR δ (CDCI3, 400MHz): 1.17-1.37 (4H, m), 1.20 (3H, t), 1.42-1.54 (2H, m), 1.88-1.96 (2H, m), 2.02-2.15 (4H, m), 2.28-2.42 (3H, m), 2.92 (2H, br d), 3.07 (2H, br s), 3.13-3.25 (2H, m), 3.51 (2H, q), 3.60 (1 H, br s), 6.25-6.40 (2H, m), 6.60-6.67 (1 H, m),
Description 73. Λ/-(5-Bromo-2-nitrophenyl)-1 -[frans-4-(ethyloxy)cyclohexyl]-4- piperidinamine (D73)
Figure imgf000084_0001
A mixture of 4-bromo-2-fluoro-1 -nitrobenzene (600mg, 2.72mmol) and 1-[frans-4- (ethoxy)cyclohexyl]-4-piperidinamine dihydrochloride (D12, 807mg, 2.72mmol) in dimethylformamide (20ml) was treated with diisopropylethylamine (1.4ml, 8.16mmol) then heated with stirring at 8O0C overnight under argon. The solution was washed with water then extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated. The residue was loaded on an SCX cartridge and eluted firstly with dichloromethane (approx. 30ml) and then with 2M NH3/MeOH (approx. 30ml). The methanolic solution was concentrated under vacuum to leave a yellow/orange solid (1.4g). This was purified by chromatography on an amino silica column (40+M) eluting with 3-25% EtOAc/hexane afford the title compound (1.15g, 99%). MH+ = 427, 428.
1H NMR δ (CDCI3, 400MHz): 1.15-1.38 (4H, m), 1.20 (3H, t), 1.58-1.72 (2H, m), 1.88-1.98 (2H, m), 2.02-2.16 (4H, m), 2.3-2.38 (1 H, m), 2.402.50 (2H, m), 2.85-2.95 (2H, m), 3.13- 3.24 (1 H, m), 3.50 (2H, t), 6.73 (1 H, dd), 7.00 (1 H, d), 8.03 (1 H, d), 8.14 (1 H, d).
Description 74. 4-Bromo-Λ/2-{1 -[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,2- benzenediamine (D74)
Figure imgf000084_0002
A stirred solution of Λ/-(5-bromo-2-nitrophenyl)-1-[frans-4-(ethyloxy)cyclohexyl]-4- piperidinamine (D73, 650mg, 1.53mmol) in ethanol (100ml) at room temperature under argon was treated with Raney Nickel (100mg) and dropwise addition of hydrazine hydrate (1.2ml, 38.25mmol) and maintained for 3hrs. The mixture was filtered through Kieselguhr and the filtrate concentrated under vacuum to leave the title compound as an amber oil (600mg, 99%). MH+ = 397, 398.
1H NMR δ (CDCI3, 400MHz): 1.20 (3H, t), 1.20-1.40 (4H, m), 1.38-1.55 (2H, m), 1.90-2.00 (2H, m), 2.00-2.15 (4H, m), 2.25-2.43 (3H, m), 2.90 (2H, br d), 3.13-3.43 (5H, m), 3.51 (2H, t), 6.57 (1 H, d), 6.70-6.78 (2H, m).
Description 75. Λ/-(5-Ethenyl-2-nitrophenyl)-1 -[frans-4-(ethyloxy)cyclohexyl]-4- piperidinamine (D75)
Figure imgf000085_0001
A solution of Λ/-(5-bromo-2-nitrophenyl)-1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinamine (D73, 500mg, 1.17mmol) and tributylvinyltin (0.42ml, 1.36mmol) in toluene (15ml) at room temperature under argon was treated with triphenylphosphine (77mg, 0.29mmol) and bis(dibenzylidene)acetone)palladium(0) (102mg, 0.18mmol) and heated at 12O0C overnight. The mixture was allowed to cool, then filtered through Kieselguhr. The organic filtrate was washed with 10% aqu. ammonium hydroxide solution and water, then dried (Na2SU4) and concentrated under vacuum to leave a brown solid (approx. 550mg). This was dissolved in dichloromethane and eluted through an SCX cartridge, then collected by elution with 2M NH3/MeOH and concentrated. The residue was chromatographed on 40+M Biotage KP-NH™-silica column to afford the title compound as an orange solid (99%). MH+ = 374. 1H NMR δ (CDCI3, 400MHz): 1.18-1.40 (4H, m), 1.20 (3H, t), 1.55-1.73 (assume 2H, m), 1.90-2.00 (2H, m), 2.03-2.18 (4H, m), 2.30-2.40 (1 H, m), 2.40-2.50 (2H, m), 2.85-2.94 (2H, m), 3.13-3.23 (1 H, m), 3.50-3.61 (1 H, m), 3.51 (2H, q), 5.46 (1 H, d), 5.87 (1 H, d), 6.66 (1 H, dd), 6.72 (2H, m), 8.14 (1 H, dd), 8.22 (1 H, d).
Description 76. 4-Ethyl-Λ/2-{1 -[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,2- benzenediamine (D76)
Figure imgf000086_0001
A mixture of Λ/-(5-ethenyl-2-nitrophenyl)-1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinamine (D75, 440mg, 1.17mmol) and ammonium formate (734mg, 1 1.7mmol) in methanol (50ml) was stirred at room temperature under argon for 10mins, then treated with 10% Pd/C (261 mg, 0.2equivalents) and stirred for 30mins. The mixture was filtered through Kieselguhr and concentrated to remove solvent. The residue was dissolved in dichloromethane, washed with 2M NaOH solution, dried (Na2SO4) and concentrated to leave the title compound as a purple sticky oil (348mg, 86%). MH+ = 346. 1H NMR δ (CDCI3, 400MHz): 1.18-1.40 (1OH, t + t + m), 1.42-1.58 (2H, m), 1.90-2.00 (2H, m), 2.03-2.16 (4H, m), 2.30-2.42 (3H, m), 2.53 (2H, q), 2.86-2.95 (2H, m), 3.00-3.40 (assume 5H, m), 3.51 (2H, q), 6.50 (2H, m), 6.65 (1 H, d).
Description 77. Λ/-(5-Cyclopropyl-2-nitrophenyl)-1 -[frans-4-(ethyloxy)cyclohexyl]-4- piperidinamine (D77)
Figure imgf000086_0002
A mixture of 4-cyclopropyl-2-fluoro-1 -nitrobenzene (200mg, 1.1 mmol) and 1-[frans-4- (ethyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D12, 327mg, 1.1 mmol) in dimethylformamide (20ml) was treated with diisopropylethylamine (0.56ml) then heated under argon at 8O0C overnight. The solution was washed with water then extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum. The residue was dissolved in dichloromethane and eluted through an SCX cartridge, firstly with dichloromethane and then with 2M NH3/MeOH. The methanolic solution was concentrated under vacuum to leave a dark orange solid (300mg), which was purified by chromatography on a 40+M Biotage KP-NH™-silica column eluting with 5-30% EtOAc/hexane to afford the title compound as an orange solid (240mg, 60%). MH+ = 388. 1H NMR δ (CDCI3, 400MHz): 0.77-0.83 (2H, m), 1.03-1.1 1 (2H, m), 1.17-1.40 (4H, m), 1.20 (3H, t), 1.58-1.72 (2H, m), 1.82-1.98 (3H, m), 2.02-2.15 (4H, m), 2.30-2.40 (1 H, m), 2.40-2.50 (2H, m), 2.82-2.92 (2H, m), 3.13-3.24 (1 H, m), 3.48-3.62 (3H, t + m), 6.18 (1 H, dd), 6.55 (1 H, d), 8.05 (1 H, d), 8.21 (1 H, d).
Description 78. 4-Cyclopropyl-Λ/2-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}- 1,2-benzenediamine (D78)
Figure imgf000087_0001
A stirred solution of Λ/-(5-cyclopropyl-2-nitrophenyl)-1-[frans-4-(ethyloxy)cyclohexyl]-4- piperidinamine (D77, 240mg, 0.62mmol) in ethanol (40ml) at room temperature under argon was treated with Raney Nickel (50mg) and dropwise addition of hydrazine hydrate (0.5ml, 15.5mmol) and maintained for 2hrs. The mixture was filtered through Kieselguhr and the filtrate concentrated under vacuum to leave the title compound as green/yellow oil (200mg, 90%). MH+ = 358.
1H NMR δ (CDCI3, 400MHz): 0.57-0.63 (2H, m), 0.83-0.90 (2H, m), 1.14-1.40 (4H, m), 1.20 (3H, t), 1.40-1.60 (assume 2H, m), 1.75-1.85 (1 H, m), 1.90-2.00 (2H, m), 2.02-2.16 (4H, m), 2.29-2.42 (3H, m), 2.87-2.93 (2H, m), 3.00-3.40 (5H, m), 3.45-3.57 (2H, q), 6.37 (1 H, dd), 6.42 (1 H, d), 6.62 (1 H, d).
Description 79. 1 -[frans-4-(Ethyloxy)cyclohexyl]-Λ/-[5-(methyloxy)-2-nitrophenyl]-4- piperidinamine (D79)
Figure imgf000088_0001
A stirred solution of 3-fluoro-4-nitroanisole (120mg, 0.70mmol) in dimethylformamide (4ml) at room temperature under argon was treated with diisopropylethylamine (0.43ml, 2.4mmol) followed by 1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D12, 200mg, 0.67mmol) and heated at 5O0C for δhrs, followed by 9O0C for 20hrs. The mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution (10ml) and extracted with dichloromethane. The extract was dried (Na2SO4), concentrated under vacuum and the residue chromatographed on silica gel (5g) eluting with 0-10% methanol/dichloromethane to give a yellow oil, which was crystallised from methanol (6ml) to afford the title compound as an yellow solid (130mg, 52%). MH+ 378. 1H NMR δ (CDCI3, 400 MHz): 1.15-1.38 (4H, m), 1.20 (3H, t), 1.6-1.75 (2H, m), 1.90-1.96 (2H, m), 2.02-2.15 (4H, m), 2.25-2.38 (1 H, m), 2.38-2.48 (2H, m), 2.82-2.92 (2H, m), 3.12- 3.23 (1 H, m), 3.43-3.56 (3H, m), 3.86 (3H, s), 6.16 (1 H, d), 6.2 (1 H, dd), 8.15 (1 H, d), 8.37 (1 H, d).
Description 80. Λ/2-{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-4-(methyloxy)- 1,2-benzenediamine (D80)
Figure imgf000088_0002
A stirred solution of 1-[frans-4-(ethyloxy)cyclohexyl]-Λ/-[5-(methyloxy)-2-nitrophenyl]-4- piperidinamine (D79, 130mg, 0.34mmol) in ethanol (15ml) at room temperature under argon was treated with Raney Nickel (~20mg) followed by hydrazine hydrate (0.10ml, 3.3mmol) and maintained for 2 hrs. The mixture was filtered through Kieselguhr to remove catalyst and the filtrate concentrated under vacuum to afford the title compound as a beige solid (120mg, 100%yield). MH+ 348.
1H NMR δ (CDCI3, 400MHz): 1.15-1.38 (4H, m), 1.18 (3H, t), 1.40-1.55 (2H, m), 1.90-1.96 (2H, m), 2.03-2.13 (4H, m), 2.23-2.38 (3H, m), 2.85-3.10 (4H, m), 3.13-3.26 (2H, m), 3.51 (2H, q), 3.60 (1 H, br s), 3.75 (3H, s), 6.15 (1 H, dd), 6.25 (1 H, d), 6.65 (1 H, d).
Description 81. 1,1 -Dimethylethyl 4-{[({2-bromo-4-[(trifluoromethyl)oxy]phenyl} amino)carbonyl]amino}-1 -piperidinecarboxylate (D81 )
Figure imgf000089_0001
)
A solution of 2-bromo-4-(trifluoromethyloxy)aniline (5.1 g), in 1 ,4-dioxane (30 ml.) was treated with bis(trichloromethyl) carbonate (2.2g). The mixture was heated to 1000C to give a clear solution then allowed to cool to ambient temperature. The solvent was evaporated and the residue was dissolved in dichloromethane (70ml) and 1 ,1- dimethylethyl 4-amino-1 -piperidinecarboxylate (4.0 g) was added. The mixture was stirred overnight at room temperature. Silica gel was added and the solvent was evaporated. The residue was loaded onto a silica gel chromatography column which was eluted with hexane/ethyl acetate 0-100% followed by chromatography on silica gel eluted with dichloromethane/methanol 0-10% to give the title compound as a white solid from diethyl ether (4.3 g).
1HNMR δ (DMSO, 400 MHz): 1.25 (2H, m), 1.40 (9H, s), 1.79 (2H, m), 2.93 (2H, broad), 3.64 (1 H, m), 3.80 (2H, m), 7.21 (1 H, d), 7.35 (1 H, d), 7.66 (1 H, s), 7.91 (1 H, s), 8.19 (1 H, d).
Description 82. 1 ,1 -Dimethylethyl 4-{2-oxo-6-[(trifluoromethyl)oxy]-2,3-dihydro-1H- benzimidazol-1 -yl}-1 -piperidinecarboxylate (D82)
Figure imgf000089_0002
A solution of tris(dibenzylideneacetone)dipalladium (0) (0.33g), 1 ,1 '- bis(diphenylphosphino)ferrocene (0.21g), sodium tert-butoxide (1.1g) in 1 ,4-dioxane (20 ml.) was stirred under an atmosphere of argon for 10 minutes. 1 ,1-Dimethylethyl 4-{[({2- bromo-4-[(trifluoromethyl)oxy]phenyl}amino)carbonyl]amino}-1 -piperidinecarboxylate (D81 , 2.7 g) was added and the mixture was heated to 9O0C. The mixture was stirred at this temperature overnight. The mixture was poured into dichloromethane which was washed with dilute ammonium chloride, brine and dried over sodium sulphate. The solvent was removed and the residue was chromatographed on silica gel eluted with ethyl acetate/hexane 0-50% to give the title compound as a solid foam (1.54 g). 1HNMR δ (DMSO, 400 MHz): 1.41 (9H, m), 1.72 (2H, s), 2.24 (2H, m), 2.85 (2H, broad), 4.18 (2H, m), 4.31 (1 H, m), 6.88 (1 H, d), 7.00 (1 H, d), 7.10 (1 H, s).
Description 83. 1 -(4-Piperidinyl)-6-[(trifluoromethyl)oxy]-1 , 3-d i hydro -2 H- benzimidazol-2-one hydrochloride (D83)
Figure imgf000090_0001
A solution of 1 ,1-dimethylethyl 4-{2-oxo-6-[(trifluoromethyl)oxy]-2,3-dihydro-1 /-/- benzimidazol-1-yl}-1-piperidinecarboxylate (D82, 1.54 g) in methanol (20 ml) was treated with a saturated solution of hydrogen chloride in ethanol (10 ml). The mixture was stirred for 1 hour when the solvent was removed to give the title compound as a white solid (1.28 g)-
1HNMR δ (DMSO, 400 MHz): 1.81 (2H, m), 2.56 (2H, m), 3.04 (2H, m), 3.40 (2H, m), 4.56 (1 H, m), 6.99 (1 H, m), 7.05 (1 H, d), 7.50 (1 H, d), 8.97 (2H, br s), 11.2 (1 H, s).
Description 84. O-1,4-Dioxaspiro[4.5]dec-8-yl S-methyl dithiocarbonate (D84)
Figure imgf000090_0002
A stirred solution of 1 ,4-dioxaspiro[4,5]decan-8-ol (D1 , 8,7g, 55mmol) in THF (110ml) at O0C was treated portionwise with sodium hydride (2.7g of 60%, 66mmol). The mixture was stirred for 1 hr at room temperature then cooled to O0C and treated dropwise with carbon disulphide (7ml, 1 10mmol). The resulting mixture was stirred at room temperature for 3 hrs before cooling to O0C and adding dropwise iodomethane (4.12ml, 66mmol). The resulting mixture was stirred for 1 hr at room temperature, then treated with aqueous NH4CI solution and extracting with Et2O. The organic phase was separated and the aqueous extracted twice with Et2O. The combined organics was washed with sat. NaCI solution containing small portion of sodium hydrogen sulphite, dried (Na2SO4) and concentrated under vacuum to afford the title compound as a yellow/orange oil (quantitative).
1 H NMR (CDCI3, 400MHz): 1.62-1.72 (2H, m), 1.78-1.92 (2H, m), 1.95-2.06 (4H, m), 2.55 (3H, s), 3.92-4.02 (4H, m), 5.64-5.74 (1 H, m).
Description 85. 8-[(Trifluoromethyl)oxy]-1 ,4-dioxaspiro[4.5]decane (D85)
Figure imgf000091_0001
A solution of O-1 ,4-dioxaspiro[4.5]dec-8-yl S-methyl dithiocarbonate (D84, 500mg) in dichloromethane (5ml) was added dropwise at 00C to a mixture of dichloromethane (5ml), 70% HF-pyridine (2ml), N-bromosuccinimide (1.8g), and pyridine (0.6ml). After a further 1 h at 00C the reaction was washed with aqueous sodium bicarbonate and aqueous sodium hydroxide at pH9. An exactly similar reaction in which the N-bromosuccinimide was replaced by 1 ,3- dibromo-5,5-dimethylhydantoin was then performed and the combined products of the two reactions purified by chromatography (2Og silica, 25% ethyl acetate in hexane) to give the title compound, 400mg.
Description 86. 8-[(Cyclopropylmethyl)oxy]-1 ,4-dioxaspiro[4.5]decane (D86)
Figure imgf000091_0002
A stirred solution of 1 ,4-dioxaspiro[4.5]decan-8-ol (D1 , 4.Og), cyclopropylmethyl bromide (4.1g) in N-methylpyrrolidinone (20ml) at ice bath temperature under argon and was treated portionwise with sodium hydride (2.Og of 60% oil dispersion). The mixture was allowed to warm to room temperature overnight. The mixture was cooled cautiously treated with methanol and then water was added and the mixture extracted with hexane. The organic extract as washed with water, then dried (Na2SO4) and solvent removed to give the title compound as oil (7.49g) contaminated with mineral oil residues.
1HNMR δ (CDCI3, 400 MHz): 0.18 (2H, m), 0.52 (2H, m), 0.85 (1 H, m), 1.05 (1 H, m), 1.55 (2H, m), 1.77-1.90 (4H, m), 3.25 (2H, m), 3.42 (1 H, m), 3.95 (4H, m).
Description 87. 4-[(Cyclopropylmethyl)oxy]cyclohexanone (D87)
Figure imgf000092_0001
A solution of 8-[(cyclopropylmethyl)oxy]-1 ,4-dioxaspiro[4.5]decane (D86, 7.46g) in tetrahydrofuran (15ml) was treated with 5M HCI acid (40ml) and stirred for 3h. The resulting mixture was partially concentrated on the rotary evaporator, diluted with water and extracted with dichloromethane (2 x). The combined extract was washed with brine and dried (Na2SU4) and concentrated under vacuum to afford the title compound as a clear oil (6.09g).
1H NMR δ (CDCI3, 400 MHz): 0.22 (2H, m), 0.55 (2H, m), 0.88 (1 H, m), 1.1 (1 H, m) 1.90- 2.00 (2H, m), 2.05-2.13 (2H, m), 2.20-2.32 (2H, m), 2.53-2.65 (2H, m), 3.54 (2H, m), 3.74 (1 H, m).
Description 88. cis/trans-1 ,1 -Dimethylethyl (1-{4- [(cyclopropylmethyl)oxy]cyclohexyl}-4-piperidinyl)carbamate (D88)
Figure imgf000092_0002
A stirred solution of 4-[(cyclopropylmethyl)oxy]cyclohexanone (D87, 6.09g) in 1 ,2- dichloroethane (200ml) under argon was treated with 1 ,1-dimethylethyl 4- piperidinylcarbamate (7.2g), sodium triacetoxyborohydride (9.8g), then the resulting mixture stirred at room temperature for 3 days. The reaction mixture was diluted with dichloromethane then washed with Na2CU3 solution (x2), brine (x2), then dried (Na2SU4) and concentrated under vacuum. The residual yellow oil was dissolved in boiling 60-80 petrol ether (~200ml) and allowed to stand at room temperature. The crystals which had formed were filtered off, washed with petrol and dried to give 3.71 g of a mixture of trans and cis isomers of the title compound. Further crops were obtained from the mother liquors. M+ + H = 353.
Description 89. cis/trans-1 -{4-[(Cyclopropylmethyl)oxy]cyclohexyl}-4- piperidinamine dihydrochloride
Figure imgf000092_0003
2HCI (D89)
cis/trans-1 , 1 -dimethylethyl (1-{4-[(cyclopropylmethyl)oxy]cyclohexyl}-4- piperidinyl)carbamate (D88, 3.71 g) was dissolved in methanol (15ml) and treated with a solution of ethanol saturated with hydrogen chloride (20ml) for 2 hours. The solvent was evaporated to give the title compound as a white solid (3.27g). M+ + H = 253.
Description 90. 1 -{frans-4-[(Cyclopropylmethyl)oxy]cyclohexyl}-Λ/-(5-methyl-2- nitrophenyl)-4-piperidinamine (D90a) and 1 -{c/s-4-
[(cyclopropylmethyl)oxy]cyclohexyl}-Λ/-(5-methyl-2-nitrophenyl)-4-piperidinamine (D90b)
Figure imgf000093_0001
(D9Oa) (D90b»
A solution of cis/trans-1-{4-[(cyclopropylmethyl)oxy]cyclohexyl}-4-piperidinamine dihydrochloride (D89, 1.2Og), diisopropylethylamine (3ml) and 3-fluoro-4-nitrotoluene (1.1g) in dry dimethylformamide (10 ml), was heated at 2000C for 20 minutes in a microwave reactor. The crude mixture was then cooled to room temperature and loaded onto a SCX cartridge. The cartridge was eluted with methanol followed by 2M methanolic ammonia. The methanolic ammonia fraction was evaporated to afford the crude product which was purified by chromatography (ethyl acetate/n-hexane) on a Biotage KP-NH™- silica column to yield, separately, the cis and trans isomers of the title compound.
Fast eluting isomer (D90a; trans isomer) was obtained as a orange solid (0.616g). MH+ = 388.
1H NMR δ (CDCI3, 400 MHz): 0.2 (2H, m), 0.55 (2H, m), 1.05 (1 H, m), 1.4 (2H , m), 1.55- 1.70 (obs, m), 1.97 (2H, m), 2.1 (2H, m), 2.45 (4H, m), 2.5 (2H, m), 2.9 (2H, m), 3.22 (2H, m), 3.52 (2H, m), 6.42 (1 H, d), 6.62 (1 H, s) 8.06 (1 H, d), 8.2 (1 H, d).
Slow eluting isomer (D90b; cis isomer) was obtained as a solid (0.417g). MH+ = 388.
1H NMR δ (CDCI3, 400 MHz): 0.2 (2H, m), 0.5 (2H, m), 1.05 (1 H, m), 1.3 (4H, m), 1.55-
1.70 (obs, m), 1.9 (2H, m), 2.1 (4H, m), 2.35 (3H, m), 2.45 (2H, m), 3.2
(1 H, m), 3.3 (2H, m), 3.56 (1 H, m), 6.43 (1 H, d), 6.61 (1 H, s) 8.08 (1 H, d), 8.2 (1 H, d).
Description 91. Λ/2-(1 -{c/s-4-[(Cyclopropylmethyl)oxy]cyclohexyl}-4-piperidinyl)-4- methyl-1 ,2-benzenediamine (D91)
Figure imgf000093_0002
1-{c/s--4-[(Cyclopropylmethyl)oxy]cyclohexyl}-Λ/-(5-methyl-2-nitrophenyl)-4-piperidinamine (D90b, 0.417g) in ethanol (30 ml), and an aqueous suspension of Raney Nickel (1 ml of a 50% suspension) was stirred at 4O0C during the addition of hydrazine hydrate (1 ml). The mixture was stirred at 4O0C for 30 minutes, cooled and filtered. The filtrate was evaporated and azeotroped with dichloromethane to give the title compound as a white solid (380mg). M+ + H = 394
Description 92. Λ/2-(1 -{frans-4-[(Cyclopropylmethyl)oxy]cyclohexyl}-4-piperidinyl)-4- methyl-1 ,2-benzenediamine (D92)
Figure imgf000094_0001
1-{frans-4-[(Cyclopropylmethyl)oxy]cyclohexyl}-Λ/-(5-methyl-2-nitrophenyl)-4- piperidinamine (D90a, 0.613g) in ethanol (30 ml), methanol (40ml) and an aqueous suspension of Raney Nickel (1 ml of a 50% suspension) was stirred at 4O0C during the addition of hydrazine hydrate (1 ml). The mixture was stirred at 4O0C for 30 minutes, cooled and filtered. The filtrate was evaporated to give the title compound as a white solid (579mg). M+ + H = 394.
Description 93. trans N-(4-Cyclobutyloxycyclhexyl)phthalimide (D93)
Figure imgf000094_0002
A solution of trans N-(4-tert-butyldimethylsilyloxycyclhexyl)phthalimide (D41 , 1.8g, 5mmol) in acetonitrile (20ml) at room temperature was treated sequentially with triethylsilane (1.0ml, 6mmol), bismuth tribromide (240mg, O.δmmol), and cyclobutanone (0.45ml, 6mmol). After 30min more the solution was partitioned aqueous sodium bicarbonate/ethyl acetate. Drying and evaporation of the organic layer gave the title compound crystallised from hexane, 820mg.
Description 94. trans 4-Cyclobutyloxycyclohexylamine (D94)
Figure imgf000095_0001
NH,
(D94)
A mixture of trans N-(4-cyclobutyloxycyclhexyl)phthalimide (D93, 820mg, 2.7mmol), hydrazine hydrate (0.5ml, lO.Ommol), and ethanol (5ml) was heated at at 800C for 2h then cooled and filtered. The filtrate was evaporated and the resulting residue redissolved in diethyl ether, filtered and again evaporated to give the title compound, 180mg.
Description 95. trans 1 -[4-(Cyclobutyloxy)-cyclohexyl]-4-piperidone (D95)
Figure imgf000095_0002
A mixture of trans 4-cyclobutyloxycyclohexylamine (D94, 180mg, 1.1 mmol), 1-ethyl-4- piperidone methiodide (D44, 540mg, 2.0mmol), potassium carbonate (15mg, O.i mmol), water (5ml), and ethanol (10ml) was heated for 1 h at 800C, then cooled, partitioned aqueous sodium bicarbonate / dichloromethane, and purified by chromatography (2Og silica, 0 to 10% methanol in dichloromethane containing 0.2M ammonia) to give the title compound, 150mg.
Description 96. trans 1 -[4-(Cyclobutyloxy)-cyclohexyl]-4-piperidinamine (D96)
O^
Figure imgf000095_0003
A mixture of trans 1-[4-(cyclobutyloxy)-cyclohexyl]-4-piperidone (D95, 150mg, O.δmmol), 2M ammonia in methanol (1OmI, 20mmol), and 10% palladium on carbon paste (20mg) was hydrogenated at 50psi at room temperature overnight then filtered and evaporated to give the title compound, 130mg.
Description 97. trans Λ/-(5-Methyl-2-nitrophenyl)-1-(4-cyclobutyloxycyclohexyl)-4- piperidinamine (D97)
Figure imgf000096_0001
A mixture of 3-fluoro-4-nitrotoluene (80mg), dimethylformamide (2.5ml), diisopropylethylamine (0.17ml), and trans 1-[4-(cyclobutyloxy)-cyclohexyl]-4- piperidinamine (D96, 130mg, O.δmmol) was heated at 8O0C overnight. The cooled reaction was diluted with ethyl acetate and washed three times with water then dried, evaporated and chromatographed (5g silica, 0 to 5% methanol in dichloromethane containing 0.2M ammonia) to give the title compound (60mg).
Description 98. trans 5-Methyl-Λ/-[1-(4-cyclobutyloxycyclohexyl)-4-piperidinyl]-1,2- benzenediamine (D98)
Figure imgf000096_0002
A stirred suspension of trans Λ/-(5-methyl-2-nitrophenyl)-1-(4-cycllbutyloxycyclohexyl)-4- piperidinamine (D97, 60mg, 0.16mmol) in ethanol (5ml) at 5O0C was treated with Raney nickel (1.0ml of 10% aqueous suspension) followed by dropwise addition of hydrazine hydrate (0.08ml). The mixture was heated at the same temperature for 1 h, then filtered through Kieselguhr and the filtrate evaporated and re-evaporated from toluene then diethyl ether to afford the title compound, 50mg.
Description 99. Λ/-(5-Bromo-2-nitrophenyl)-1 -[frans-4-(propyloxy)cyclohexyl]-4- piperidinamine (D99)
Figure imgf000097_0001
A mixture of 4-bromo-2-fluoro-1 -nitrobenzene (300mg, 1.36mmol) and 1-[frans-4- (propyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D49, 422mg, 1.36mmol) in dimethylformamide (20ml) at room temperature was treated with diisopropylethylamine (0.8ml,3equivalents) then heated at 9O0C for 5hrs under argon. The mixture was washed with water and sat. NaHCOs solution then extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum. The residue was loaded on an SCX cartridge and eluted first with dichloromethane and then with 2M NH3/MeOH to remove the product, which was concentrated under vacuum to afford the title compound (610mg, 99%). MH+ = 441 , 442.
1H NMR δ (CDCI3, 400MHz): 0.91 (3H, t), 1.18-1.40 (4H, m), 1.51-1.72 (assume 4H, m), 1.85-1.97 (2H, m), 2.02-2.18 (4H, m), 2.29-2.39 (1 H, m), 2.39-2.50 (2H, m), 2.84-2.94 (2H, m), 3.10-3.20 (1 H, m), 3.40 (2H, t), 3.41-3.55 (1 H, m), 6.73 (1 H, dd), 7.00 (1 H, d), 8.03 (1 H1 d), 8.13 (1 H1 d).
Description 100. 4-Bromo-Λ/2-{1 -[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,2- benzenediamine (D100)
Figure imgf000097_0002
A stirred solution of Λ/-(5-bromo-2-nitrophenyl)-1-[frans-4-(propyloxy)cyclohexyl]-4- piperidinamine (D99, 620mg, 1.41 mmol) in ethanol (100ml) at room temperature under argon was treated with Raney Nickel (80mg) and dropwise addition of hydrazine hydrate (1.1 ml, 35.25mmol) and maintained for 3hrs. The mixture was filtered through Kieselguhr and the filtrate concentrated under vacuum to leave the title compound as a brown oil (574mg, 99%). MH+ = 41 1 , 412.
1H NMR δ (CDCI3, 400MHz): 0.90 (3H, t), 1.20-1.40 (4H, m), 1.40-1.65 (4H, m), 1.85-1.98 (2H, m), 2.01-2.15 (4H, m), 2.26-2.40 (3H, m), 2.85-2.95 (2H, m), 3.05-3.45 (5H, m), 3.40 (2H, t), 6.57 (1 H, m), 6.69-6.76 (2H, m).
Description 101. Λ/-(5-Ethenyl-2-nitrophenyl)-1 -[frans-4-(propyloxy)cyclohexyl]-4- piperidinamine (D101)
Figure imgf000098_0001
A solution of Λ/-(5-bromo-2-nitrophenyl)-1-[frans-4-(propyloxy)cyclohexyl]-4-piperidinamine (D99, 340mg, 0.77mmol) and tributylvinyltin (0.28ml, 0.89mmol) in toluene (10ml) at room temperature under argon was treated with triphenylphosphine (51 mg, 0.19mmol) and bis(dibenzylidene)acetone)palladium(0) (68mg, 0.12mmol) and heated at 12O0C overnight. The mixture was allowed to cool, then filtered through Kieselguhr and concentrated under vacuum. The residue was dissolved in dichloromethane and washed with 10% aqu. ammounium hydroxide solution, then dried (Na2SC>4) and concentrated under vacuum. The residue was dissolved in dichloromethane and eluted through an SCX cartridge, then collected by elution with 2M NH3/MeOH and concentrated. The residue was chromatographed on a 25+M Biotage KP-NH™-silica column using 5-30% solvent to afford the title compound as a yellow solid (240mg, 80%). MH+ = 388. 1H NMR δ (CDCI3, 400MHz): 0.91 (3H, t), 1.20-1.38 (4H, m), 1.52-1.72 (assume 4H, m), 1.88-1.97 (2H, m), 2.03-2.16 (4H, m), 2.29-2.39 (1 H, m), 2.39-2.50 (2H, m), 2.82-2.92 (2H, m), 3.10-3.21 (1 H, m), 3.39 (2H, t), 3.52-3.63 (1 H, t), 5.46 (1 H, d), 5.87 (1 H, d), 6.66 (1 H, dd), 6.71-6.76 (2H, m), 8.15 (1 H, d), 8.22 (1 H, d).
Description 102. 4-Ethyl-Λ/2-{1 -[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,2- benzenediamine (D102)
Figure imgf000099_0001
A mixture of Λ/-(5-ethenyl-2-nitrophenyl)-1-[frans-4-(propyloxy)cyclohexyl]-4- piperidinamine (D101 , 240mg, 0.61 mmol) and ammonium formate (382.7mg, 6.1 mmol) in methanol (25ml) was stirred at room temperature under argon for 10mins, then treated with 10% Pd/C (136mg, 0.2equivalents) and stirred for 30mins. The mixture was filtered through Kieselguhr and concentrated to remove solvent. The residue was dissolved in dichloromethane, washed with 2M NaOH solution, dried (Na2SO4) and concentrated under vacuum to leave the title compound as a purple sticky oil (180mg, 82%). MH+ = 360. 1H NMR δ (CDCI3, 400MHz): 0.91 (3H, t), 1.16-1.38 (7H, m), 1.42-1.62 (4H, m), 1.88-1.97 (2H, m), 2.01-2.12 (4H, m), 2.25-2.42 (3H, m), 2.53 (2H, q), 2.84-2.94 (2H, m), 2.95-3.40 (5H, m), 3.40 (2H, t), 6.47-6.61 (2H, m), 6.65 (1 H, d).
Description 103. Λ/-(5-Cyclopropyl-2-nitrophenyl)-1 -[frans-4-(propyloxy)cyclohexyl]- 4-piperidinamine (D103)
Figure imgf000099_0002
A mixture of 4-cyclopropyl -2-fluoro-1 -nitrobenzene (100mg, 0.55mmol) and 1-[frans-4- (propyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D49, 170mg, 1 equivalent) in dimethylformamide (10ml) was treated with diisopropylethylamine (0.28ml) then heated and stirred under argon at 8O0C overnight. The solution was washed with water then extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum. The residue was dissolved in dichloromethane and eluted through an SCX cartridge, firstly with dichloromethane and then with 2M NH3/MeOH. The methanolic solution was concentrated under vacuum to leave a dark orange solid (140mg), which was purified by chromatography on a 40+M Biotage KP-NH™-silica column eluting with 5-30% EtOAc/hexane to afford the title compound as an orange solid (1 10mg, 50%). MH+ = 402. 1H NMR δ (CDCI3, 400MHz): 0.76-0.82 (2H, m), 0.90 (3H, t), 1.03-1.11 (2H, m), 1.19-1.40 (assume 4H, m), 1.52-1.72 (assume 4H, m), 1.82-1.98 (assume 3H, m), 2.02-2.15 (4H, m), 2.18-2.39 (1 H, m), 2.40-2.50 (2H, m), 2.80-2.92 (2H, m), 3.10-3.20 (1 H, m), 3.40 (2H, t), 3.50-3.60 (1 H, m), 6.19 (1 H, dd), 6.55 (1 H, d), 8.05 (1 H, d), 8.21 (1 H, d).
Description 104. 4-Cyclopropyl-Λ/2-{1-[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}- 1,2-benzenediamine (D104)
Figure imgf000100_0001
A stirred solution of Λ/-(5-cyclopropyl-2-nitrophenyl)-1-[frans-4-(propyloxy)cyclohexyl]-4- piperidinamine (D103, 1 10mg, 0.27mmol) in ethanol (20ml) at room temperature under argon was treated with Raney Nickel (30mg) and dropwise addition of hydrazine hydrate (0.2ml, 6.75mmol) and maintained for 2hrs. The mixture was filtered through Kieselguhr and the filtrate concentrated under vacuum to leave the title compound as a green/yellow oil (70mg, 70%). MH+ = 372.
Description 105. 1 -[c/s-4-(Ethyloxy)-1 -methylcyclohexyl]-Λ/-(5-methyl-2-nitrophenyl)- 4-piperidinamine (D105)
Figure imgf000101_0001
A stirred solution of 1-[c/s-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinamine (D62, 140mg, 0.58mmol) in dimethylformamide (3ml) at room temperature under argon was treated with diisopropylethylamine (0.124ml, 0.70mmol) and 3-fluoro-4-nitrotoluene (124mg, O.δOmmol) and heated at 8O0C for 18hrs. The mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution and extracted with dichloromethane. The extract was dried (Na2SO4), concentrated under vacuum and the residue chromatographed on silica gel (1Og) eluting with 0-10% methanol/dichloromethane to afford the title compound as an yellow oil (170mg, 78%). MH+ 376.
1H NMR δ (CDCI3, 400 MHz): 0.85 (3H, s), 1.05-1.20 (2H, m), 1.21 (3H, t), 1.60-1.72 (6H, m), 1.90-2.00 (2H, m), 2.00-2.10 (2H, m), 2.28-2.40 (2H, m), 2.33 (3H, s), 2.80-2.90 (2H, m), 3.22-3.32 (1 H, m), 3.47-3.57 (3H, t + m), 6.41 (1 H, dd), 6.62 (1 H, s), 8.06 (1 H, d), 8.19 (1 H1 d).
Description 106. Λ/2-{1 -[c/s-4-(Ethyloxy)-1 -methylcyclohexyl]-4-piperidinyl}-4- methyl-1 ,2-benzenediamine (D106)
Figure imgf000101_0002
A stirred solution of 1-[c/s-4-(ethyloxy)-1-methylcyclohexyl]-Λ/-(5-methyl-2-nitrophenyl)-4- piperidinamine (D105, 170mg, 0.45mmol) in ethanol (12ml) at room temperature under argon was treated with Raney Nickel (~20mg) followed by hydrazine hydrate (0.15ml, 4.8mmol) and maintained for 2 hrs. The mixture was filtered through Kieselguhr to remove catalyst and the filtrate concentrated under vacuum to afford the title compound as a pale grey oil (150mg, 96%yield). MH+ 346.
1H NMR δ (CDCI3, 400MHz): 0.85 (3H, s), 1.05-1.15 (2H, m), 1.20 (3H, t), 1.40-1.52 (2H, m), 1.60-1.75 (4H, m), 1.90-2.00 (2H, m), 2.00-2.10 (2H, m), 2.18-2.30 (2H, m), 2.25 (3H, s), 2.85-2.92 (2H, m), 3.00-3.35 (5H, m), 3.50 (2H, q), 6.44-6.50 (2H, m), 6.62 (1 H, d).
Description 107. 1 -[frans-4-(Ethyloxy)-1 -methylcyclohexyl]-Λ/-(5-methyl-2- nitrophenyl)-4-piperidinamine (D107)
Figure imgf000102_0001
A stirred solution of 1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinamine (D58 free base, 200mg, 0.83mmol) in dimethylformamide (5ml) at room temperature under argon was treated with diisopropylethylamine (0.28ml, 1.6mmol) and 3-fluoro-4-nitrotoluene (170mg, 1.1 mmol) and heated at 8O0C for 18hrs. The mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution and extracted with dichloromethane. The extract was dried (Na2SO4), concentrated under vacuum and the residue chromatographed on silica gel (10g) eluting with 0-10% methanol/dichloromethane to afford the title compound as an yellow oil (180mg, 58%). MH+ 376.
1H NMR δ (CDCI3, 400 MHz): 0.93 (3H, s), 1.20 (3H, t), 1.40-1.70 (8H, m), 1.80-1.90 (2H, m), 2.02-2.12 (2H, m), 2.28-2.38 (2H, m), 2.33 (3H, s), 2.90-2,98 (2H, m), 3.34-3.42 (1 H, m), 3.45-3.58 (3H, q + m), 6.42 (1 H, dd), 6.62 (1 H, s), 8.05 (1 H, d), 8.17 (1 H, d).
Description 108. Λ/2-{1 -[frans-4-(Ethyloxy)-1 -methylcyclohexyl]-4-piperidinyl}-4- methyl-1 ,2-benzenediamine (D108)
Figure imgf000103_0001
A stirred solution of 1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-Λ/-(5-methyl-2-nitrophenyl)- 4-piperidinamine (D107, 180mg, 0.48mmol) in ethanol (12ml) at room temperature under argon was treated with Raney Nickel (~20mg) followed by hydrazine hydrate (0.15ml, 4.8mmol) and maintained for 2 hrs. The mixture was filtered through Kieselguhr to remove catalyst and the filtrate concentrated under vacuum to afford the title compound as a very pale yellow oil (160mg, 97%yield). MH+ 346.
1H NMR δ (CDCI3, 400MHz): 0.92 (3H, s), 1.20 (3H, t), 1.38-1.57 (6H, m), 1.62-1.72 (2H, m), 1.80-1.90 (2H, m), 2.07 (2H, br d), 2.22-2.32 (2H, m), 2.24 (3H, s), 2.96 (2H, br d), 3.00-3.30 (4H, m), 3.33-3.38 (1 H, m), 3.48 (2H, q), 6.42-6.50 (2H, m), 6.62 (1 H, d).
Description 109. cis/trans 1 ,1 -Dimethylethyl {1 -[1 -methyl-4-(propyloxy)cyclohexyl]- 4-piperidinyl}carbamate (D109)
Figure imgf000103_0002
A three-necked flask was equipped with a Dean-Stark trap and an argon-connected condenser. The flask was charged with 1 ,1-dimethylethyl 4-piperidinylcarbamate (1.1 eq., 7 mmol, 1.4 g), 4-(propyloxy)cyclohexanone (D19, 1 eq., 6.4 mmol, 1 g), 1 ,2,3-triazole (1.2 eq., 7.7 mmol, 0.53 g) and 50 ml of dry toluene. The mixture was refluxed at 13O0C for 6 hours under argon then cooled to room temperature and added to a solution of methylmagnesium bromide (3M in Et2O) (4 eq., 25.6 mmol, 8.5 ml) at < 250C over 20 minutes. Precipitation of a solid was observed: 50 ml extra of tetrahydrofuran were added and the temperature was rigorously kept at 1O0C by an ice bath. The mixture was stirred at room temperature overnight. The mixture was then cooled to O0C and it was slowly quenched with an aqueous saturated solution of ammonium chloride. The mixture was subsequently brought to room temperature, diluted with EtOAc and the two phases were separated. The aqueous phase was the extracted with EtOAc (2x), the organics were combined, dried over sodium sulphate, filtered and the solvent was evaporated to afford the crude product that was subsequently purified by silica gel chromatography (MeOH- NH3-DCM) to afford of the title compound as a yellow oil (0.66 g, 30%). M+ + H = 355.
Description 110. cis/trans 1-[1-Methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D110)
Figure imgf000104_0001
cis/trans 1 ,1-dimethylethyl {1-[1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}carbamate (D109, 0.66g, 1.8 mmol) was dissolved in Et2O (10 ml) and HCI (5 ml of a 4M solution in 1 ,4-dioxane) was added at room temperature. The mixture was stirred at room temperature for 6 hours. The solvent was subsequently evaporated to afford the crude product (440 mg) which was directly used for the next step. M+ + H = 255.
Description 111. cis and trans Λ/-(5-Methyl-2-nitrophenyl)-1 -[1 -methyl-4- (propyloxy)cyclohexyl]-4-piperidinamine (cis = D111a; trans = D111 b)
Figure imgf000104_0002
cis/trans 1-[1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D1 10, 1 eq., 440 mg, 1.3 mmol) was dissolved in dimethylformamide (4 ml) and Hunigh base (3 eq., 0.68 ml) followed by 2-fluoro-4-methyl-1-nitrobenzene (1 eq., 200 mg) were added at room temperature and the mixture was stirred at 1000C overnight. The crude mixture was then cooled to room temperature and poured onto water/brine. The aqueous solution was extracted with EtOAc (3x) and organics were alternatively washed with water (1x) and brine (1x). The organics were combined, dried over Na2SO4, filtered and the solvent was evaporated to afford the crude product that was purified by chromatography and SCX cartridge to yield the two separate title compound isomers, (cis, 57 mg) and (trans, 49 mg). M+ + H = 390. cis isomer (D11 1a): 1HNMR δ (DMSO, 500 MHz): 0.868 (6H, m), 1.392 (2H, m broad), 1.478 (8H, m), 1.739 (2H, m), 1.992 (2H, d), 2.294 (5H, m), 2.821 (2H, d), 3.300 (2H under water peak), 3.359 (1 H, s broad), 3.646 (1 H, s broad), 6.504 (1 H, d), 6.932 (1 H, s), 7.954 (1 H1 d), 8.023 (1 H1 d). trans isomer (D1 11 b): 1HNMR δ (DMSO, 500 MHz): 0.849 (6H, m), 1.107 (2H, t), 1.499 (8H, m), 1.869 (2H, d), 1.993 (2H, d), 2.886 (5H, m), 2.790 (2H, d), 3.197 (1 H, m), 3.315 (2H under the water peak), 3.652 (1 H, m broad), 6.505 (1 H, d), 6.936 (1 H, s), 7.957 (1 H, d), 8.040 (1 H, d).
Description 112. (2-Amino-5-methylphenyl){1-[c/s-1 -methyl-4-
(propyloxy)cyclohexyl]-4-piperidinyl}amine (D112)
Figure imgf000105_0001
2)
Λ/-(5-Methyl-2-nitrophenyl)-1-[c/s-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine
(D11 1a, 57 mg, 0.147mmol) was dissolved into EtOH (5 ml) and Raney-Ni (0.2 ml of a 50% aqueous suspension) was added at room temperature. The mixture was heated to 6O0C and hydrazine hydrate (10 eq., 1.47 mmol, 0.046 ml) was added dropwise at 6O0C. The reaction was stirred at 6O0C for 4 hours. The mixture was cooled to room temperature and it was filtered through celite. The solvent was subsequently evaporated to afford the title compound (53 mg, complete conversion). M+ + H = 360. 1HNMR δ (DMSO, 400 MHz): 0.861 (6H, m), 1.413 (10H, m), 1.723 (2H, dd), 1.939 (2H, d), 2.100 (3H, s), 2.151 (2H, t), 2.881 (2H, d), 3.177 (1 H, s broad), 3.306 (nH under the water peak), 4.043 (1 H, d), 4.253 (1 H, s broad), 6.178 (1 H, d), 6.263, (1 H, s), 6.413 (1 H, d).
Description 113. (2-Amino-5-methylphenyl){1-[frans-1-methyl-4- (propyloxy)cyclohexyl]-4-piperidinyl}amine (D113)
Figure imgf000106_0001
Λ/-(5-Methyl-2-nitrophenyl)-1-[frans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine (D11 1 b, 49mg, 0.126 mmol) was dissolved into EtOH (5 ml) and Raney-Ni (0.2 ml of a 50% aqueous suspension) was added at room temperature. The mixture was heated to 6O0C and hydrazine hydrate (10 eq., 1.26mmol, 0.039ml) was added dropwise at 6O0C. The reaction was stirred at 6O0C for 4 hours. The mixture was cooled to room temperature and it was filtered through celite. The solvent was subsequently evaporated to afford the title compound (45 mg, complete conversion). M+ + H = 360.
1HNMR δ (DMSO, 400 MHz): 0.841 (6H, m), 1.086 (2H, t), 1.335 (2H, q), 1.481 (6H, m), 1.871 (2H, d), 1.942 (2H, d), 2.121 (5H, m), 2.855 (2H, d), 3.186 (2H, m broad), 3.326 (2H under water peak), 4.074 (1 H, d), 4.258 (1 H, s broad), 6.177 (1 H, d), 6.268 (1 H, s), 6.412 (1 H, d).
Description 114. c/s-Ethyl 1-ethyl-4-(tert-butyldimethylsilyloxy)- cyclohexanecarboxylate (D114)
Figure imgf000106_0002
To a solution of diisopropylamine (5.7ml, 40mmol) in THF (150ml) at 00C was added n- butyllithium (16ml of 2.5M in hexane, 40mmol). After 10min more at 00C, it was cooled to -700C and ethyl 4-(tert-butyldimethylsilyloxy)cyclohexanecarboxylate (D50, 8.6g) in tetrahydrofuran (30ml) was added. After 1 h at -700C iodoethane (7.2ml) was added and the solution was allowed to warm to room temperature. After 2h at room temperature it was partitioned between aqueous ammonium chloride / ethyl acetate and the organic layer dried, evaporated, and purified by chromatography (5Og silica, 0 to 10% ethyl acetate in hexane) to give the title compound, 6.2g.
Description 115. c/s-Ethyl i-ethyM-hydroxycyclohexanecarboxylate (D115)
Figure imgf000107_0001
A mixture of c/s-ethyl i-ethyl-^tert-butyldimethylsilyloxyj-cyclohexanecarboxylate (D1 14, 6.2g, 20mmol) and tetrabutylammonium fluoride (25ml of 1 M in tetrahydrofuran, 25mmol) was stirred for 18h at room temperature, then partitioned between aqueous citric acid / diethyl ether and the organic layer dried, evaporated, and purified by chromatography (2Og silica, 0 to 50% ethyl acetate in hexane) to give the title compound, 4.Og.
Description 116. frans-Ethyl 1-ethyl-4-(chloroacetoxy)cyclohexanecarboxylate (D116)
Figure imgf000107_0002
To a mixture of c/s-ethyl 1-ethyl-4-hydroxycyclohexanecarboxylate (D1 15, 4.Og, 20mmol), triphenylphosphine (6.5g, 25mmol), chloroacetic acid (2.4g, 25mmol), and THF (100ml) at 00C was added diisopropyl azodicarboxylate (5.0ml, 25mmol) dropwise. After a further 76h at room temperature the solution was evaporated and purified by chromatography (5Og silica, 10 to 50% ethyl acetate in hexane) to give the title compound, 3.Og.
Description 117. frans-Ethyl i-ethyM-hydroxycyclohexanecarboxylate (D117)
Figure imgf000108_0001
A mixture of frans-ethyl 1-ethyl-4-(chloroacetoxy)-cyclohexanecarboxylate (D116, 3.Og, 12mmol) and potassium carbonate (1.7g, 12mmol) in methanol (50ml) was stirred 1 h at room temperature then partitioned aqueous ammonium chloride / ethyl acetate and the organic layer dried, evaporated, and purified by chromatography (2Og silica, 0 to 50% ethyl acetate in hexane) to give the title compound, 1.5g.
Description 118. frans-Ethyl 1-ethyl-4-(tert-butyldimethylsilyloxy)- cyclohexanecarboxylate (D118)
Figure imgf000108_0002
A mixture of frans-ethyl i-ethyW-hydroxycyclohexanecarboxylate (D1 17, 1.5g, 7.5mmol), tert-butyldimethylsilyl chloride (1.2g, δ.Ommol), imidazole (1.1g, 16.0mmol), and dimethylformamide (10ml) was stirred overnight at room temperature then partitioned water / ethyl acetate and the organic layer dried, evaporated, and purified by chromatography (2Og silica, 0 to 10% ethyl acetate in hexane) to give the title compound, 1.8g.
Description 119. frans-Ethyl i-ethyM-propoxycyclohexanecarboxylate (D119)
Figure imgf000108_0003
To a mixture of frans-ethyl 1-ethyl-4-(tert-butyldimethylsilyloxy)-cyclohexanecarboxylate (D118, 1.8g, 6.0mmol), triethylsilane (1.3ml, δ.Ommol), bismuth tribromide (0.3g, O.δmmol), and acetonitrile (25ml) at O0C was added propanal (0.6ml, δ.Ommol). The mixture was stirred 30min at room temperature then partitioned aqueous sodium bicarbonate / ethyl acetate and the organic layer dried and evaporated, giving the title compound as a 1 :1 mixture with tert-butyldimethylsilyl triethyl siloxane, 2.7g.
Description 120. frans-i -Ethyl-4-propoxycyclohexanecarboxylic acid (D120)
Figure imgf000109_0001
A mixture of frans-ethyl i-ethyM-propoxycyclohexanecarboxylate (D119, 2.7g, 5.5mmol), methanol (50ml), THF (50ml) and 12.5M aqueous sodium hydroxide (4.0ml, 50mmol) was stirred overnight at 500C then concentrated under vacuo and partitioned water/ethyl acetate. The aqueous layer was acidified and extracted with diethyl ether which was dried and evaporated, giving the title compound, 450mg.
Description 121. frans-i -Ethyl-4-propoxycyclohexyl isocyanate (D121)
)
Figure imgf000109_0002
A mixture of frans-1 -ethyW-propoxycyclohexanecarboxylic acid (D120, 450mg, 2.1 mmol), diphenylphosphoryl azide (0.4ml, 1.8mmol), triethylamine (0.27ml, 0.2mmol), and toluene (10ml) was heated for 30min at 1000C, then cooled, washed with water, and purified by chromatography (1Og silica, 0 to 20% ethyl acetate in hexane) to give the title compound, 240mg.
Description 122. frans-1 -Ethyl-4-propoxycyclohexylamine (D122)
Figure imgf000110_0001
A mixture of frans-i-ethyl-4-propoxycyclohexyl isocyanate (D121 , 240mg, 1.1 mmol), THF (4ml), and 5M aqueous hydrochloric acid (1 ml, δ.Ommol) was stirred at room temperature for 2h then purified by ion exchange chromatography using SCX resin to give the title compound, 90mg.
Description 123. frans-1 -[4-(Propoxy)-1 -ethylcyclohexyl]-4-piperidone (D123)
Figure imgf000110_0002
A mixture of frans-i-ethyM-propoxycyclohexylamine (D122, 90mg, O.δmmol), 1 -ethyl-1 - methyl-4-oxopiperidinium iodide (D44, 210mg, O.δmmol), potassium carbonate (10mg, O.Oδmmol), water (2ml), and ethanol (4ml) was heated for 1 h at 800C, then cooled, partitioned water / dichloromethane, and purified by chromatography (1 Og silica, 0 to 10% methanol in dichloromethane containing 0.2M ammonia) to give the title compound, 30mg.
Description 124. frans-1 -[4-(Propoxy)-1 -ethylcyclohexyl]-4-piperidinamine (D124)
Figure imgf000110_0003
A mixture of trans-1 -[4-(propoxy)-1-ethylcyclohexyl]-4-piperidone (D123, 30mg, O.U mmol), 2M ammonia in methanol (20ml, 40mmol), and 10% palladium on carbon paste (30mg) was hydrogenated at 50psi at room temperature overnight then filtered and evaporated to give the title compound, 30mg.
Description 125. frans-Λ/-(5-Methyl-2-nitrophenyl)-1-(1-ethyl-4-propoxycyclohexyl)-4- piperidinamine (D125)
Figure imgf000111_0001
A stirred solution of 3-fluoro-4-nitrotoluene (30mg, 0.20mmol) in dimethylformamide (1 ml) at room temperature under argon was treated with diisopropylethylamine (0.1 ml, O.δOmmol) and trans-1 -[4-(propoxy)-1-ethylcyclohexyl]-4-piperidinamine (D124, 30mg, O.U mmol) and heated at 8O0C for 18h. The cooled reaction was diluted with ethyl acetate and washed three times with water then dried, evaporated and chromatographed (5g silica, 0-5% methanol in dichloromethane containing 0.2M ammonia) to give the title compound (40mg).
Description 126. frans-5-Methyl-Λ/-[1-(1-ethyl-4-propoxycyclohexyl)-4-piperidinyl]- 1,2-benzenediamine (D126)
Figure imgf000111_0002
A stirred suspension of frans-Λ/-(5-methyl-2-nitrophenyl)-1-(1-ethyl-4-propoxycyclohexyl)- 4-piperidinamine (D125, 40mg, O.I Ommol) in ethanol (5ml) at 5O0C was treated with
Raney nickel (0.5ml of 10% aqueous suspension) followed by hydrazine hydrate (0.1 ml,
2.0mmol). The mixture was heated at the same temperature for 1 h, then filtered through
Celite and the filtrate evaporated and re-evaporated from toluene then diethyl ether to afford the title compound, 40mg.
Description 127. 3-({1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}amino)-4- nitrobenzonitrile (D127)
Figure imgf000112_0001
A stirred solution of 3-fluoro-4-nitrobenzonitrile (133mg, O.δOmmol) in dimethylformamide (4ml) at room temperature under argon was treated with diisopropylethylamine (0.46ml, 2.6mmol) followed by 1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D12, 225mg, 0.75mmol) and heated at 7O0C for 6hrs. The solution was concentrated under vacuum and the residue treated with 10% Na2CO3 solution (10ml) and extracted with dichloromethane (2x15ml). The combined extract was dried (Na2SO4), concentrated under vacuum and the residual solid chromatographed on silica gel (5g) eluting with 0- 10% methanol/dichloromethane to give an orange solid, which was recrystallised from MeOH (8ml) to afford the title compound as an orange solid (175mg, 63%). MH+ 373. 1H NMR δ (CDCI3, 400 MHz): 1-18-1.40 (4H, m), 1.21 (3H, t), 1.60-1.72 (2H, m), 1.90-1.98 (2H, m), 2.03-2.18 (4H, m), 2.32-2.50 (3H, m), 2.88-2.98 (2H, m), 3.13-3.23 (1 H, m), 3.42- 3.58 (3H, q + m), 6.84 (1 H, dd), 7.15 (1 H, d), 8.08 (1 H, d), 8.25 (1 H, d).
Description 128. 4-Amino-3-({1 -[frans-4-(ethyloxy)cyclohexyl]-4- piperidinyl}amino)benzonitrile (D128)
Figure imgf000112_0002
A stirred suspension of 3-({1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}amino)-4- nitrobenzonitrile (D127, 145mg, 0.39mmol) in ethanol (8ml) and water (2ml) at room temperature under argon was treated with iron powder (220mg), then cone. HCI acid (0.2ml) and maintained for 1.5hrs. The mixture was concentrated under vacuum and the residue treated with NaHCOs solution (15ml) and EtOAc (20ml), then shaken well and filtered through Kieselguhr. The EtOAc layer was isolated, dried (Na2SU4) and concentrated under vacuum to afford the title compound as a green/grey solid (120mg, 90%). MH+ 343. 1H NMR δ (CDCI3, 400MHz): 1.15-1.40 (7H, m), 1.42-1.55 (2H, m), 1.80-1.98 (assume 2H, m), 2.00-2.20 (assume 4H, m), 2.28-2.50 (assume 3H, m), 2.85-2.95 (2H, m), 3.00- 3.30 (3H, m), 3.51 (2H, q), 3.78 (2H, s), 6.69 (1 H, d), 6.85 (1 H, d), 6.99 (1 H, dd).
Description 129. 3-({1-[frans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}amino)- 4-nitrobenzonitrile (D129)
Figure imgf000113_0001
A solution of 3-fluoro-4-nitrobenzonitrile (1 11 mg, 0.67mmol) and 1-[frans-4-(ethyloxy)-1- methylcyclohexyl]-4-piperidinamine dihydrochloride (D58, 200mg, 0.61 mmol) in dimethylformamide (3ml) under argon was treated with diisopropylethylamine (0.3ml, 1.38 mmol) and the reaction mixture heated at 1 1O0C for 20mins in a microwave reactor. The resulting mixture was then concentrated under vacuum, the residue treated using aqueous NaHCO3 solution (30ml) and then extracted using ethyl acetate (2x40ml). The combined extract was dried (MgSO4) and concentrated under vacuum to give crude material as an orange residue. The residue was then chromatographed on silica eluting 0- 10% methanol/dichloromethane to yield the title compound (200mg, 80%) as an orange oil. M+ + H = 387
Description 130. 4-Amino-3-({1 -[frans-4-(ethyloxy)-1 -methylcyclohexyl]-4- piperidinyl}amino)benzonitrile (D130)
Figure imgf000114_0001
A stirred solution of 3-({1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}amino)-4- nitrobenzonitrile (1 10mg, 0.285mmol) in ethanol/Water (10ml/2ml) at room temperature under argon was treated with iron powder (250mg), followed by cone. HCI (0.3ml) and the reaction mixture maintained for 30mins. The homogeneous mixture was then concentrated under vacuum, the resultant residue treated with aqueous NaHCOs solution
(50ml) and ethyl acetate (50ml). The biphasic mixture was then well shaken before filtration through Kieselguhr, the organic phase was then separated, dried (MgSO4) and volatiles removed by evaporation under vacuum to afford crude product (90mg, 58% by
NMR). M+ + H = 357.
Description 131. 8-(2-Propyn-1-yloxy)-1 ,4-dioxaspiro[4.5]decane (D131)
Figure imgf000114_0002
A stirred solution of 1 ,4-dioxaspiro[4.5]decan-8-ol (D1 , 5.Og), propargyl bromide (4.6g) in N-methylpyrrolidinone (25ml) at ice bath temperature under argon and was treated portionwise with sodium hydride (2.6g of 60% oil dispersion), then the mixture was allowed to warm to room temperature overnight. The mixture was treated with water was added and the mixture extracted with a hexane - ethyl acetate - ether mixture. The organic extract as washed with sodium bicarbonate, then dried (Na2SO4) and solvent removed and the residue was chromatographed on silica gel eluted with hexane/ethyl acetate 10-30% to give the title compound as oil (3.1 1g)
1HNMR δ (CDCI3, 400 MHz): 1.55 (2H, m), 1.7-1.9 (6H, m), 2.41 (1 H, m), 3.55 (1 H, m), 3.92 (4H, m), 4.17 (2H, m).
Description 132. 4-(2-Propyn-1-yloxy)cyclohexanone (D132)
Figure imgf000114_0003
A solution of 8-(2-propyn-1-yloxy)-1 ,4-dioxaspiro[4.5]decane (D131 , 3.1 g) in tetrahydrofuran (5ml) was treated with 5M HCI acid (20ml) and stirred for 2h. The resulting mixture was diluted with water and extracted with dichloromethane (2 x). The combined extract was washed with brine and dried (Na2SO4) and concentrated under vacuum to afford the title compound as oil (2.37g).
1H NMR δ (CDCI3, 400 MHz): 2.00 (2H, m), 2.12 (2H, m), 2.3 (2H, m), 2.46 (1 H, m) 2.6 (2H1 m), 3.96 (1 H, m), 4.25 (2H1 s).
Description 133. cis/trans-1,1-Dimethylethyl {1-[4-(2-propyn-1 -yloxy)cyclohexyl]-4- piperidinyljcarbamate (D133)
Figure imgf000115_0001
A stirred solution of 4-(2-propyn-1-yloxy)cyclohexanone (D132, 1g) in 1 ,2-dichloroethane (50ml) under argon was treated with 1 ,1-dimethylethyl 4-piperidinylcarbamate (1.4g), sodium triacetoxyborohydride (2.Og), then the resulting mixture stirred at room temperature for 2 hours. The reaction mixture was diluted with dichloromethane then washed with Na2CO3 solution, brine, then dried (Na2SO4) and concentrated under vacuum. The crude product which was purified by chromatography (ethyl acetate/n- hexane) on a Biotage KP-NH™-silica column to yield, as a mixture of cis and trans isomers (1.1g). MH+ = 337
Description 134. cis/trans-1 -[4-(2-Propyn-1 -yloxy)cyclohexyl]-4-piperidinamine di- hydrochloride (D134)
Figure imgf000115_0002
cis/trans-1 ,1-Dimethylethyl{1-[4-(2-propyn-1-yloxy)cyclohexyl]-4-piperidinyl}carbamate (D133, 1.1g) was stirred in a solution of ethanol saturated with hydrogen chloride (25ml) for 2 hours. The solvent was evaporated to give the title compound as a white solid (1.27g). M+ + H = 253.
Description 135. Λ/-(5-Methyl-2-nitrophenyl)-1 -[frans-4-(2-propyn-1 - yloxy)cyclohexyl]-4-piperidinamine (D135a) and Λ/-(5-methyl-2-nitrophenyl)-1 -[c/s-4- (2-propyn-1 -yloxy)cyclohexyl]-4-piperidinamine (D135b)
Figure imgf000116_0001
(D135a) (D135b)
A solution of cis/trans-1-[4-(2-propyn-1-yloxy)cyclohexyl]-4-piperidinamine di- hydrochloride (D134, 0.2Og) diisopropylethylamine (1 ml) and 3-fluoro-4-nitrotoluene (0.2g) in dry dimethylformamide (3 ml), was heated at 2000C for 20 minutes in a microwave reactor. The crude mixture was then cooled to room temperature, the solvent was evaporated and the residue was loaded onto a SCX cartridge. The cartridge was eluted with methanol followed by 2M methanolic ammonia. The methanolic ammonia fraction was evaporated to afford the crude product. The above was repeated multiple times. The separate cis and trans isomers of the title compound were obtained by repeated chromatography on a Biotage KP-NH™-silica using a ethyl acetate/n-hexane gradient.
Fast eluting isomer (cis isomer; D135b) was obtained as a yellow solid. MH+ = 372. 1H NMR δ (CDCI3, 400 MHz): 0.94 (2H, m), 1.05-1.25 (obs, m), 1.95-2.14 (4H , m), 1.55- 1.70 (obs, m), 2.33 (3H, t), 2.35-2.55 (4H, m), 2.88 (2H, m), 3.15 (1 H, m), 3.22 (1 H, m), 4.14 (2H, m), 3.52 (2H, m), 6.14 (1 H, d), 6.61 (1 H, s) 8.04 (1 H, d), 8.19 (1 H, d).
Slow eluting isomer (trans isomer; D135a) was obtained as a white solid. MH+ = 372. 1H NMR δ (CDCI3, 400 MHz): 1.2-1.4 (4H, m), 1.65 (2H, m), 1.95 (2H, m), 2.05-2.18 (4H, m), 2.33 (3H, t), 2.35-2.5 (4H, m), 2.88 (2H, m), 3.42 (1 H, m), 2.55 (1 H, m), 4.19 (2H, m), 6.42 (1 H1 d), 6.61 (1 H, s) 8.07 (1 H, d), 8.2 (1 H, d).
Description 136. 4-Methyl-Λ/2-{1 -[c/s-4-(2-propyn-1 -yloxy)cyclohexyl]-4-piperidinyl}- 1,2-benzenediamine (D136)
Figure imgf000116_0002
A solution of Λ/-(4-fluoro-5-methyl-2-nitrophenyl)-1-[c/s-1-methyl-4-(propyloxy)cyclohexyl]- 4-piperidinamine (D135b, 0.18mg) in ethanol (7ml) was added over 10 min to a solution of tin (II) chloride ( 0.45g) in cone hydrochloric acid (5ml) stirred at 6O0C. The mixture was heated at 60°C for 0.5hr then poured into a mixture of dilute sodium hydroxide solution and dichloromethane. The dichloromethane layer was separated, washed with brine and dried with sodium sulfate and the solvent was removed to give the title compound as a oil (0.2g). MH+ = 342. Description 137. 4-Methyl-Λ/2-{1 -[frans-4-(2-propyn-1-yloxy)cyclohexyl]-4- piperidinyl}-1 ,2-benzenediamine (D137)
Figure imgf000117_0001
A solution of Λ/-(4-fluoro-5-methyl-2-nitrophenyl)-1-[frans-1-methyl-4-
(propyloxy)cyclohexyl]-4-piperidinamine (D135a, 0.269mg) in ethanol (15ml) was added over 5 min to a solution of tin (II) chloride (0.8g) in cone hydrochloric acid (8ml) stirred at 6O0C. The mixture was heated at 60°C for 0.5hr then poured into a mixture of dilute sodium hydroxide solution and dichloromethane. The dichloromethane layer was separated, washed with brine and dried with sodium sulfate and the solvent was removed to give the title compound as a glass (0.28g). MH+ = 342.
Description 138. Ethyl 4-{[2-nitro-5-(trifluoromethyl)phenyl]amino}-1 - piperidinecarboxylate (D138)
Figure imgf000117_0002
Ethyl-4-amino-i-piperidine-carboxylate (16.0 g, 92 mmol) was added to a stirred suspension of 3-chloro-4-nitrobenzotrifluoride (19.0 g, 84 mmol), sodium carbonate (8.9 g, 84 mmol) and potassium iodide (0.14 g, 0.84 mmol) in dimethylformamide (200 ml_). The mixture was heated to 90 0C, stirred for 15 hours and then allowed to cool. The reaction mixture was diluted with water (200ml) and ethyl acetate (200ml). The aqueous phase was separated and the organic phase was extracted with water (2 x 200ml). The organic phase was dried over MgSO4 and evaporated under reduced pressure. The residue was purified by column chromatography on silica, eluting with ethyl acetate/hexane (1 :5) to give the title compound (12.0 g, 40% yield) as an orange solid. (Rf: 0.4 (ethyl acetate/hexane 1 :5))
Description 139. Ethyl 4-{[2-amino-5-(trifluoromethyl)phenyl]amino}-1 - piperidinecarboxylate (D139)
Figure imgf000117_0003
A suspension of ethyl 4-{[2-nitro-5-(trifluoromethyl)phenyl]amino}-1-piperidinecarboxylate (D138, 18.0 g, 50 mmol) and 5% Pd/C (1.7 g) in methanol (400ml) in an autoclave (1000ml) was put under an atmosphere of hydrogen (~ 30 atm). The mixture was stirred at room temperature for 3 hours and then filtered through a pad of celite. The filtrate was concentrated under reduced pressure to give the title compound (15.9 g, 96% yield) as a brown solid that was used without further purification. (Rf: 0.3 (ethyl acetate/hexane 7:8))
Description 140. Ethyl 4-[2-oxo-6-(trifluoromethyl)-2,3-dihydro-1H-benzimidazol-1 - yl]-1 -piperidinecarboxylate (D140).
Figure imgf000118_0001
1 ,1 '-Carbonyldiimidazole (9.9 g, 61 mmol) was added portionwise over 10 minutes to a stirred solution of ethyl 4-{[2-amino-5-(trifluoromethyl)phenyl]amino}-1- piperidinecarboxylate (D139, 12.7 g, 38 mmol) in acetonitrile (200ml). The reaction mixture stirred at room temperature for 5 hours and then the solvent was removed under reduced pressure. The residue was diluted with dichloromethane (200ml) and extracted with a 10% aqueous solution of citric acid (2 x 100ml). The organic phase was dried over MgSO4 and evaporated under reduced pressure to give the title compound (13.5 g, 99% yield) as a brown solid that was used without further purification. (Rf: 0.2 (ethyl acetate))
Description 141. 1 -(4-Piperidinyl)-6-(trifluoromethyl)-1 ,3-dihydro-2H-benzimidazol- 2-one (D141).
Figure imgf000118_0002
lodotrimethylsilane (17ml, 120 mmol) was added to a stirred solution of ethyl 4-[2-oxo-6-
(trifluoromethyl)-2,3-dihydro-1/-/-benzimidazol-1-yl]-1-piperidinecarboxylate (D140, 13.5 g, 38 mmol) in chloroform (150ml) under argon. The reaction mixture was refluxed for 15 hours and then allowed to cool. Methanol (30ml) was added and the reaction mixture was stirred for 30 minutes. The precipitate was collected by filtration and washed with chloroform (2 x 20ml). The solid was dissolved in water (150ml) and the solution basified to pH 13 with solid sodium hydroxide. After stirring for 30 minutes, 6 M HCI was added until pH 8.5 was reached and the resulting precipitate was collected by filtration. The solid was dried under vacuum at 40 0C for 15 hours to give the title compound (11.1 g, 97% yield) as a colourless solid (Rf: Baseline (ethyl acetate/methanol (19:1 )). 1H-NMR (300 MHz, DMSOd6): δ 7.60 (1 H, s), 7.34 (1 H, d), 7.14 (1 H, d), 4.55 (1 H, m), 3.40 (2H, d), 3.05 (2H, t), 2.50 (2H, m), 1.88 (2H, m); m.p. >200 0C (decomp.).
Description 142. 1,1 -Dimethylethyl 4-[(5-methyl-2-nitrophenyl)amino]-1 - piperidinecarboxylate (D142)
Figure imgf000119_0001
A stirred solution of 3-fluoro-4-nitrotoluene (1 Og, 0.064mol) in dimethylformamide (40ml) at room temperature under argon was treated with diisopropylethylamine (14ml, O.OδOmol) followed by 1 ,1-dimethylethyl 4-amino-1-piperidinecarboxylate (11.3g, 0.064mol) and then heated at 9O0C for 18hrs. The mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution (100ml) and extracted with dichloromethane (2 x 150ml). The combined extract was washed with water (150ml), dried (Na2SO4) and concentrated under vacuum. The residue was treated with Et2O (200ml) and allowed to stand overnight. The crystals which had formed were filtered off, washed with Et2O and dried to afford the title compound as an orange solid (16g, 74%). 1H NMR δ (CDCI3, 400MHz): 1.45-1.65 (2H, m), 1.48 (9H, s), 2.00-2.10 (2H, m), 2.35 (3H, s), 3.00-3.15 (2H, m), 3.62-3.72 (1 H, m), 3.92-4.12 (2H, br m), 6.46 (1 H, dd), 6.63 (1 H, s), 8.07 (1 H, d), 8.15 (1 H, d).
Description 143. 1,1-Dimethylethyl 4-[(2-amino-5-methylphenyl)amino]-1 - piperidinecarboxylate (D143)
Figure imgf000119_0002
A stirred suspension of 1 ,1-dimethylethyl 4-[(5-methyl-2-nitrophenyl)amino]-1- piperidinecarboxylate (D142, 16g, 0.050mol) in ethanol (350ml) was treated with 10% Pd/C (1.5g) and maintained under a hydrogen atmosphere at room temperature and pressure for 16hrs. The mixture was filtered through Kieselguhr to remove the catalyst and the filtrate concentrated under vacuum to leave the title compound as a pale purple solid (13.5g, 93%).
1H NMR δ (CDCI3, 400MHz): 1.28-1.52 (2H, m), 1.48 (9H, s), 2.04 (2H, br d), 2.26 (3H, s), 2.90-3.02 (2H, m), 3.20 (3H, br s), 3.35-3.46 (1 H, m), 4.02 (2H, br s), 6.46-6.50 (2H, m), 6.64 (1 H, d).
Description 144. 1,1-Dimethylethyl 4-(6-methyl-2-oxo-2,3-dihydro-1H-benzimidazol- 1 -yl)-1 -piperidinecarboxylate (D144)
Figure imgf000120_0001
A stirred solution of 1 ,1-dimethylethyl 4-[(2-amino-5-methylphenyl)amino]-1- piperidinecarboxylate (13.5g, 0.044mol) in acetonitrile (300ml) at room temperature under argon was treated over 10 minutes with a solution of 1 ,1 '-carbonyldiimidazole (1 1.4g, 0.070mol) in acetonitrile (150ml), then heated at 4O0C for 6hrs followed by 18hrs at room temperature. The solid which had formed was filtered off, washed with acetonitrile and dried to afford 4.6g of title compound as a pale purple solid. The filtrate was concentrated under vacuum and the residue dissolved in dichloromethane (300ml) and washed with water (3 x 200ml), then dried (Na2SU4) and concentrated under vacuum to leave a brown oil. This was treated with 1 :1 EtOAc/60-80 petrol (200ml) to cause crystallisation of more title compound (5.6g).
1H NMR δ (CDCI3, 400MHz): 1.52 (9H, s), 1.83 (2H, br d), 2.26-2.45 (2H, m), 2.39 (3H, s), 2.80-3.00 (2H, br m), 4.30 (2H, br s), 4.41-4.52 (1 H, m), 6.87 (1 H, d), 6.94 (1 H, s), 6.98 (1 H1 d), 9.30 (1 H1 s).
Description 145. 6-Methyl-1 -(4-piperidinyl)-1 ,3-dihydro-2H-benzimidazol-2-one (D145)
Figure imgf000120_0002
A stirred solution of 1 ,1-dimethylethyl 4-(6-methyl-2-oxo-2,3-dihydro-1/-/-benzimidazol-1- yl)-1 -piperidinecarboxylate (D144, 10.2g, 0.031 mol) in a mixture of dichloromethane (80ml) and MeOH (20ml) at room temperature under argon was treated with 4M HCI in dioxane (35ml, 0.14mol) and stirred at room temperature for 20hrs. The solid which had formed was filtered off, washed with Et2O and dried to afford the HCI salt of the title compound as a pale grey solid (7.95g, 96%). Most of this material (7.8Og) was treated with DCM (220ml) and 10% Na2CO3 solution (200ml), shaken well until solid had dissolved, then the DCM layer was separated, dried (Na2SO4) and concentrated under vacuum to afford the title compound as a beige solid (6.8Og).
1H NMR (free base) δ (CDCI3, 400MHz): 1.64 (1 H, br s), 1.80-1.90 (2H, m), 2.30 -2.45 (2H, m), 2.39 (3H, s), 2.75-2.86 (2H, m), 3.23-3.31 (2H, m), 4.38-4.50 (1 H, m), 6.86 (1 H, d), 6.98 (1 H, d), 7.1 1 (1 H, s), 9.50 (1 H, br s).
Description 146. 1 -[frans-4-(Ethyloxy)-1 -methylcyclohexyl]-Λ/-(5-fluoro-2- nitrophenyl)-4-piperidinamine (D146)
Figure imgf000121_0001
A solution of 2, 4-difluoro-1 -nitrobenzene (0.115ml, 1.06mmol) and 1-[frans-4-(ethyloxy)-1- methylcyclohexyl]-4-piperidinamine dihydrochloride (D58, 300mg, 0.962mmol) in N1N- dimethylformamide (5ml) under argon was treated with diisopropylethylamine (0.49ml, 2.88 mmol) and the reaction mixture heated at 1 1O0C for 40mins in a microwave reactor. The resulting mixture was then concentrated under vacuum, the residue treated using dil. NaHCO3 solution (30ml) and then extracted using ethyl acetate (2x50ml). The combined extract was dried (MgSO4) and concentrated under vacuum to give crude material as an orange residue. The residue was chromatographed on silica gel eluting 0-10% methanol/dichloromethane to yield the title compound (130mg, 27%) as a yellow residue. MH+ = 380.
Description 147. (2-Amino-5-fluorophenyl){1 -[frans-4-(ethyloxy)-1 - methylcyclohexyl]-4-piperidinyl}amine.
Figure imgf000122_0001
A stirred solution of the 1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-Λ/-(5-fluoro-2- nitrophenyl)-4-piperidinamine (D146, 130mg, 0.342mmol) in EtOH (1 OmI) at room temperature under argon was treated with Raney Nickel (25mg), followed by hydrazine hydrate (166μl_, 3.42mmol). The reaction mixture left to stir for 2h when the initial yellow colour had been lost. The catalyst was removed by filtration through Kieselguhr and the filtrate concentrated under vacuum to leave the title compound as an off-white residue (97mg, 81 %). MH+ = 350.
Description 148. cis/trans-Λ -Methyl-4-(methyloxy)cyclohexanecarboxylic acid (D148)
Figure imgf000122_0002
A stirred solution of diisopropylamine (16.1 ml, 115 mmol, 2.1 eq.) in tetrahydrofuran (200ml) at O0C under argon was treated with 2.5M n-butyllithium in hexane (1.05 eq., 110 mmol, 44ml) and it was then stirred at the same temperature for 10 minutes. The mixture was then treated with a solution of 4-(methyloxy)cyclohexanecarboxylic acid (1 eq., 55 mmol, 8.7g) in 50 ml of dry tetrahydrofuran. The resulting yellow solution was heated at 5O0C for 2 hrs, then cooled to O0C and treated with iodomethane (3 eq., 12 ml). The mixture was allowed to warm to room temperature and was stirred for 2 hrs. The mixture was partitioned between citric acid (10% aqueous solution) and Et2O, the two phases were separated and the aqueous was extracted with Et2O (2x). Organics were combined, dried (Na2SO4), filtered and concentrated under vacuum to leave a yellow solid (9.8g) a mixture of cisitrans isomers.
1H NMR δ (d6DMSO, 400MHz): 1.078-2.018 (11 H, cis/trans isomers), 3.074 (1 H, m single isomer), 3.193 (3H, s single isomer), 3.213 (3H, s single isomer), 3.606 (1 H, s broad, single isomer), >12.5 (1 H, s broad, cis/trans isomers).
Description 149. frans-1-Methyl-4-(methyloxy)cyclohexanecarboxylic acid (D149) O
Figure imgf000123_0001
c/s/frans-1-methyl-4-(methyloxy)cyclohexanecarboxylic acid (D148, 41.3 mmol, 7.7 g) was dissolved in thionyl chloride (15.3 eq., 631 mmol, 46 ml). The mixture was refluxed at 9O0C for 4 hours. The solvent was evaporated and the crude product treated with toluene and concentrated in vacuo. The residual brown oil was treated with 5% Na2CO3 solution
(400 ml) and tetrahydrofuran (40 ml) and the mixture was stirred at room temperature for
30 minutes. The aqueous solution was washed with Et2O (2x) and the aqueous phase was acidified with 2M HCI acid and extracted with ethyl acetate (2x). The combined organics were dried over Na2SO4, filtered and the solvent was evaporated to afford the titled compound, 2.8 g, 40%.
1H NMR δ (d6DMSO, 400MHz): 1.085 (3H, s), 1.419 (2H, m), 1.485 (4H, m), 1.701 (2H, m), 3.225 (4H1 m), 3.342 (1 H1 s).
Description 150. trans-Λ -lsocyanato-1 -methyl-4-(methyloxy)cyclohexane (D150)
Figure imgf000123_0002
To a solution of frans-1 -methyl-4-(methyloxy)cyclohexanecarboxylic acid (D149, 15.0 mmol, 2.8 g) in dry toluene (70 ml), Et3N (1.3 eq., 19.6 mmol, 2.7 ml), and diphenylphosphoryl azide (1.0 eq., 15.0 mmol, 3.2 ml) were added at room temperature.
The mixture was refluxed at 8O0C for 2 hours. The mixture was cooled to room temperature and poured onto 1 M NaOH (70 ml); the aqueous solution was extracted with
EtOAc (2x). The organics were combined dried over Na2SO4, filtered and the solvent was evaporated to afford the crude compound. The crude product was then purified by chromatography (EtOAc-nhex) on silica column to afford the title compound, 1.33 g, 48%.
1H NMR δ (d6DMSO, 400MHz): 1.327 (3H, s), 1.61 (8H, m), 3.197 (3H, s) 3.355 (1 H, m).
Description 151. frans-1-Methyl-4-(methyloxy)cyclohexanamine monohydrochloride (D151) )
Figure imgf000124_0001
To a solution of frans-1 -isocyanato-1-methyl-4-(methyloxy)cyclohexane (D150, 7.27 mmol, 1.33 g) in THF (30 ml), concentrated HCI (6 ml) was added at room temperature. The mixture was stirred for 4 hours at room temperature and concentrated HCI (a few drops) was added. The reaction was left overnight and the solvent evaporated to afford the title compound, 0.9 g, 69%.
1H NMR δ (d6DMSO, 400MHz): 1.260 (3H, s), 1.39 (2H, m), 1.632 (4H, m), 1.87 (2H, m), 3.157 (1 H1 m), 3.217 (3H1 s).
Description 152. 1 -[frans-1-Methyl-4-(methyloxy)cyclohexyl]-4-piperidinone (D152)
Figure imgf000124_0002
Trans-1-methyl-4-(methyloxy)cyclohexanamine monohydrochloride (D151 , 7.69 mmol, 1.1 g), 1-ethyl-1-methyl-4-oxopiperidinium iodide (D49, 1.7 eq., 13.1 mmol), 3.5 g, K2CO3 (1.5 eq., 1 1.5 mmol, 1.5 g), water (40 ml) and ethanol (80 ml) were refluxed at 8O0C until the starting material was not observed on TLC. The mixture was partitioned between NaHCO3 and dichloromethane. Some product was lost due to mechanical spillage. The work up was repeated. The crude product was then purified by chromatography (MeOH-NH3- dichloromethane) on silica column to afford the title compound, 650 mg, 35 %. 1H NMR δ (d6DMSO, 400MHz) 0.85 (3H, s), 1.50 (8H, m)1.762 (2H, t), 2.301 (4H, t), 2.725 (4H, t), 3.207 (3H, s), 3.274 (1 H, m).
Description 153. 1-[frans-1 -Methyl-4-(methyloxy)cyclohexyl]-4-piperidinamine (D153)
Figure imgf000124_0003
To a solution of 1-[frans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinone (D152, 2.67 mmol, 650 mg) in 2M NH3 in methanol (15.0 eq., 40.0 mmol, 20 ml), 10% Pd/C paste (65 mg) was added. The mixture hydrogenated at 50psi for 24 hours at room temperature. The mixture filtered through kieselguhr and washed with ethanol (100 ml). The solvent was evaporated to afford the crude product. The reaction was repeated on the crude product and left for 24 hours. The mixture was filtered through celite and washed with ethanol and the solvent was evaporated to afford the titled compound, 390 mg, 68%, M+ + H = 227. Description 154. Λ/-(5-Fluoro-2-nitrophenyl)-1 -[trans-Λ -methyl-4- (methyloxy)cyclohexyl]-4-piperidinamine (D154)
Figure imgf000125_0001
Diisopropylethylamine (0.55mL, 3.23mmol) and 2,4-difluoro-1 -nitrobenzene (123μl_, 1.12mmol) were added to a solution of 1-[frans-4-(methyloxy)-1-methylcyclohexyl]-4- piperidinamine dihydrochloride (D153, 306mg, 1.02mmol) in N,N-dimethylformamide (5ml) under argon. The reaction was heated at 100°C in a microwave reactor for 30min and then for a further 30min. The mixture was poured on to sat. NaHCO3 (5OmL) and extracted with EtOAc (3x). The combined organics were washed sequentially with brine, H2O and brine, dried (Na2SO4) and concentrated via rotary evaporation. The crude residue was purified by SCX (5g) and then chromatographed (silica, CH2CI2-0.5% NH3 /9.5% MeOH /90% CH2CI2) to give a yellow oil. The yellow oil was then chromatographed (amine doped silica, hexane-EtOAc) to yield the title compound (204mg, 55%) as a yellow oil. MH+ 366
Description 155. (2-Amino-5-fluorophenyl){1 -[frans-4-(methyloxy)-1 - methylcyclohexyl]-4-piperidinyl}amine (D155)
Figure imgf000125_0002
Raney Nickel (0.25ml_, 10% sol. in H2O) was added to a vigorously stirred solution of N- (5-fluoro-2-nitrophenyl)-1-[frans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinamine
(D154, 245mg, 0.67mmol) in EtOH (1 OmL) under argon. Hydrazine hydrate (220μL, 7.06mmol) was added dropwise followed by a second portion of Raney Nickel (0.25ml_, 10% sol. in H2O). The reaction was stirred for 1 h and then filtered through Kieselguhr using EtOH. The solvent was removed via rotary evaporation to give the title compound (205mg, 91 %) as a brown oil which solidified on standing to a brown solid. MH+ 336.
Description D156. Λ/-(5-Chloro-2-nitrophenyl)-1 -[trans-Λ -methyl-4- (methyloxy)cyclohexyl]-4-piperidinamine (D156)
Figure imgf000126_0001
Diisopropylethylamine (0.53ml_, 3.12mmol) and 6-chloro-2-fluoro-1 -nitrobenzene (197mg, 1.12mmol) were added to a solution of 1-[frans-4-(methyloxy)-1-methylcyclohexyl]-4- piperidinamine dihydrochloride (D153, 318mg, 1.06mmol) in N,N-dimethylformamide (5ml) at r.t. under argon. The reaction was heated at 11 O0C in a microwave reactor for 30min and then for a further 30min after the addition of a second portion of 6-chloro-2-fluoro-1- nitrobenzene (81 mg, 0.46mmol). The reaction was poured on to sat. NaHCO3 (5OmL) and extracted with EtOAc (3x). The combined organics were washed sequentially with brine, H2O and brine, dried (Na2SO4) and concentrated via rotary evaporation. The crude residue was purified by SCX (5g) and then chromatographed (silica, CH2CI2-0.5% NH3 /9.5% MeOH /90% CH2CI2) to yield the title compound (323mg, 85%) as a yellow oil. M(CI-35)+ 382, M(CI-37)H+ 384.
Description D157. (2-Amino-5-chlorophenyl){1-[frans-1-methyl-4- (methyloxy)cyclohexyl]-4-piperidinyl}amine (D157)
Figure imgf000126_0002
Λ/-(5-Chloro-2-nitrophenyl)-1-[frans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinamine (D156, 323mg, 0.85mmol) was stirred vigorously in EtOH (1OmL) at r.t. under argon. Raney Nickel (0.25ml_, 10% sol. in H2O) was added, followed by the hydrazine hydrate (260μL, 8.35mmol). A second portion of Raney Nickel (0.25ml_, 10% sol. in H2O) was added and the reaction was stirred vigorously for 30min. The mixture was filtered through Kieselguhr using EtOH and concentrated by rotary evaporation to give the title compound (305mg) as a golden-brown solid. M(CI-35)+ 352, M(CI-37)H+ 354
Description 158. 2-Fluoro-4-ethoxy-1 -nitrobenzene (D158)
Figure imgf000127_0001
A solution of 3-fluoro-4-nitrophenol (3g), iodoethane (3ml) and potassium carbonate (5.5g) in butan-2-one (100ml) was heated at 850C for 2.5 hours. The mixture was cooled, filtered and the filtrate was evaporated. Trituration with hexane gave the title compound as an off white solid (3g).
Description 159. Λ/-[5-(Ethyloxy)-2-nitrophenyl]-1-[frans-1-methyl-4-
(methyloxy)cyclohexyl]-4-piperidinamine (D159)
Figure imgf000127_0002
A microwave vessel was charged with 2-fluoro-4-ethoxy-1 -nitrobenzene (D158, 0.3g), 1- [trans-i -methyl-4-(methoxy)cyclohexyl]-4-piperidinamine dihydrochloride (diHCI salt of D153, 0.3g), dimethylformamide (4ml) and diisopropylethylamine (1.0ml) and heated at 2000C for 20 minutes in a microwave reactor. The cooled reaction was evaporated, dissolved in methanol and loaded onto a SCX cartridge which was eluted with methanol then 2M methanolic ammonia. The methanolic ammonia fraction was evaporated and the residue was chromatographed on silica gel eluted with 0-5% dichloromethane - methanolic ammonia to give the title compound as a yellow glass (0.358g). MH+ = 392.
Description 160. 4-(Ethyloxy)-Λ/2-{1-[frans-1-methyl-4-(methyloxy)cyclohexyl]-4- piperidinyl}-1 ,2-benzenediamine (D160)
Figure imgf000128_0001
A solution of Λ/-[5-(ethyloxy)-2-nitrophenyl]-1-[frans-1-methyl-4-(methyloxy) cyclohexyl]-4- piperidinamine (D159, 0.35g) in ethanol (50ml), Raney-nickel (~2ml) and hydrazine hydrate (2ml) was stirred at 4O0C for 30 minutes, then cooled, filtered and the filtrate was evaporated and azeotroped with ethanol to give the title compound as a glass (0.26g). MH+ = 362.
Description 161. Λ/-[5-(Ethyloxy)-2-nitrophenyl]-1 -[trans-Λ -methyl-4- (ethyloxy)cyclohexyl]-4-piperidinamine (D161)
Figure imgf000128_0002
)
A microwave vessel was charged with 2-fluoro-4-ethoxy-1 -nitrobenzene (D158, 0.3g), 1- [frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinamine dihydrochloride (D58, 0.312g), dimethylformamide (4ml) and diisopropylethylamine (1.0ml) and heated at 2000C for 20 minutes in a microwave reactor. The cooled reaction was evaporated, dissolved in methanol and loaded onto a SCX cartridge, which was eluted with methanol then 2M methanolic ammonia. The methanolic ammonia fraction was evaporated and the residue was chromatographed on silica gel eluted with 0-5% dichloromethane - methanolic ammonia to give the title compound as a yellow glass (0.123g). MH+ = 406.
Description 162. 4-(Ethyloxy)-Λ/2-{1 -[trans-Λ -methyl-4-(ethyloxy)cyclohexyl]-4- piperidinyl}-1 ,2-benzenediamine (D162)
Figure imgf000128_0003
A solution of Λ/-[5-(ethyloxy)-2-nitrophenyl]-1-[frans-1-methyl-4-(ethyloxy) cyclohexyl]-4- piperidinamine (D161 , 0.123g) in ethanol (30ml), Raney-nickel (~1 ml) and hydrazine hydrate (1 ml) was stirred at 4O0C for 30 minutes then cooled, filtered and the filtrate was evaporated and azeotroped with ethanol to give the title compound as a glass (0.092g). MH+ = 376. Description 163. Λ/-(5-Chloro-2-nitrophenyl)-1 -[frans-4-(ethyloxy)-1 - methylcyclohexylj^-piperidinamine (D163)
Figure imgf000129_0001
Diisopropylethylamine (0.52ml_, 3.06mmol) and 4-chloro-2-fluoro-1 -nitrobenzene (364mg, 2.07mmol) were added to a solution of 1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4- piperidinamine dihydrochloride (D58, 318mg, 1.02mmol) in N,N-dimethylformamide (5ml) at r.t. under argon. The reaction was heated at 11 O0C in a microwave reactor for 30min and then the mixture was poured on to sat. NaHCO3 (5OmL) and extracted with EtOAc (3x). The combined organics were washed sequentially with brine, H2O and brine, dried (Na2SO4) and concentrated via rotary evaporation. The crude residue was purified by SCX (5g) and then chromatographed (silica, CH2CI2-0.5% NH3 /9.5% MeOH /90% CH2CI2) to yield the title compound (153mg, 38%) as a yellow oil. M(CI-35)+ 396, M(CI-37)H+ 398.
Description 164. (2-Amino-5-chlorophenyl){1 -[frans-4-(ethyloxy)-1 - methylcyclohexyl]-4-piperidinyl}amine (D164)
Figure imgf000129_0002
Λ/-(5-Chloro-2-nitrophenyl)-1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinamine (D163, 153mg, 0.40mmol) was stirred vigorously in EtOH (1 OmL) under argon. Raney Nickel (0.25mL, 10% sol. in H2O) was added, followed by the hydrazine hydrate (130μL, 4.17mmol). A second portion of Raney Nickel (0.25mL, 10% sol. in H2O) was added and the reaction was stirred vigorously for 30min. The mixture was filtered through Kieselguhr using EtOH and concentrated by rotary evaporation to give the title compound (139mg, 95%) as a yellow oil. M(CI-35)+ 366, M(CI-37)H+ 368.
Example 1. 6-Methyl-1 -[1 -(c/s-4-methoxycyclohexyl)-4-piperidinyl]-1 , 3-d i hydro -2 H- benzimidazol-2-one hydrochloride (E1)
Figure imgf000130_0001
A solution of cis 5-methyl-Λ/-[1-(4-methoxycyclohexyl)-4-piperidinyl]-1 ,2-benzenediamine (D7, 320mg; 0.9mmol) in dichloromethane (20ml) at O0C was treated with triphosgene
(110mg, 0.4eq) then diisopropylethylamine (0.23ml, 1.5eq), and then maintained at O0C for 1 h. The mixture was washed with water at pH9. Drying, evaporation, and chromatography (2Og silica, 0-10% methanol in dichloromethane) gave 220mg (71 %) of the free base compound from diethyl ether. This was then converted to 230mg of the hydrochloride salt from diethyl ether, 230mg.
1H NMR (HCI salt) δ (d6DMSO): 1.4 (2H, m), 1.7 (2H, m), 1.8-2.1 (6H, m), 2.35 (3H, s), 2.9 (2H, m), 3.2 (3H, s), 3.2-3.6 (6H, m), 4.55 (1 H, m), 6.8 (2H, ABq), 7.5 (1 H, s), 10.55 (1 H, br s), 10.8 (1 H, s), MH+ 344.
Example 2. θ-Methyl-i-II-ffrans^-methoxycyclohexyl^-piperidinyll-I.S-dihydro- 2/-/-benzimidazol-2-one hydrochloride (E2)
Figure imgf000130_0002
A solution of trans 5-methyl-Λ/-[1-(4-methoxycyclohexyl)-4-piperidinyl]-1 ,2- benzenediamine (D8, 100mg, 0.3mmol) in dichloromethane (6ml) at O0C was treated with triphosgene (40mg, 0.4eq) then diisopropylethylamine (0.08ml, 1.5eq), and then maintained at O0C for 1 h. The mixture was washed with water at pH9. Drying, evaporation and chromatography (10g silica, 0-10% methanol in dichloromethane) gave the title compound isolated as the hydrochloride salt from diethyl ether, 65mg. 1H NMR (HCI salt) δ (d6DMSO): 1.2 (2H, m), 1.6 (2H1 m), 1.9 (2H1 m), 2.15 (4H, m), 2.35 (3H, s), 2.9 (2H, m), 3.25 (3H, s), 3.1-3.6 (6H, m), 4.55 (1 H, m), 6.8 (2H, ABq), 7.5 (1 H, s), 10.55 (1 H, br s), 10.8 (1 H, s), MH+ 344.
Example 3. 1 -{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-methyl-1 ,3-dihydro- 2/-/-benzimidazol-2-one hydrochloride (E3)
Figure imgf000131_0001
To a solution of (2-amino-5-methylphenyl){1-[frans-4-(ethyloxy)cyclohexyl]-4- piperidinyl}amine (D14, 110mg, 0.33 mmol) in dichloromethane (10 ml), diisopropylethylamine (0.085ml, 1.5eq., 0.50 mmol) was added at room temperature. The mixture was cooled to O0C and bis(trichloromethyl)carbonate (40mg, 0.4eq., 0.13 mmol) was added. After 30 minutes the mixture was poured onto water; the aqueous solution was extracted with dichloromethane (2x) and the organics were alternatively washed with brine and water (2x). The organics were combined, dried over Na2SC>4, filtered and the solvent was evaporated. The product was treated with HCI (3 ml of a 1 M solution in diethyl ether) to yield the title product (44 mgs, 37%). M+ - H = 356.
1H NMR (HCI salt) δ (d6DMSO, 400MHz) 1.093 (3H, t), 1.221 (2H, m), 1.542 (2H, m) 1.887 (2H, m) 2.108 (3H, d) 2.333 (3H, s) 2.782 (2H, m), 3.202 (4H, m) 3.473 (4H, m) 4.542 (1 H, m) 6.805 (1 H, d) 6.871 (1 H, d) 7.345 (1 H, s), 10.00 (1 H, br), 10.80 (1 H, s).
Example 4. 1 -{1 -[c/s-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-methyl-1 ,3-dihydro-2H- benzimidazol-2-one hydrochloride (E4)
Figure imgf000132_0001
To a solution of (2-amino-5-methylphenyl){1-[c/s-4-(ethyloxy)cyclohexyl]-4- piperidinyl}amine (D17, 147mg, 0.4 mmol) in dichloromethane (10 ml), diisopropylethylamine (0.09ml, 1.5eq., 0.7 mmol) was added at room temperature. The mixture was cooled to O0C and bis(trichloromethyl)carbonate (0.053g, 0.4eq., 0.2 mmol) was added under argon. After 30 minutes waster was added; the aqueous solution was extracted with dichloromethane (2x) and the organics were alternatively washed with brine and water (2x). The organics were combined, dried over Na2SO4, filtered and the solvent was evaporated. The product was treated with HCI (3 ml of a 1 M solution in diethyl ether). The product was further purified by chromatography (EtOAc 60%: hexane), SCX followed by Waters Xbridge chromatography column eluting with acetonitrile/water/0/1 % formic acid, to yield the title product (33 mgs, 21 %). M+ - H = 358. 1H NMR (HCI salt) δ (d6DMSO 400MHz): 1.129 (3H, t), 1.441 (2H, t), 1.689 (2H, q), 1.887 (4H, t), 1.982 (2H, d), 2.331 (3H, s), 2.828 (2H, m), 3.247 (3H, m), 3.427 (2H, q), 3.492 (3H, m), 4.555 (1 H, m), 6.801 (1 H, d), 6.870 (1 H, d), 7.462 (1 H, s), 10.3 (1 H, br s), 10.8 (1 H1 S).
Example 5. 6-Methyl-1 -{1 -[c/s-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 , 3-d i hydro - 2H-benzimidazol-2-one (E5)
Figure imgf000132_0002
A stirred solution of (2-amino-5-methylphenyl){1-[c/s-4-(propyloxy)cyclohexyl]-4- piperidinyl}amine (D23, 400mg, 1.15mmol) and diisopropylethylamine (0.25ml, 1.4mmol, 1.5eq) in dichloromethane (35ml) at O0C under argon was treated with solid triphosgene (138mg, 0.46mmol, 0.4eq) and maintained at room temperature for 3 days (64% of conversion). The mixture was treated with water (20ml) and extracted with dichloromethane (2 x 20ml). The combined extract was dried on MgSO4 and concentrated under vacuum to leave a beige solid, which was chromatographed on silica column (4Og of silica for 200mg of crude: 5% to 15% 0.4M NH3 in methanol/dichloromethane 12CV) to give 150mg (35% yield) of title compound. 1H NMR (free base) δ (CDCI3 400MHz): 0.9 (3H, t), 1.4 (2H, m), 1.6 (6H, m), 1.7 (2H, m), 1.85 (2H, m), 2.0 (2H, m), 2.4 (6H, m), 3.1 (2H, m), 3.35 (2H, t), 3.5 (1 H, s), 4.3-4.4 (1 H, m), 6.85 (1 H, d), 6.9 (1 H, d), 7.15 (1 H, s), 8.3 (1 H, s). MH+ 372 and 373.
Example 6. 6-Methyl-1-{1 -[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,3- dihydro-2/-/-benzimidazol-2-one hydrochloride (E6)
Figure imgf000133_0001
A stirred solution of (2-amino-5-methylphenyl){1-[frans-4-(propyloxy)cyclohexyl]-4- piperidinyl}amine (D24, 310mg, 0.89 mmol) and diisopropylethylamine (0.23ml, 0.36 mmol, 1.5eq) in dichloromethane (20ml) at O0C under argon was treated with solid triphosgene (107mg,0.4eq) and maintained at O0C for 30 minutes. The mixture was treated with water and extracted with dichloromethane. The combined extract was dried on MgSO4 and concentrated under vacuum to leave 330mg of title compound as a brown solid. This material was dissolved in dichloromethane, treated with 1 M HCI/diethyl ether (5ml) and concentrated under vacuum to give the hydrochloride salt as a white solid (36Og, 99% yield). 1H NMR (HCI salt) δ (CD3OD 400MHz): 0.95 (3H, t), 1.3-1.4 (2H, m), 1.5-1.7 (4H, m), 2.05 -2.3 (6H, m), 2.4 (3H, m), 2.75-2.9 (2H, m), 3.25-3.4 (4H, m), 3.45 (2H, t), 3.6-3.7 (2H, m), 4.5-4.6 (1 H, m), 6.9 (2H, m), 7.15 (1 H, m). MH+ 372 and 373. Example 7. 6-Methyl-1 -(1 -{frans-4-[(1 -methylethyl)oxy]cyclohexyl}-4-piperidinyl)- 1,3-dihydro-2/-/-benzimidazol-2-one hydrochloride (E7)
Figure imgf000134_0001
A stirred solution of (2-amino-5-methylphenyl)(1-{frans-4-[(1-methylethyl)oxy]cyclohexyl}- 4-piperidinyl)amine (D31 , 187mg, 0.54mmol) and diisopropylethylamine (0.144ml, 0.81 mmol) in dichloromethane (15ml) at O0C under argon was treated with solid triphosgene (64mg, 0.22mmol) and maintained at O0C for 45 minutes. The mixture was treated with water (10ml) followed by dil. NaHCO3 solution (15ml) and extracted with dichloromethane (2 x 20ml). The combined extract was dried (Na2SC>4) and concentrated under vacuum. Trituration of the residue with 1 :1 ethyl acetate/diethyl ether (8ml) produced a white solid which was filtered off after 15 minutes, washed with cold 1 :1 ethyl acetate/diethyl ether and dried at 5O0C under vacuum to afford a white solid. This material was dissolved in dichloromethane (2ml) and methanol (0.3ml), treated with 1 M HCI/diethyl ether (0.60ml) and concentrated under vacuum. The residue was triturated with diethyl ether (5ml) to give a white solid, which was filtered off, washed with diethyl ether and dried to afford the title compound as a white solid. 1H NMR (HCI salt) δ (d6DMSO, 400 MHz): 1.07 (6H, d), 1.12-1.28 (2H, m), 1.48-1.63 (2H, m), 1.78-1.90 (2H, m), 1.97-2.08 (2H, m), 2.10-2.20 (2H, m), 2.32 (3H, s), 2.82-3.00 (2H, m), 3.12-3.35 (4H, m), 3.42-3.55 (2H, m), 3.62-3.75 (1 H, m), 4.50-4.65 (1 H, m), 6.79 (1 H, d), 6.86 (1 H, d), 7.61 (1 H, s), 10.78 (1 H1 s), 10.85 (1 H, br s).
Example 8. 6-Methyl-1 -{1 -[c/s-1 -methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3- dihydro-2/-/-benzimidazol-2-one hydrochloride (E8)
Figure imgf000135_0001
(2-Amino-5-methylphenyl){1-[c/s-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}amine (D36, 91 mg, 0.27 mmol) was dissolved in dichloromethane (5 ml) and cooled to 0 0C; bis(trichloromethyl) carbonate (0.4 eq., 0.11 mmol, 31 mg) was then added followed by Hunig's base diisopropylethylamine (1.5 eq., 68μl) at 0 0C; the mixture was stirred at the same temperature for 1 hour and then it was quenched with NaHCO3 (aqueous saturated solution). The two phases were separated and the organic phase was dried over Na2SO4, filtered and the solvent was evaporated to afford the crude product, which was purified by chromatography (MeOH-NH3-DCM) which gave the title compound, 76 mg, 80%, 99.7% = isomeric purity. The title compound was subsequently converted into the hydrochloride salt using HCI solution (1 M in diethyl ether, 2 eq.).
1H NMR δ (d6DMSO, 400 MHz) 0.851 (3H, s), 1.139 (2H, t), 1.585 (4H, m), 1.669 (2H, d), 1.884 (2H, d), 2.141 (2H, t), 2.262 (2H, t), 2.316 (3H, s), 3.01 1 (2H, d), 3.241 (3H, s), 4.020 (1 H, m br), 6.768 (1 H, d), 6.836 (1 H, d), 6.994 (1 H, s) 10.7 (1 H, s br).
Example 9. 6-Methyl-1 -{1 -[frans-1 -methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}- 1 ,3-dihydro-2H-benzimidazol-2-one hydrochloride (E9)
Figure imgf000135_0002
(2-Amino-5-methylphenyl){1-[frans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}amine (D37, 30 mg, 0.091 mmol) was dissolved in dichloromethane (2 ml) and cooled to O0C. Bis(trichloromethyl) carbonate (0.4 eq., 0.036 mmol, 11 mg) was then added followed by Hunig's base diisopropylethylamine (1.5 eq., 23 μl) at O0C. The mixture was stirred at the same temperature for 1 hour and then it was quenched with NaHCO3 (aqueous saturated solution). The two phases were separated and the organic phase was dried over Na2SO4, filtered and the solvent was evaporated to afford the crude product, which was purified by chromatography (MeOH-NH3-DCM) which gave the title compound, 9 mg, 28%, 97.8% = isomeric purity. The title compound was subsequently converted into the hydrochloride salt using HCI solution (1 M in diethyl ether, 2 eq.).
1H NMR δ (d6DMSO, 400 MHz) 0.851 (3H, s), 1.503 (6H, m), 1.663 (2H, d br), 1.794 (2H, m br), 2.157 (2H, t), 2.272 (2H, t), 2.320 (3H, s), 3.045 (2H, d), 3.161 (3H, s), 4.027 (1 H, m br), 6.768 (1 H, d), 6.836 (1 H, d), 7.000 (1 H, s), 10.7 (1 H, s br).
Example 10. θ-Methyl-i^i^c/s^-^i-methylethylJoxylcyclohexy^^-piperidinylJ-ijS- dihydro-2/-/-benzimidazol-2-one hydrochloride (E10)
Figure imgf000136_0001
A stirred solution of (2-amino-5-methylphenyl)(1-{c/s-4-[(1-methylethyl)oxy]cyclohexyl}-4- piperidinyl)amine (D39, 170mg, 0.49mmol) in dichloromethane (15ml) at O0C under argon was treated with diisopropylethylamine (0.13ml, 0.74mmol) followed by solid triphosgene (57mg, 0.196mmol) and maintained at O0C for 1 h. The mixture was treated with water (10ml) followed by dil. NaHCO3 solution (15ml) and extracted with dichloromethane (2 x 25ml). The combined extract was dried (Na2SO4) and concentrated under vacuum. The residue was dissolved in dichloromethane (4ml), treated with 1 M HCI/diethyl ether (0.7ml) and concentrated under vacuum. The residue was triturated with diethyl ether (10ml) to give a white solid, which was filtered off, washed with diethyl ether and dried at 5O0C under vacuum to afford the hydrochloride salt a white solid (170mg, 85%). 1H NMR (HCI salt) δ (d6DMSO, 400 MHz): 1.10 (6H, d), 1.39-1.52 (2H, m), 1.62-1.80 (2H, m), 1.80-2.00 (6H, m), 2.32 (3H, s), 2.82-3.00 (2H, m), 3.18-3.32 (3H, m), 3.40-3.55 (2H, m), 3.55-3.70 (2H, m), 4.50-4.65 (1 H, m), 6.80 (1 H, d), 6.87 (1 H, d), 7.60 (1 H, s), 10.73 (1 H, br s), 10.80 (1 H, s).
Examples 11 and 12. cis and trans 1-(1-[4-(Ethoxyl)cyclohexyl]-4-piperidinyl)-1 ,3- dihydro-2H-benzimidazol-2-one hydrochloride (cis = E11 ; trans = E12)
Figure imgf000137_0001
E11 E12
A microwave vessel was charged with 4-(2-oxo-1-benzimidazolinyl)piperidine (0.217g, 1 mmol), 4-ethoxycyclohexanone (D10, 0.22g, 1.55mmol), acetic acid (0.2ml), dichloromethane (15ml) and (polystyrymethyl)trimethylammonium cyanoborohydride (4.3meq/g) (750mg) and heated at 11 O0C for 20 minutes in a microwave reactor. Further 4-ethoxycyclohexanone (146mg, LOmmol) and (polystyrymethyl)trimethylammonium cyanoborohydride (300mg) were added and mixture heated at 11 O0C for a further 20 minutes in a microwave reactor. The cooled mixture was filtered under vacuum and the filtrate loaded onto a 5g SCX cartridge, which was eluted with methanol followed by methanolic ammonia. The solvent was removed from the methanolic ammonia fraction to give 260mg of a clear oil, which was purified using a Waters Xbridge chromatography column and a gradient of aqueous ammonium bicarbonate (10mmolar; adjusted to pH10 with ammonia) and acetonitrile as the mobile phase to give the cis and trans isomers. Once obtained each isomer was redissolved in dichloromethane (2ml), and 1 molar HCI in diethyl ether (0.5ml) added, then the solvent was removed to afford the title compounds.
Fast eluting isomer (trans isomer; E12) was obtained as an off white solid (0.024g). MH+ = 344. 1HNMR δ. d6DMSO, 250MHz): 1.1-1.4 (assume 8H, m), 1.65 (assume 2H, m), 1.8 (assume 2H, m), 2.0 (assume 2H, m), 2.2-2.4 (assume 6H, m), 2.9 (assume 2H, d), 3.1- 3.2 (assume 1 H, m), 3.4-3.5 (assume 2H, q), 4.0-4.2 (assume 1 H, m), 7.0 (assume 3H, m), 7.2 (assume 1 H, m).
Slow eluting isomer (cis isomer; E1 1 ) was obtained as a white solid (0.026g). MH+ = 344. 1HNMR δ CDCI3, 250MHz): 1.29 (assume 3H, t), 1.25-1.5 (assume 3H, m), 1.6-2.05 (m), 2.3-2.5 (assume 5H, m), 3.0-3.1 (assume 2H, m), 3.4-3.6 (assume 4H, m), 4.25-4.45 (assume 1 H, m), 7.0-7.1 (assume 3H, m), 7.3 (assume 1 H, m), 8.05 (assume 1 H, s).
Example 13. 1 -{1-[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-fluoro-1,3-dihydro- 2/-/-benzimidazol-2-one hydrochloride (E13)
Figure imgf000138_0001
A stirred solution of Λ/2-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-4-fluoro-1 ,2- benzenediamine (D72, <0.33mmol) in dichloromethane (10ml) at O0C under argon was treated with diisopropylethylamine (0.087ml, 0.49mmol) followed by the addition of solid triphosgene (38mg, 0.13mmol) and maintained for 30mins. The mixture was treated with dil. NaHCC>3 solution (10ml) and extracted with dichloromethane (2x20ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave a beige solid, which was recrystallised from EtOAc/Et2O to afford the free base of the title compound as a white solid (90mg, >76%). This was dissolved in dichloromethane (2ml), treated with 1 M HCI/Et2O (0.30ml) and concentrated under a stream of argon to afford the title compound as a white solid MH+ = 362.
1H NMR (free base) δ (CDCI3, 400MHz): 1.15-1.42 (assume 7H, t + m), 1.82 (2H, br m), 1.92 (2H, br m), 2.12 (2H, br m), 2.30-2.50 (5H, m), 3.10-3.13 (2H, m), 3.13-3.35 (1 H, m), 3.52 (2H, q), 4.25-4.40 (1 H, m), 6.73-6.80 (1 H, m), 6.96-7.02 (1 H, m), 7.05 (1 H, br d), 9.83 (1 H, s).
Example 14. 6-Bromo-1-{1 -[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1,3-dihydro- 2/-/-benzimidazol-2-one hydrochloride (E14)
Figure imgf000138_0002
A stirred solution of 4-bromo-Λ/2-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,2- benzenediamine (D74, 600mg, 1.5mmol) and diisopropylethylamine (0.4ml, 2.25mmol) in dichloromethane (50ml) at O0C was treated with triphosgene (178mg, O.δmmol) and stirred for 30mins. The mixture was washed with water and saturated NaHCOs solution, then extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum to leave a white solid, which was washed with 10% Et2O/petrol ether to afford the free base of the title compound as a white solid (426mg, 67%). A portion of this (226mg) was dissolved in dichloromethane (10ml), treated with 1 M HCI/Et2O (5ml), stirred for 30mins, then concentrated under vacuum to afford the title compound as a white solid (220mg). MH+ = 423, 424.
1H NMR δ (d6DMSO, 400MHz): 1.09 (3H, t), 1.12-1.30 (2H, m), 1.48-1.62 (2H, m), 1.90 (2H, br d), 2.05-2.18 (4H, m), 2.70-2.85 (2H, m), 3.15-3.30 (4H, m), 3.41-3.55 (4H, m), 4.53-4.65 (1 H, m), 6.95 (1 H, d), 7.16 (1 H, dd), 7.66 (1 H, d), 10.35 (1 H, br m), 11.1 1 (1 H, s).
Example 15. 1 -{1 -[c/s^^EthyloxyJcyclohexyll^-piperidiny^-θ^trifluoromethylJ-i ,3- dihydro-2H-benzimidazol-2-one monohydrochloride (E15)
Figure imgf000139_0001
To a solution of 1-(4-piperidinyl)-6-(trifluoromethyl)-1 ,3-dihydro-2H-benzimidazol-2-one (D141 , 0.63 mmol, 180 mg) in dichloroethane (5 ml), 4-(ethyloxy)cyclohexanone (D10, 4 eq., 2.52 mmol, 358 mg), Et3N (a few drops) and 5A molecular sieves were added. The reaction was left stirring overnight. NaBH(OAc)3 (1.5 eq., 0.9464 mmol, 0.2g) was added and the reaction left stirring for four overnights. The mixture was basified with 2M NaOH
(1 ml). The reaction was quenched with NaHCO3 and the aqueous solution was extracted with dichloromethane The organics were combined and washed with water (2x50ml), dried over Na2SO4, filtered and the solvent was evaporated to afford the crude product.
The crude product was purified by chromatography (10% MeOH /dichloromethane) on silica column followed by another column chromatography (1 1 % - 13% EtOAc in nhex) on
Biotage KP-NH™-silica column to yield to afford the free base of the title compound, 23 mg, 9%. M+ + H = 412. This was subsequently converted into the title compound using
HCI solution (1 M in Et2O) to afford 23 mg. 1H NMR δ (d6DMSO, 400MHz) 1.11 1 (3H, t), 1.397 (2H, m), 1.694 (2H, q), 1.937 (6H, m), 2.782 (2H q), 3.240 (3H, m), 3.404 (2H, q), 3.536 (3H, m), 4.626 (1 H m), 7.172 (1 H, d), 7.373 (1 H, d), 7.707 (1 H, s), 10.05 (1 H, s br), 11.45 (1 H, s).
Example 16 6-Ethyl-1-{1 -[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1,3-dihydro- 2H-benzimidazol-2-one hydrochloride (E16)
Figure imgf000140_0001
A stirred solution of 4-ethyl-Λ/2-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,2- benzenediamine (D76, 348mg, 1 mmol) and diisopropylethylamine (0.17ml, 1.5mmol) in dichloromethane (25ml) at O0C was treated with triphosgene (118mg, 0.4mmol) and stirred at 0°C for 30mins. The mixture was washed with water and saturated NaHCO3 solution, then extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum to leave a pale yellow solid. This was dissolved in dichloromethane (5ml), treated with HCI/Et2O (3ml) and concentrated under vacuum to afford the title compound as a white solid (260mg, 65%). MH+ = 372.
1H NMR δ (d6DMSO, 400MHz): 1.05-1.33 (2H, m), 1.10 (3H, t), 1.21 (3H, t), 1.47-1.63 (2H, m), 1.85 (2H, br d), 2.05-2.25 (4H, m), 2.50-2.68 (2H, m), 2.80-3.00 (2H, m), 3.13- 3.30 (4H, m), 3.35-3.55 (4H, m), 4.50-4.62 (1 H, m), 6.80-6.90 (2H, m), 7.54 (1 H, s), 10.7 (1 H, br m), 10.80 (1 H1 s).
Example 17 6-Cyclopropyl-1 -{1 -[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,3- dihydro-2H-benzimidazol-2-one hydrochloride (E17)
Figure imgf000141_0001
A stirred solution of 4-cyclopropyl-Λ/2-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,2- benzenediamine (D78, 200mg, 0.56mmol) and diisopropylethylamine (0.14ml, 0.84mmol) in dichloromethane (20ml) at O0C was treated with triphosgene (66mg, 0.23mmol) and stirred for 30mins at 0°C. The solution was washed with water and sat. NaHCO3 solution, then extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum. The residue was dissolved in dichloromethane (10ml), treated with 1 M HCI/Et2O (3ml), stirred for 30mins, then concentrated under vacuum to afford the title compound as a white solid (165mg, 72%). MH+ = 384.
1H NMR δ (d6DMSO, 400MHz): 0.70-0.77 (2H, m), 0.84-0.94 (2H, m), 1.09 (3H, t), 1.10- 1.30 (2H, m), 1.48-1.62 (2H, m), 1.85 (2H, br d), 1.88-2.00 (1 H, m), 2.04-2.20 (4H, m), 2.78-2.95 (2H, m), 3.15-3.30 (4H, m), 3.40-3.55 (4H, m), 4.50-4.62 (1 H, m), 6.71 (1 H, d), 6.85 (1 H, d), 7.28 (1 H, s), 10.6 (1 H, br m), 10.78 (1 H, s).
Example 18. 1 -{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-(methyloxy)-1 ,3- dihydro-2/-/-benzimidazol-2-one hydrochloride (E18)
Figure imgf000141_0002
A stirred solution of Λ/2-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-4-(methyloxy)-1 ,2- benzenediamine (D80, 120mg, 0.35mmol) in dichloromethane (10ml) at O0C under argon was treated with diisopropylethylamine (0.092ml, 0.52mmol) followed by the addition of solid triphosgene (40mg, 0.14mmol) and maintained for 30mins. The mixture was treated with 10% Na2CC>3 solution (10ml) and extracted with dichloromethane (2x15ml). The combined extract was dried (Na2SU4) and concentrated under vacuum to leave a beige solid, which was recrystallised from 1 :1 EtOAc/Et2O to afford the free base of the title compound as a white solid (105mg, 81 %). This was dissolved in dichloromethane (5ml), treated with 1 M HCI/Et2O (0.3ml) and concentrated under vacuum to afford the title compound as a white solid (1 10mg) MH+ = 374.
1H NMR δ (d6DMSO, 400MHz): 1.07 (3H, t), 1.10-1.30 (4H, m), 1.47-1.67 (2H, m), 1.80- 1.92 (2H, m), 2.03-2.23 (4H, m), 2.80-3.00 (2H, m), 3.12-3.32 (4H, m), 3.40-3.65 (assume 2H), 3.79 (3H, s), 4.50-4.67 (1 H, m), 6.58 (1 H, d), 6.87 (1 H, d), 7.26 (1 H, s), 10.71 (1 H, s), 10.8 (1 H, br m).
Examples 19 and 20. cis and frans-1 -{1-[4-(Ethoxy)cyclohexyl]-4-piperidinyl}-6- [(trifluoromethyl)oxy]-1,3-dihydro-2H-benzimidazol-2-one (cis = E19; trans = E20)
Figure imgf000142_0001
E19 E20
A microwave vessel was charged with 1-(4-piperidinyl)-6-[(trifluoromethyl)oxy]-1 ,3- dihydro-2H-benzimidazol-2-one (D83, 337mg), 4-(ethoxy)cyclohexanone (D10, 190mg) (polystyrylmethyl)trimethylammonium cyanoborohydride (4.3meq/g 0.6g), sodium acetate (100mg), dichloromethane (10ml), acetic acid (200μl) and heated at 1 1O0C for 20 minutes in a microwave reactor. Further 4-(ethoxy)cyclohexanone (D10, 0.06g) and (polystyrylmethyl)trimethylammonium cyanoborohydride (4.3meq/g 0.6g) were added and heated at 1 1O0C for 20 minutes in a microwave reactor. The cooled mixture was filtered and the filtrate was loaded onto a SCX cartridge which was eluted with methanol followed by methanolic ammonia. The methanolic ammonia fraction was evaporated and the resulting mixture was purified using a Waters Xbridge chromatography column. A gradient of aqueous ammonium bicarbonate (10mmolar adjusted to pH10 with ammonia) and acetonitrile was used as the mobile phase to give the cis and trans isomers. Once obtained each isomer was redissolved in dichloromethane (2ml), and 1 molar HCI in diethyl ether (0.5ml) added, the solvent was then removed.
Fast eluting isomer (trans isomer E20) was obtained as a white solid (0.035g). MH+ =.428 1H NMR δ (DMSO, 250 MHz): 1.1 (3H, t), 1.1-1.3 (2H ,m), 1.4-1.7 (2H, m), 1.8-2.0 (2H, m), 2.0-2.2 (4H, m), 2.7-2.9 (2H, m), 3.1-3.4 (4H, m), 3.4-3.6 (4H, m), 4.5-4.7 (1 H, br m), 6.95-7.1 (2H, m), 7.15 (1 H, s), 10.4 (1 H, br), 1 1.2 (1 H, s).
Slow eluting isomer (cis isomer E19) was obtained as a white solid (0.015g). MH+ = 428 1H NMR δ (DMSO, 250 MHz): 1.1 (3H, t), 1.35-1.5 (2H , m), 1.6-1.8 (2H, m), 1.8-2.1 (6H, m), 2.6-2.8 (2H, m), 3.1-3.6 (obs, m), 4.5-4.7 (1 H, m), 7.0-7.1 (2H, m), 7.5 (1 H, s), 9.6-9.8 (1 H1 br), 1 1.2 (1 H1 s).
Example 21. c/s/frans-θ-Methyl-i -II -^-trifluoromethoxycyclohexylJ^-piperidinyl]- 1,3-dihydro-2/-/-benzimidazol-2-one hydrochloride (E21)
Figure imgf000143_0001
)
A mixture of 8-[(trifluoromethyl)oxy]-1 ,4-dioxaspiro[4.5]decane (D85, 400mg), THF (5ml), and 5M aqueous hydrochloric acid (5ml) was stirred at room temperature for 2h then partitioned dichloromethane / water. The organic layer was then dried and evaporated to give the crude ketone. This crude ketone was combined with 1-(4-piperidinyl)-6-methyl- 1 ,3-dihydro-2H-benzimidazol-2-one (D145, 110mg, O.δmmol), (polystyrylmethyl)trimethylammonium cyanoborohydride (600mg of 2.04mmol/g, 1.25mmol), dichloromethane (2.5ml), and acetic acid (0.15ml, 2.5mmol) and heated at 11O0C for 10 minutes in a microwave reactor. The cooled mixture was filtered and the filtrate was loaded onto a SCX cartridge which was eluted with methanol followed by methanolic ammonia. The methanolic ammonia fraction was evaporated and the resulting mixture was purified using a Waters Xbridge chromatography column. A gradient using aqueous ammonium bicarbonate (10mmolar) adjusted to pH10 with ammonia and acetonitrile was used as the mobile phase to give the title compound, which was converted to the hydrochloride salt and crystallised from diethyl ether as a mixture of isomers, 42mg. 1 HNMR (HCI salt) δ (d6DMSO): 1.5-2.2 (9H, m), 2.35 (3H, s), 2.8 (2H, m), 3.2-3.6 (11 H, m), 4.4 (0.4H, m), 4.55 (1 H, m), 4.7 (0.6H,br s), 6.8-6.9 (2H, m), 7.5 (1 H, 2s), 10.55 (0.6H, br s), 10.7 (0.4H, br s), 10.8 (1 H, 2s), MH+ 398. Example 22. 1 -(1 -{c/s-4-[(Cyclopropylmethyl)oxy]cyclohexyl}-4-piperidinyl)-6- methyl-1 ,3-dihydro-2/-/-benzimidazol-2-one hydrochloride (E22)
Figure imgf000144_0001
A stirred solution of Λ/2-(1-{c/s-4-[(cyclopropylmethyl)oxy]cyclohexyl}-4-piperidinyl)-4- methyl-1 ,2-benzenediamine (D91 , 600mg) and diisopropylethylamine (0.6ml) in dichloromethane (20ml) at 0°C under argon was treated with solid triphosgene (0.2g, 0.67mmol) in one portion and stirred to room temperature overnight. The mixture was diluted with dichloromethane, washed with dil. NaHCO3 solution, brine and dried with Na2SC>4 and solvent removed and the residue was chromatographed on silica gel eluted with dichloromethane - methanolic ammonia 0-10%. The product was dissolved in methanol, treated with 1 M HCI/diethylether and concentrated under vacuum to give the hydrochloride salt of the title compound as a white solid (38mg). MH+ = 384. 1H NMR δ (DMSO, 400 MHz): 0.2 (2H, m), 0.5 (2H, m), 1.05 (1 H, m), 1.4 (2H , m), 1.7 (2H, m), 1.9 (4H, m), 2.0 (2H, m), 2.33 (3H, s), 2.75 (2H, m), 3.3 (obs, m), 3.55 (3H, m), 4.55, (1 H, m), 6.79 (1 H, d), 6.88 (1 H, d) 7.33 (1 H, s), 9.75 (1 H, m), 10.8 (1 H, s).
Example 23. 1 -(1 -{frans-4-[(Cyclopropylmethyl)oxy]cyclohexyl}-4-piperidinyl)-6- methyl-1 ,3-dihydro-2H-benzimidazol-2-one (E23)
Figure imgf000144_0002
A stirred solution of Λ/2-(1-{frans-4-[(cyclopropylmethyl)oxy]cyclohexyl}-4-piperidinyl)-4- methyl-1 ,2-benzenediamine (D92, 380mg, 1.06mmol) and diisopropylethylamine (0.3ml) in dichloromethane (20ml) at 0°C under argon was treated with solid triphosgene (126mg,
0.42mmol) and stirred to room temperature overnight. The mixture was diluted with dichloromethane, washed with dil. NaHCO3 solution, brine and dried with Na2SO4 and solvent removed. The title compound was obtained as a white solid from ethanol (270mg). This material was dissolved in methanol/dichloromethane, treated with 1 M HCI/diethylether and concentrated under vacuum to give the hydrochloride salt of the title compound as a white solid (270mg). MH+ = 384.
1H NMR δ (DMSO, 400 MHz): 0.15 (2H, m), 0.45 (2H, m), 0.95 (1 H, m), 1.2 (2H , m), 1.55 (2H, m), 1.85 (2H, m), 2.1 (4H, m), 2.32 (3H, s), 2.85 (2H, m), 2.9 (2H, m), 3.22 (obs, m), 3.5 (2H1 m), 4.55, (1 H1 m), 6.80 (1 H1 d), 6.87 (1 H1 d) 7.51 (1 H1 s), 10.6 (1 H1 m), 10.8 (1 H, s).
Example 24. frans-6-Methyl-1 -[1 -(4-cyclopropyloxycyclohexyl)-4-piperidinyl]-1 ,3- dihydro-2H-benzimidazol-2-one hydrochloride (E24)
Figure imgf000145_0001
A solution of frans-5-methyl-Λ/-[1-(4-cyclobutyloxycyclohexyl)-4-piperidinyl]-1 ,2- benzenediamine (D98, 50mg, 0.14mmol) in dichloromethane (3ml) at O0C was treated with triphosgene (20mg, 0.4eq) then diisopropylethylamine (0.04ml, 1.5eq), and then maintained at O0C for 1 h. The mixture was partitioned between dichloromethane and washed with aqueous sodium bicarbonate. Drying, evaporation and crystallisation gave the title compound, isolated as the hydrochloride salt also crystallised from diethyl ether, 31 mg. 1 HNMR (HCI salt) δ (d6DMSO): 1.2 (2H, m), 1.5 (4H, m), 1.9 (3H, m), 2.15 (5H, m), 2.35 (3H, s), 2.8 (2H, m), 3.2 (4H, m), 3.5 (2H, m), 4.0 (1 H, m), 4.6 (1 H, m), 6.8 (2H, m), 7.4 (1 H, s), 10.2 (1 H, br s), 10.8 (1 H, s), MH+ 384.
Examples 25 and 26. cis and frans-1 -(1 -[4-(Propyloxy)cyclohexyl]-4-piperidinyl)-1,3- dihydro-2H-benzimidazol-2-one hydrochloride (cis = E25; trans = E26)
Figure imgf000146_0001
E25 E26
A microwave vessel was charged with 4-(2-oxo-1-benzimidazolinyl)piperidine (0.217g, 1 mmol), 4-propoxycyclohexanone (D19, 0.22g, 1.41 mmol), acetic acid (0.2ml), dichloromethane (15ml) and (polystyrymethyl)trimethylammonium cyanoborohydride (4.3meq/g) (0.75g) and heated at 11 O0C for 20 minutes in a microwave reactor. Further 4- propoxycyclohexanone (0.156g, LOmmol) and (polystyrymethyl)trimethylammonium cyanoborohydride (300mg) added and the mixture heated at 1 1O0C for further 20 minutes in a microwave reactor. The cooled mixture was filtered under vacuum and the filtrate loaded onto a 5g SCX cartridge, which was eluted with methanol followed by methanolic ammonia. The solvent was removed from the methanolic ammonia fraction to give 300mg of clear crystals, which was purified using a Waters Xbridge chromatography column and a gradient of aqueous ammonium bicarbonate (10mmolar; adjusted to pH10 with ammonia) and acetonitrile as the mobile phase to give the cis and trans isomers. Once obtained each isomer was redissolved in dichloromethane (2ml), and 1 molar HCI in diethyl ether (0.5ml) added, then the solvent was removed to afford the title compounds.
Fast eluting isomer (trans isomer; E26) was obtained as a white solid (44mg). MH+ = 358 1HNMR δ d6DMSO, 250MHz): 0.86 (3H, t), 1.1-1.3 (3H, m), 1.4-1.7 (4H, m), 1.8-2.0 (2H, m), 2.0-2.2 (4H, d), 2.7-2.9 (2H, m), 3.1-3.5 (assume 5H, m), 3.5-3.6 (2H, m), 4.5-4.7 (1 H, m), 7.0 (3H, m), 7.4-7.6 (1 H, m), 10.0 (1 H, s), 10.9 (1 H, s).
Slow eluting isomer (cis isomer; E25) was obtained as a white solid (15mg). MH+ = 358 1HNMR δ d6DMSO, 250MHz): 0.9 (3H, t), 1.35-2.1 (assume 13H, br m), 2.6-2.9 (2H, br s), 3.1-3.45 (assume 5H, br m), 3.5 (2H, br s), 4.45-4.7 (1 H, br m), 7.0 (3H, s), 7.5 (1 H, br m), 10.0 (1 H, br s), 10.9 (1 H, s).
Example 27 6-Bromo-1 -{1 -[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3- dihydro-2/-/-benzimidazol-2-one hydrochloride (E27)
Figure imgf000147_0001
A stirred solution of 4-bromo-Λ/2-{1-[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,2- benzenediamine (D100, 574mg, 1.4mmol) and diisopropylethylamine (0.35ml, 2.1 mmol) in dichloromethane (50ml) at O0C was treated with triphosgene (166mg, 0.56mmol) and stirred at 0°C for 30mins. The mixture was washed with water and sat. NaHCO3 solution, then extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum to leave a white solid, which was washed with a mixture of 10% Et2O/petrol ether to afford the free base of the title compound (398mg, 65%). A portion of this (198mg) was dissolved in dichloromethane (10ml), treated with 1 M HCI/Et2O (5ml), stirred for 30mins, then concentrated under vacuum to afford the title compound as a white solid (200mg). MH+ = 437, 438.
1H NMR δ (d6DMSO, 400MHz): 0.87 (3H, t), 1.12-1.30 (2H, m), 1.42-1.63 (4H, m), 1.90 (2H, br d), 2.05-2.20 (4H, m), 2.70-2.85 (2H, m), 3.10-3.30 (4H, m), 4.43-4.54 (2H, m), 4.50-4.65 (1 H, m), 6.95 (1 H, d), 7.16 (1 H, dd), 7.68 (1 H, s), 10.32 (1 H, br m), 1 1.12 (1 H, s).
Example 28 6-Ethyl-1 -{1 -[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro- 2H-benzimidazol-2-one hydrochloride (E28)
Figure imgf000147_0002
A stirred solution of 4-ethyl-Λ/2-{1-[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,2- benzenediamine (D102, 180mg, O.δmmol) and diisopropylethylamine (0.085ml, 0.75mmol) in dichloromethane (15ml) at O0C was treated with triphosgene (59.2mg, 0.12mmol) and stirred at 0°C for 30mins. The mixture was washed with water and sat. NaHCO3 solution, then extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum to leave a white solid. This was dissolved in dichloromethane (5ml), treated with HCI/Et2O (3ml) and concentrated under vacuum to afford the title compound as a white solid (200mg, 95%). MH+ = 386. 1H NMR δ (d6DMSO, 400MHz): 0.86 (3H, t), 1.15-1.30 (5H, t + m), 1.42-1.62 (4H, m), 1.82-1.92 (2H, m), 2.08-2.18 (4H, m), 2.61 (2H, q), 2.76-2.90 (2H, m), 3.14-3.3 (4H, m), 3.38 (2H, t), 3.50 (2H, br d), 4.50-4.62 (1 H, m), 6.83 (1 H, d), 6.89 (1 H, d), 7.43 (1 H, s), 10.35 (1 H, br m), 10.78 (1 H, s).
Example 29 6-Cyclopropyl-1 -{1 -[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3- dihydro-2/-/-benzimidazol-2-one hydrochloride (E29)
Figure imgf000148_0001
(E29)
A stirred solution of 4-cyclopropyl-Λ/2-{1-[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,2- benzenediamine (D104, 70mg, 0.2mmol) and diisopropylethylamine (0.5ml) in dichloromethane (10ml) at O0C was treated with triphosgene (28mg, O.i mmol) and stirred at 0°C for 30mins. The solution was washed with water and sat. NaHCO3 solution, then extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum. The residue was dissolved in dichloromethane (5ml), treated with 1 M HCI/Et2O (1 ml), stirred for 30mins and concentrated under vacuum to afford the title compound (70mg, 81 %). MH+ = 398. 1H NMR δ (d6DMSO, 400MHz): 0.70 -0.78 (2H, m), 0.83-0.91 (5H, t + m), 1.12-1.28 (2H, m), 1.42-1.62 (4H, m), 1.82 (2H, br d), 1.90-2.00 (1 H, m), 2.10 (2H, br d), 2.18 (2H, br d), 2.85-3.00 (2H, m), 3.12-3.30 (4H, m), 3.37 (2H, t), 3.48 (2H, br d), 4.52-4.62 (1 H, m), 6.70 (1 H1 dd), 6.85 (1 H1 d), 7.38 (1 H, s), 10.78 (1 H, s), 1 1.04 (1 H, br m).
Examples 30 and 31. cis and frans-1 -{1-[ 4-(Propyloxy)cyclohexyl]-4-piperidinyl}-6- [(trifluoromethyl)oxy]-1 ,3-dihydro-2H-benzimidazol-2-one (cis = E30; trans = E31)
Figure imgf000149_0001
E30 E31
A microwave vessel was charged with 1-(4-piperidinyl)-6-[(trifluoromethyl)oxy]-1 ,3- dihydro-2/-/-benzimidazol-2-one (D83, 337mg), 4-(propyloxy)cyclohexanone (D19, 190mg) (polystyrylmethyl)trimethylammonium cyanoborohydride (4.3meq/g 0.6g), sodium acetate (100mg), dichloromethane (10ml), acetic acid (200μl) and heated at 1 1O0C for a total of 30 minutes in a microwave reactor. The cooled mixture was filtered and the filtrate was loaded onto a SCX cartridge which was eluted with methanol followed by methanolic ammonia. The methanolic ammonia fraction was evaporated and the resulting mixture was purified using a Waters Xbridge chromatography column. A gradient using aqueous ammonium bicarbonate (10mmolar adjusted to pH10 with ammonia) and acetonitrile was used as the mobile phase to give the cis and trans isomers.
Fast eluting isomer (trans isomer; E31 ) was obtained as a white solid (0.071 g). MH+ =
442.
1H NMR δ (CDCI3, 400 MHz): 0.91 (3H, t), 1.2-1.4 (5H , m), 1.85 (2H, m), 1.94 (2H, m),
2.11 (2H, m), 2.4 (4H, m), 3.07 (2H, m), 3.15 (1 H, m), 3.41 (2H, t), 4.30 (1 H, m), 6.93 (1 H, d), 7.02 (1 H, d) 7.16 (1 H, m), 9.02 (1 H, s).
19F NMR δ (d6DMSO) -58.24ppm
Slow eluting isomer (cis isomer: E30) was obtained as a white solid (0.077g). MH+ = 442. 1H NMR δ (CDCI3, 400 MHz): 0.91 (3H, t), 1.4 (2H , m), 1.55-1.75 (6H, m), 1.82 (2H, m), 2.00 (2H, m), 2.3-2.5 (4H, m), 3.07 (2H, m), 3.15 (1 H, m), 3.33 (2H, t), 3.45 (1 H, m), 4.30 (1 H, m), 6.93 (1 H, d) 7.04 (1 H, d), 7.17 (1 H, m), 9.16 (1 H, s). 19F NMR δ (d6DMSO) -58.23ppm
Example 32. 1 -{1 -[c/s-4-(Ethyloxy)-1 -methylcyclohexyl]-4-piperidinyl}-6-methyl-1 ,3- dihydro-2/-/-benzimidazol-2-one hydrochloride (E32)
Figure imgf000150_0001
A stirred solution of /^-{Hc/s^ethyloxyJ-i-methylcyclohexylH-piperidinylJ^-methyl-i ^- benzenediamine (D106, 150mg, 0.44mmol) in dichloromethane (10ml) at O0C under argon was treated with diisopropylethylamine (0.1 16ml, 0.65mmol) followed by the addition of solid triphosgene (51 mg, 0.174mmol) and maintained at 0°C for 1.5hrs. The mixture was treated with dil. NaHCOs solution (10ml) and extracted with dichloromethane (2x1 OmI). The combined extract was dried (Na2SO4), concentrated under vacuum and the solid residue recrystallised from dichloromethane /EtOAc to afford the free base of the title compound as a white solid (115mg, 71 %). A portion of this material (84mg) was dissolved in a mixture of dichloromethane (2ml) and MeOH (5ml), treated with 1 M HCI/Et2O (0.35ml) and concentrated under vacuum. Trituration with Et2O gave a solid which was filtered off, washed with Et2O and dried to afford the title compound as a white solid (86mg) MH+ = 372. 1H NMR δ (d6DMSO, 400MHz): 1.13 (3H, t), 1.36 (3H, s), 1.48-1.62 (2H, m), 1.67-1.77 (2H, m), 1.80-1.92 (4H, br m), 1.92-2.05 (2H, m), 2.33 (3H, s), 2.82-3.00 (2H, m), 3.13- 3.27 (2H, m), 3.41 (2H, q), 3.50 (1 H, s), 3.67 (2H, br d), 4.55-4.67 (1 H, m), 6.79 (1 H, d), 6.87 (1 H, d), 7.55 (1 H, s), 9.95 (1 H, br m), 10.80 (1 H, s).
Example 33. 1-{1-[frans-4-(ethyloxy)-1 -methylcyclohexyl]-4-piperidinyl}-6-methyl- 1,3-dihydro-2H-benzimidazol-2-one hydrochloride (E33)
Figure imgf000150_0002
A stirred solution of Λ/2-{1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-4-methyl- 1 ,2-benzenediamine (D108, 160mg, 0.464mmol) in dichloromethane (10ml) at O0C under argon was treated with diisopropylethylamine (0.124ml, 0.696mmol) followed by the addition of solid triphosgene (55mg, 0.186mmol) and maintained at O0C for 1.5hrs. The mixture was treated with dil. NaHCOs solution (10ml) and extracted with dichloromethane (2x1 OmI). The combined extract was dried (Na2SO4), concentrated under vacuum and the residue crystallised from 1 :1 Et2O/EtOAc to afford the free base of the title compound as a white solid (120mg, 70%). A portion of this material (85mg) was dissolved in a mixture of dichloromethane (3ml) and MeOH (5ml), treated with 1 M HCI/Et2O (0.35ml) and concentrated under vacuum. Trituration of the residue with Et2O gave a solid which was filtered off, washed with Et2O and dried to afford the title compound as a white solid (86mg) MH+ = 372.
1H NMR δ (d6DMSO, 400MHz): 1.11 (3H, t), 1.22-1.40 (2H, m), 1.34 (3H, s), 1.85 (2H, br d), 1.90-2.05 (6H, m), 2.32 (3H, s), 2.86-3.01 (2H, m), 3.12-3.38 (3H, m), 3.47 (2H, q), 3.65 (2H, br d), 4.54-4.68 (1 H, m), 6.79 (1 H, d), 6.86 (1 H, d), 7.65 (1 H, s), 10.40 (1 H, br m), 10.76 (1 H, s).
Example 34. 6-Methyl-1 -{1 -[c/s-1 -methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3- dihydro-2/-/-benzimidazol-2-one monohydrochloride (E34)
Figure imgf000151_0001
(2-Amino-5-methylphenyl){1 -[c/s-1 -methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}amine (D112, 53 mg, 0.128 mmol) was dissolved in dichloromethane (5 ml) and Hunigh base diisopropylethylamine (1.5 eq., 32 microliters) was added. The mixture was then cooled to 00C and bis(trichloromethyl) carbonate (0.4 eq., 0.05 mmol, 15 mg) was then added at 00C portionwise. The mixture was stirred at the same temperature for 1.5 hours and then it was quenched with brine, basified to pH=10 and the aqueous obtained was extracted with EtOAc (2x). The organics were combined, dried (Na2SO4), filtered and the solvent was evaporated to afford the crude product which was purified by silica chromatography (MeOH-NH3- dichloromethane) to afford the free base of the title compound (40mg, 75%). This was subsequently dissolved in dichloromethane (2 ml) and treated at room temperature with HCI solution (1 M in Et2O, 0.2 ml). The mixture was stirred at room temperature overnight and the solvent was then evaporated to afford the title compound (43 mgs, complete conversion). M+ + H = 385.
1HNMR δ (DMSO, 500 MHz): 0.900 (3H, t), 1.351 (3H, s), 1.524 (4H, m), 1.728 (2H, d), 1.909 (6H, m), 2.341 (3H, s), 2.809 (2H, q), 3.177 (2H, q), 3.329 (2H, t), 3.467 (1 H, s br), 3.667 (2H, d), 3.567 (1 H, m), 6.805 (1 H, m), 6.872 (1 H, d), 7.361 (1 H, s), 9.461 (1 H, t broad), 10.774 (1 H, s).
Example 35. 6-Methyl-1 -{1 -[frans-1 -methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}- 1,3-dihydro-2H-benzimidazol-2-one monohydrochloride (E35)
Figure imgf000152_0001
(2-Amino-5-methylphenyl){1-[frans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}amine (D113, 45 mg, 0.128 mmol) was dissolved in dichloromethane (5 ml) and Hunigh base (1.5 eq., 32 microliters) was added. The mixture was then cooled to 00C and bis(trichloromethyl) carbonate (0.4 eq., 0.05 mmol, 15 mg) was then added at 00C portionwise. The mixture was stirred at the same temperature for 1.5 hours and then it was quenched with brine, basified to pH=10 and the aqueous obtained was extracted with EtOAc (2x). The organics were combined, dried over Na2SO4, filtered and the solvent was evaporated to afford the crude product that was purified by silica chromatography (MeOH-NH3- dichloromethane) to afford the free base of the title compound (50 mg, complete conversion). This was subsequently dissolved in dichloromethane (2 ml) and treated at room temperature with HCI solution (1 M in Et2O, 0.2 ml). The mixture was stirred at room temperature overnight, then the solvent was evaporated to afford the title compound (55 mgs, complete conversion). M+ + H = 385.
1HNMR δ (DMSO, 500 MHz): 0.444 (3H, t), 1.287 (5H, m), 1.485 (2H, m), 1.919 (8H, m), 2.326 (3H, s), 2.903 (2H, q), 3.190 (3H, m), 3.376 (2H under the water peak), 3.640 (2H, d), 4.589 (1 H, m), 6.793 (1 H, d), 6.862 (1 H, d), 7.578 (1 H, s), 10.203 (1 H, t broad), 10.760 (1 H1 S).
Example 36. trans θ-Methyl-i-II-fi-ethyM-propoxycyclohexyl^-piperidinyll-I .S- dihydro-2H-benzimidazol-2-one hydrochloride (E36)
Figure imgf000153_0001
A solution of trans 5-methyl-Λ/-[1-(1-ethyl-4-propoxycyclohexyl)-4-piperidinyl]-1 ,2- benzenediamine (D126, 40mg, O.i mmol) in dichloromethane (3ml) at O0C was treated with triphosgene (12mg, 0.04mmol) then diisopropylethylamine (0.03ml, 0.15mmol), and then maintained at O0C for 30min. The mixture was partitioned between dichloromethane and aqueous sodium bicarbonate. Drying, evaporation and crystallisation from diethyl ether gave the title compound as a free base. This was converted to the hydrochloride salt which was isolated also from diethyl ether, 20mg. 1 HNMR (HCI salt) δ (d6DMSO): 0.85 (3H, t), 1.05 (3H, t), 1.3 (2H, m), 1.5 (2H, m), 1.9 (4H, m), 2.05 (4H, m), 2.35 (3H, s), 2.8 (2H, m), 3.2 (2H, m), 3.6 (2H, m), 4.6 (1 H, m), 6.8 (2H, m), 7.35 (1 H, s), 9.1 (1 H, br s), 10.8 (1 H, s), MH+ 400.
Example 37. 3-{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-2-oxo-2,3-dihydro- IH-benzimidazole-5-carbonitrile hydrochloride (E37)
Figure imgf000153_0002
A stirred solution of 4-amino-3-({1-[frans-4-(ethyloxy)cyclohexyl]-4- piperidinyl}amino)benzonitrile (D128, 120mg, 0.35mmol) in dichloromethane (10ml) at O0C under argon was treated with diisopropylethylamine (0.092ml, 0.52mmol) followed by the addition of solid triphosgene (40mg, 0.14mmol) and maintained for 1 hr. The mixture was treated with 10% Na2COs solution (10ml) and extracted with dichloromethane (2x15ml). The combined extract was dried (Na2SO4), concentrated under vacuum and the residue was purified using a Waters Xbridge chromatography column, eluting with acetonitrile/water/0.1 % formic acid, to afford the free base of the title compound as a white solid (50mg, 39%). This material (85mg) was dissolved in dichloromethane (5ml), treated with 1 M HCI/Et2O (0.2ml) and concentrated under vacuum to afford the title compound as a white solid (54mg) MH+ = 369.
1H NMR δ (d6DMSO, 400MHz): 1.09 (3H, t), 1.10-1.30 (2H, m), 1.47-1.63 (2H, m), 1.92 (2H, br d), 2.05-2.18 (4H, m), 2.71-2.88 (2H, m), 3.18-3.40 (assume 4H, m), 3.4-3.55 (assume 4H, m), 4.57-4.70 (1 H, m), 7.16 (1 H, d), 7.48 (1 H, d), 7.99 (1 H, s), 10.26 (1 H, br m), 1 1.55 (1 H, s).
Example 38. S-fi-Ifrans-^EthyloxyJ-i-methylcyclohexyll^-piperidinyl^-oxo^, 3- dihydro-1H-benzimidazole-5-carbonitrile hydrochloride (E38)
Figure imgf000154_0001
A stirred solution of the 4-amino-3-({1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4- piperidinyl}amino)benzonitrile (D130, 60mg, 0.168mmol) in dichloromethane (10ml) at O0C under argon was treated with diisopropylethylamine (42μl_, 0.252mmol, 32.5mg) followed by solid triphosgene (19mg, 0.067mmol) and maintained at O0C for 1 h. The mixture was treated with aqueous NaHCOs solution (10ml) and extracted with dichloromethane (2 x 15ml). The combined extract was dried (MgSO4) and concentrated under vacuum to afford an orange residue. The residue was then purified using a Waters Xbridge chromatography column at high pH to afford the free base of the title compound (24mg, 38%), which was then treated with 1 M HCI/diethyl ether (0.25ml) and solvents removed by evaporation to yield the title compound (24mg, 34%) as a white solid.
1H NMR (free base) δ (CDCI3, 400 MHz): 0.96 (3H, s), 1.21 (3H, t), 1.43-1.71 (6H, m), 1.84-1.94 (4H, m), 2.23-2.30 (4H, m), 3.18 (2H, d) 3.5 (1 H, m), 3.52 (2H, q), 4.29 (1 H, m), 7.15 (1 H, d), 7.4 (1 H, d), 7.52 (1 H, s), 9.81 (1 H, s).
Example 39. 1 -{1-[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-(methylsulfonyl)- 1,3-dihydro-2H-benzimidazol-2-one hydrochloride (E39)
Figure imgf000155_0001
A stirred solution of 6-bromo-1-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro- 2/-/-benzimidazol-2-one (free base of E14) (130mg, 0.31 mmol) in DMSO (1 ml) at room temperature under argon was treated with sodium methanesulphinate (35mg, 0.34mmol), copper (I) iodide (5.9mg, 0.031 mmol) and L-proline sodium salt (8.5mg, 0.062mmol), then heated at 950C for 18hrs. Further sodium sulphinate (70mg), copper (I) iodide (12mg) and L-proline sodium salt (17mg) were added and the mixture heated at 950C for an additional 58hrs. The mixture was allowed to cool, then treated with 10% Na2CO3 solution (20ml) and EtOAc (25ml), shaken well and filtered through Kieselguhr. The EtOAc layer was isolated, dried (Na2SO4) and concentrated under vacuum. The residue was purified using a Waters Xbridge chromatography column column, eluting with acetonitrile/water/0.1 % formic acid, to afford the free base of the title compound as a white solid (12mg). This was converted to the title compound as a yellow solid. MH+ = 422. 1H NMR (free base) δ (CDCI3, 400MHz): 1.20-1.40 (4H, m), 1.21 (3H, t), 1.80-2.05 (4H, m), 2.10-2.20 (2H, m), 2.34-2.52 (assume 5H, m), 3.02-3.12 (assume 2H, m), 3.10 (3H, s), 3.17-3.27 (1 H, m), 3.52 (2H, q), 4.23-4.37 (1 H, m), 7.24 (1 H, d), 6.89 (1 H, dd), 7.80 (1 H, d), 10.20 (1 H, br s).
Example 40. 6-Methyl-1-{1 -[c/s-4-(2-propyn-1-yloxy)cyclohexyl]-4-piperidinyl}-1 ,3- dihydro-2H-benzimidazol-2-one (E40)
Figure imgf000155_0002
A stirred solution of 4-methyl-Λ/2-{1-[c/s-4-(2-propyn-1-yloxy)cyclohexyl]-4-piperidinyl}-1 ,2- benzenediamine (D136, 200mg, 0.58mmol) and diisopropylethylamine (200μl) in dichloromethane (10ml) at 0°C under argon was treated with solid triphosgene (0.07mg) and stirred for 2 hours. The mixture was diluted with dichloromethane, washed with dil. NaHCC>3 solution, dried with sodium sulfate and the solvent was removed. The title compound was obtained as a white solid (156mg) from ether. MH+ = 368. 1H NMR δ (CDCI3, 400 MHz): 1.45 (2H, m), 1.55-1.8 (obs, m), 1.85 (2H, m), 2.02 (2H , m), 2.4 (obs, m), 3.05 (2H, m), 3.75 (1 H, m), 4.15 (2H, s), 4.34 (1 H, m), 6.83 (1 H, d), 6.92 (1 H1 d), 7.14 (1 H, s), 8.44 (1 H, s).
Example 41. 6-Methyl-1 -{1 -[frans-4-(2-propyn-1 -yloxyjcyclohexylj^-piperidinyl}-! ,3- dihydro-2H-benzimidazol-2-one (E41 )
Figure imgf000156_0001
A stirred solution of 4-methyl-Λ/2-{1-[frans-4-(2-propyn-1-yloxy)cyclohexyl]-4-piperidinyl}- 1 ,2-benzenediamine (D137, 280mg) and diisopropylethylamine (0.3ml) in dichloromethane (20ml) at 0°C under argon was treated with solid triphosgene (97mg) and stirred for 1 hour. The mixture was diluted with dichloromethane, washed with dil. NaHCO3 solution, dried with hydromatrix and the solvent was removed. The residue was chromatographed on silica gel eluted with dichloromethane - methanolic ammonia 0- 10%. The title compound was obtained as a white solid (180mg). MH+ = 368. 1H NMR δ (CDCI3, 400 MHz): 1.2-1.4 (5H, m), 1.8 (2H, m), 1.95 (1 H, m), 2.12 (2H , m), 2.4 (8H, m), 3.06 (2H, m), 3.45 (1 H, m), 4.19 (2H, s), 4.33 (H, m), 6.83 (1 H, d), 6.93 (1 H, d), 7.12 (1 H, s), 8.17 (1 H, s).
Example 42. 1 -{1 -[frans-4-(Ethyloxy)-1 -methylcyclohexyl]-4-piperidinyl}-6-fluoro-1 ,3- dihydro-2H-benzimidazol-2-one hydrochloride (E42)
Figure imgf000156_0002
A stirred solution of (2-amino-5-fluorophenyl){1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4- piperidinyl}amine (D147, 97mg, 0.277mmol) in dichloromethane (7ml) at O0C under argon was treated with diisopropylethylamine (70μl_, 0.415mmol, 53mg) followed by solid triphosgene (33mg, O.H mmol) and stirred at O0C for 1 h. The mixture was treated with dil. NaHCC>3 solution (20ml) and extracted with dichloromethane (2 x 25ml). The combined extract was dried (MgSO4) and concentrated under vacuum to afford the free base of the title compound. This residue was then treated with Et2O (5ml) and the resulting precipitate collected as the free base (31 mg). This was then treated with 1 M HCI/diethyl ether (0.25ml) and stirred for 20 mins, and the solid filtered to yield the title compound (38mg, 33%) as a white solid. MH+ 376.
1H NMR (free base) δ (CDCI3, 400 MHz): 0.94 (3H, s), 1.19-1.26 (4H, m), 1.48-1.52 (2H, m), 1.64-1.70 (2H, m), 1.82-1.92 (4H, m), 2.22-2.36 (4H, m), 3.14-3.16 (2H, d), 3.43-3.53 (4H, m), 4.23-4.28 (1 H, m), 6.74- 6.79 (1 H), 6.95-7.02 (2H, m), 8.63 (1 H, s).
Example 43. θ-Fluoro-i^i -Ifrans-i-methyl^^methyloxyJcyclohexyll^-piperidinyl}- 1,3-dihydro-2H-benzimidazol-2-one hydrochloride (E43)
Figure imgf000157_0001
Diisopropylethylamine (210μl_, 1.23mmol) was added to a solution of (2-amino-5- fluorophenyl){1-[frans-4-(methyloxy)-1-methylcyclohexyl]-4-piperidinyl}amine (D155,
205mg, 0.61 mmol) in CH2CI2 (1OmL) at room temperature under argon. The reaction was cooled to O0C and triphosgene (69mg, 0.23mmol) was added portion-wise. The reaction was stirred for 1 h before the addition of 2M NaOH (1OmL). The mixture was then diluted with CH2CI2 (2OmL) and sat. NaHCO3 (2OmL). The aqueous layer was extracted with CH2CI2 (2x) and the combined organics were dried and concentrated via rotary evaporation to give a purple solid. This residue was treated with EtOAc-Et2O (1 :1 , 4mL) to give a white solid which was azeotroped with toluene (2x5mL) to give the free base of the title compound as a white solid. The free base was treated with MeOH (2mL) and then 1 M HCI in Et2O (0.58mL). The mixture was stirred for 30min and then the solvent was removed by rotary evaporation to give the title compound (103mg, 42%) as a pale yellow solid. MH+ 362. 1H NMR δ (DMSO-de, 400 MHz): 1.22-1.38 (5 H, m), 1.78-2.08 (8 H, m), 2.73-2.88 (2 H, m), 3.07-3.30 (3 H, m), 3.23 (3 H, s), 3.62-3.71 (2 H, m), 4.62 (1 H, m), 6.79-6.88 (1 H, m), 6.94-7.00 (1 H, m), 7.56 (1 H, m), 9.80 (1 H, m), 10.99 (1 H, s).
Example 44. 6-Chloro-1-{1 -[frans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}- 1 ,3-dihydro-2H-benzimidazol-2-one hydrochloride (E44)
Figure imgf000158_0001
Diisopropylethylamine (290μl_, 1.70mmol) was added to a solution of (2-amino-5- chlorophenyl){1-[frans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}amine (D157,
305mg, 0.87mmol) in CH2CI2 (1OmL) at room temperature under argon. The reaction was cooled to O0C and triphosgene (86mg, 0.29mmol) was added portion-wise. The reaction was stirred for 1 h before the addition of 2M NaOH (1OmL). The mixture was then diluted with CH2CI2 (2OmL) and sat. NaHCU3 (2OmL). The aqueous layer was extracted with CH2CI2 (2x) and the combined organics were dried and concentrated via rotary evaporation. The crude residue was treated with CH2CI2 and filtered. The solid was triturated with EtOAc to give a pink solid, which was azeotroped with toluene (6x2mL) and then dissolved in hot MeOH-CH2CI2 and the solvent was removed by rotary evaporation. The solid was dissolved a second time in hot MeOH-CH2CI2 and the solvent was removed by rotary evaporation to give the free base of the title compound as an off-white solid. The free base was suspended in MeOH (2mL) and then 1 M HCI in Et2O (0.45mL). The mixture was stirred for 30min and then the solvent was removed by rotary evaporation to give the title compound (92mg, 26%) as a pale pink solid. M(CI-35)+ 378, M(CI-37)H+ 380. 1H NMR δ (DMSO-de, 400 MHz): 1.24-1.38 (5 H, m), 1.71-1.82 (2 H, m), 1.90-2.08 (6 H, m), 2.67-2.79 (2 H, m), 3.08-3.26 (3 H, m), 3.26 (3 H, s). 3.62-3.31 (2 H, m), 4.49 (1 H, m), 6.98-7.07 (2 H, m), 7.52-7.58 (1 H, m), 9.36 (1 H, m), 1 1.12 (1 H, s)
Example 45. 6-(Ethyloxy)-1 -{1-[frans-1-methyl-4-(methyloxy)cyclohexyl]-4- piperidinyl}-1 ,3-dihydro-2H-benzimidazol-2-one hydrochloride (E45)
Figure imgf000159_0001
Triphoshene (0.082g) was added to a solution of 4-(ethyloxy)-Λ/2-{1-[frans-1-methyl-4- (methyloxy)cyclohexyl]-4-piperidinyl}-1 ,2-benzenediamine (D160, 0.26g,), dichloromethane (20ml) and diisopropylethylamine (1 ml) stirred at ice bath temperature. The solution was stirred to room temperature overnight then washed with saturated sodium bicarbonate solution and the solvent was removed. The residue was chromatographed on silica gel eluted with 0-10% dichloromethane - methanolic ammonia to give the free base of the title compound as a white solid (0.12g). This was dissolved in dichloromethane, treated with hydrogen chloride in ether and the solvent was removed to give the title compound as a white solid from diethyl ether (0.105g). MH+ = 388. 1H NMR δ (d6DMSO, 400 MHz) (free base): 0.93 (3H, s), 1.45-1.7 (-11 H, m), 1.8-2.0 (4H, m), 2.2-2.4 (4H, m), 3.1 (2H, m), 3.3 (obs, m), 4.05 (2H, m), 6.59 (1 H, d of d), 6.86 (1 H, d), 6.92 (1 H1 d), 8.65 (1 H1 s).
Example 46. 6-(Ethyloxy)-1 -{1 -[frans-4-(ethyloxy)-1 -methylcyclohexyl]-4-piperidinyl}- 1,3-dihydro-2H-benzimidazol-2-one hydrochloride (E46)
Figure imgf000159_0002
Triphoshene (0.02g) was added to a solution of 4-(ethyloxy)-Λ/2-{1-[frans-1-methyl-4- (ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,2-benzenediamine (D162, 0.09g), dichloromethane (10ml) and diisopropylethylamine (1 ml) stirred at ice bath temperature. The solution was stirred to room temperature overnight then washed with saturated sodium bicarbonate solution and the solvent was removed. The residue was chromatographed on silica gel eluted with 0-10% dichloromethane - methanolic ammonia to give the free base of the title compound as a oil (0.08g). This was dissolved in dichloromethane, treated with hydrogen chloride in ether and the solvent was removed to give the title compound as a white solid from diethyl ether (0.067g). MH+ = 402. 1H NMR δ (d6DMSO, 250 MHz) (free base): 0.94 (3H, s), 1.22 (3H, t), 1.4-1.7 (obs, m), 1.8-2.0 (4H, m), 2.2-2.4 (4H, m), 3.15 (2H, m), 34-3.6 (3H, m), 4.05 (2H, q), 4.25 (1 H, m), 6.60 (1 H, d of d), 6.80 (1 H, d), 7.00 (1 H, d), 9.8 (1 H, s).
Example 47. 6-Chloro-1 -{1 -[frans-4-(ethyloxy)-1 -methylcyclohexyl]-4-piperidinyl}- 1,3-dihydro-2H-benzimidazol-2-one hydrochloride (E47)
Figure imgf000160_0001
Solid-supported diisopropylbenzylamine (293mg, 1.04mmol) was added to a solution of (2-amino-5-chlorophenyl){1 -[frans-4-(ethyloxy)-1 -methylcyclohexyl]-4-piperidinyl}amine
(D164, 139mg, 0.38mmol) in CH2CI2 (1OmL) at room temperature under argon. The reaction was cooled to O0C and triphosgene (42mg, 0.14mmol) was added portion-wise. The reaction was stirred for 2h before the addition of 2M NaOH (1 OmL). The mixture was then filtered and washed with sat. NaHCU3 solution. The aqueous layer was extracted with CH2CI2 (2x) and the combined organics were dried (Na2SO4) and concentrated via rotary evaporation to give a brown solid. The solid was triturated with EtOAc to give a pale brown solid which was purified by chromatography (amine doped silica, hexane- EtOAc) to give the free base of the title compound as a pale brown solid. The free base was suspended in MeOH (2mL) and then 1 M HCI in Et2O (0.33mL) was added. The mixture was stirred for 30min and then filtered to give the title compound (63mg, 38%) as a pale pink solid. M(CI-35)+ 392, M(CI-37)H+ 394.
1H NMR δ (DMSO-d6, 400 MHz): 1.10 (3 H, t, J l), 1.28-1.40 (5 H, m), 1.76 (2 H, m), 1.90- 2.05 (6 H, m), 2.71 (2 H, m), 3.15 (3 H, m), 3.48 (2 H, q, J 7), 3.66 (2 H, m), 4.58 (1 H, m), 7.02 (2 H, m), 7.55 (1 H, s), 9.34 (1 H, m), 11.11 (1 H, s)

Claims

1. A compound of formula (I) or a salt or solvate thereof:
Figure imgf000161_0001
(i) wherein:
• R6 is selected from hydrogen, cyano, halogen, Ci-6alkyl, Ci-6alkyl substituted with one or more fluorine atoms, C1-6alkylsulfonyl, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms,
Figure imgf000161_0002
and
Figure imgf000161_0003
substituted with one or more fluorine atoms;
• R is selected from C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-6alkyl and C2-6alkynyl, any alkyl or cycloalkyl group being optionally substituted by one or more fluorine atoms; and
• Q is hydrogen or C1-6alkyl.
2. A compound as claimed in claim 1 , wherein R6 is selected from hydrogen, cyano, halogen, C1-6alkyl, C1-6alkyl substituted with one, two or three fluorine atoms, C3- 6cycloalkyl, d-βalkylsulfonyl, d-βalkoxy, and
Figure imgf000161_0004
substituted with one, two or three fluorine atoms.
3. A compound as claimed in claim 2, wherein R6 is selected from hydrogen, cyano, fluoro, bromo, methyl, ethyl, methoxy, trifluoromethoxy, methylsulfonyl, trifluoromethyl and cyclopropyl.
4. A compound as claimed in any of claims 1-3, wherein R is selected from Ci-6alkyl, C3-6cycl oa I kyl, C3-6cycloalkylC1-6alkyl and C2-4alkynyl, any alkyl or cycloalkyl group being optionally substituted by one, two or three fluorine atoms.
5. A compound as claimed in claim 4, wherein R is selected from methyl, ethyl, propyl, isopropyl, CF3, cyclopropylmethyl, propynyl and cyclobutyl.
6. A compound as claimed in any of claims 1-5, wherein Q is selected from hydrogen and Ci-3alkyl.
7. A compound as claimed in claim 1 , which is:
1. 6-Methyl-1-[1-(c/s-4-methoxycyclohexyl)-4-piperidinyl]-1 ,3-dihydro-2H- benzimidazol-2-one
2. 6-Methyl-1-[1-(frans-4-methoxycyclohexyl)-4-piperidinyl]-1 ,3-dihydro-2/-/- benzimidazol-2-one 3. 1-{1-[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-methyl-1 ,3-dihydro-2H- benzimidazol-2-one
4. 1 -{1 -[c/s-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-methyl-1 ,3-dihydro-2H- benzimidazol-2-one
5. 6-Methyl-1 -{1 -[c/s-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
6. 6-Methyl-1 -{1 -[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
7. 6-Methyl-1 -(1 -{frans-4-[(1 -methylethyl)oxy]cyclohexyl}-4-piperidinyl)-1 ,3-dihydro- 2/-/-benzimidazol-2-one
8. 6-Methyl-1-{1-[c/s-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one
9. 6-Methyl-1 -{1 -[frans-1 -methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro- 2/-/-benzimidazol-2-one
10. 6-Methyl-1-(1-{c/s-4-[(1-methylethyl)oxy]cyclohexyl}-4-piperidinyl)-1 ,3-dihydro-2/-/- benzimidazol-2-one
11. cis -(1 -[4-(Ethoxyl)cyclohexyl]-4-piperidinyl)-1 ,3-dihydro-2H-benzimidazol-2-one
12. trans 1-(1-[4-(Ethoxyl)cyclohexyl]-4-piperidinyl)-1 ,3-dihydro-2H-benzimidazol-2- one
13. 1 -{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-fluoro-1 ,3-dihydro-2H- benzimidazol-2-one
14. 6-Bromo-1-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one
15. 1 -{1 -[c/s-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-(trifluoromethyl)-1 ,3-dihydro-2H- benzimidazol-2-one
16. 6-Ethyl-1-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one
17. 6-Cyclopropyl-1-{1-[frans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
18. 1 -{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-(methyloxy)-1 ,3-dihydro-2H- benzimidazol-2-one
19. ^-^{^^-(EthoxyJcyclohexyO^-piperidinylJ-δ-^trifluoromethylJoxyl-I .S-dihydro- 2H-benzimidazol-2-one
20. frans-1-{1-[4-(Ethoxy)cyclohexyl]-4-piperidinyl}-6-[(trifluoromethyl)oxy]-1 ,3-dihydro- 2H-benzimidazol-2-one
21. 6-Methyl-1 -[1 -(4-trifluoromethoxycyclohexyl)-4-piperidinyl]-1 ,3-dihydro-2H- benzimidazol-2-one
22. 1 -(1 -{c/s-4-[(Cyclopropylmethyl)oxy]cyclohexyl}-4-piperidinyl)-6-methyl-1 ,3- dihydro-2/-/-benzimidazol-2-one
23. 1 -(1 -{frans-4-[(Cyclopropylmethyl)oxy]cyclohexyl}-4-piperidinyl)-6-methyl-1 ,3- dihydro-2/-/-benzimidazol-2-one
24. frans-6-Methyl-1-[1-(4-cyclopropyloxycyclohexyl)-4-piperidinyl]-1 ,3-dihydro-2H- benzimidazol-2-one
25. cis -1 -(1 -[4-(Propyloxy)cyclohexyl]-4-piperidinyl)-1 ,3-dihydro-2H-benzimidazol-2- one
26. frans-1-(1-[4-(Propyloxy)cyclohexyl]-4-piperidinyl)-1 ,3-dihydro-2H-benzimidazol-2- one
27. 6-Bromo-1 -{1 -[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
28. 6-Ethyl-1-{1-[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one
29. 6-Cyclopropyl-1-{1-[frans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one
30. ^-^{^^-(PropyloxyJcyclohexyO^-piperidinylJ-δ-^trifluoromethylJoxyl-I .S- dihydro-2/-/-benzimidazol-2-one
31. frans-1-{1-[4-(Propyloxy)cyclohexyl]-4-piperidinyl}-6-[(trifluoromethyl)oxy]-1 ,3- dihydro-2/-/-benzimidazol-2-one
32. ^{^[^^-(EthyloxyJ-i-methylcyclohexyO^-piperidinylJ-δ-methyl-I .S-dihydro^/-/- benzimidazol-2-one
33. 1-{1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-6-methyl-1 ,3-dihydro- 2/-/-benzimidazol-2-one
34. 6-Methyl-1 -{1 -[c/s-1 -methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
35. 6-Methyl-1 -{1 -[frans-1 -methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro- 2/-/-benzimidazol-2-one
36. frans-6-Methyl-1-[1-(1-ethyl-4-propoxycyclohexyl)-4-piperidinyl]-1 ,3-dihydro-2/-/- benzimidazol-2-one
37. 3-{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-2-oxo-2,3-dihydro-1 H- benzimidazole-5-carbonitrile
38. 3-{1-[frans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-2-oxo-2, 3-dihydro-1 H- benzimidazole-5-carbonitrile 39. 1 -{1 -[frans-4-(Ethyloxy)cyclohexyl]-4-piperidinyl}-6-(methylsulfonyl)-1 ,3-dihydro-
2/-/-benzimidazol-2-one
40. 6-Methyl-1 -{1 -[c/s-4-(2-propyn-1 -yloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2H- benzimidazol-2-one
41. 6-Methyl-1-{1-[frans-4-(2-propyn-1-yloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro-2/-/- benzimidazol-2-one
42. 1-{1-[frans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-6-fluoro-1 ,3-dihydro-2/-/- benzimidazol-2-one
43. 6-Fluoro-1 -{1 -[frans-1 -methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro- 2/-/-benzimidazol-2-one
44. 6-Chloro-1 -{1 -[frans-1 -methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3-dihydro- 2/-/-benzimidazol-2-one
45. 6-(Ethyloxy)-1-{1-[frans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}-1 ,3- dihydro-2/-/-benzimidazol-2-one
46. 6-(Ethyloxy)-1-{1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-1 ,3-dihydro- 2/-/-benzimidazol-2-one
47. 6-Chloro-1-{1-[frans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-1 ,3-dihydro- 2/-/-benzimidazol-2-one or a salt or solvate thereof.
8. A pharmaceutical composition comprising a compound claimed in any one of claims 1 to 7 and a pharmaceutically acceptable carrier.
9. A compound as claimed in any one of claim 1 to 7 for use in therapy.
10. A compound as claimed in any one of claims 1 to 7 for use in the treatment of a condition which requires agonism of a muscarinic M1 receptor.
1 1 A compound as claimed in any one of claims 1 to 7 for use in the treatment of a psychotic disorder or cognitive impairment.
12. Use of a compound as claimed in any one of claims 1 to 7 in the manufacture of a medicament for the treatment of a condition which requires agonism of a muscarinic M1 receptor.
13. Use of a compound as claimed in any one of claims 1 to 7 in the manufacture of a medicament for the treatment of a psychotic disorder or cognitive impairment.
14. A method of treating a condition which requires agonism of a muscarinic M1 receptor, which comprises administering to a mammal in need thereof an effective amount of a compound as claimed in any one of claims 1 to 7.
15. A method of treating a psychotic disorder or cognitive impairment, which comprises administering to a mammal in need thereof an effective amount of a compound as claimed in any of claims 1 to 7.
16. A process for preparing a compound as claimed in claim 1 , which process is selected from:
(i) process (A1 ), which comprises coupling a compound of formula (II)
Figure imgf000165_0001
wherein R6 is a group R6 as defined in claim 1 , or a group convertible to R6, with a compound of formula (III):
Figure imgf000165_0002
wherein R' is a group R as defined in claim 1 , or a group convertible to R, under conditions suitable for reductive alkylation;
(ii) process (A2), which comprises reacting a compound of formula (II) as defined for process (A1 ), with a compound of formula (III) as defined for process (A1 ), in the presence of a source of cyanide to form the cyano intermediate (XXXX):
Figure imgf000165_0003
(XXXX)
wherein R6 is a group R6 as defined in claim 1 , or a group convertible to R6, R' is a group R as defined in claim 1 , or a group convertible to R, Q is Ci-6alkyl, and X is bromo, iodo or chloro, under conditions suitable for Grignard reactions;
(iii) process (B), which comprises reacting a compound of formula (IV):
Figure imgf000166_0001
wherein R6 is a group R6 as defined in claim 1 , or a group convertible to R6, R' is a group R as defined in claim 1 , or a group convertible to R, Q is as defined in claim 1 , with a compound of formula (V):
Figure imgf000166_0002
wherein X and Y both represent leaving groups optionally in an inert solvent, optionally in the presence of a base, and optionally with heating;
(iv) process (C), which comprises treatment of a compound of formula (Vl):
Figure imgf000166_0003
wherein R6 is a group R6 as defined in claim 1 , or a group convertible to R6, R' is a group R as defined in claim 1 , or a group convertible to R, Q is as defined in claim 1 , and Z is a leaving group such as bromo, iodo, chloro or triflate, with a palladium or copper catalyst (VII) to effect an intramolecular cyclisation;
(v) process (D), which comprises coupling a compound of formula (VIII):
Figure imgf000166_0004
wherein R6 is a group R6 as defined in claim 1 , or a group convertible to R6, with a compound of formula (IX):
Figure imgf000167_0001
wherein R' is a group R as defined in claim 1 , or a group convertible to R, Q is as defined in claim 1 , and Ra is Ci-5alkyl, by heating in an inert solvent, for example xylene, followed by reduction of the piperidine double bond;
(vi) process (E), which comprises reaction of a compound of formula (X):
Figure imgf000167_0002
wherein R6 is a group R6 as defined in claim 1 , or a group convertible to R6, R' is a group R as defined in claim 1 , or a group convertible to R, Q is as defined in claim 1 , with a reagent/combination of reagents to effect a Curtius rearrangement of compound (X), followed by intramolecular cyclisation; and
(vii) process (F), which comprises coupling a compound of formula (Xl):
Figure imgf000167_0003
wherein R6 is a group R6 as defined in claim 1 , or a group convertible to R6, with a compound of formula (XII):
Figure imgf000167_0004
wherein R' is a group R as defined in claim 1 , or a group convertible to R, Q is as defined in claim 1 , and Z is hydroxy or a leaving group under alkylation or Mitsunobu reaction conditions; and optionally thereafter, for any of the above processes: - removing any protecting groups; and/or
- converting a compound of formula (I) or a salt or solvate thereof to another compound of formula (I) or a salt or solvate thereof.
17. A compound of formula (II) or a salt or solvate thereof, or formula (IV) or a salt or solvate thereof or formula (Vl) or a salt or solvate thereof, or formula (X) or a salt or solvate thereof:
Figure imgf000168_0001
wherein in each of formula (II), formula (IV), formula (Vl), and formula (X), R6 is a group R6 as defined in claim 1 , or a group convertible to R6, and Z is a leaving group.
PCT/EP2007/052638 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine WO2007107565A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU2007228716A AU2007228716A1 (en) 2006-03-22 2007-03-20 Benzimidazoles which have activity at M1 receptor and their uses in medicine
US12/293,625 US20100280071A1 (en) 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine
JP2009500852A JP5256187B2 (en) 2006-03-22 2007-03-20 Benzimidazoles having activity at the M1 receptor and their use in medicine
CN2007800188235A CN101448495B (en) 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine
BRPI0708999-6A BRPI0708999A2 (en) 2006-03-22 2007-03-20 benzimidazoles that have m1 receptor activity and their uses in medicine
EP07727115.3A EP2004182B1 (en) 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine
EA200870360A EA200870360A1 (en) 2006-03-22 2007-03-20 BENZIMIDAZOLY, possessing activity in relation to M1 receptors, and their use in medicine
MX2008012160A MX2008012160A (en) 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine.
CA002646896A CA2646896A1 (en) 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine
IL194206A IL194206A0 (en) 2006-03-22 2008-09-18 Benzimidazoles which have activity at m1 receptor and their uses in medicine
NO20084048A NO20084048L (en) 2006-03-22 2008-09-23 Benzimidazoles that have activity at the M1 receptor and their applications in medicine
US13/282,610 US20120041028A1 (en) 2006-03-22 2011-10-27 Benzimidazoles which have activity at m1 receptor and their uses in medicine
US13/584,956 US20120316202A1 (en) 2006-03-22 2012-08-14 Compounds which have activity at M1 receptor and their uses in medicine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0605786.3A GB0605786D0 (en) 2006-03-22 2006-03-22 Compounds
GB0605786.3 2006-03-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/293,625 A-371-Of-International US20100280071A1 (en) 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine
US13/282,610 Continuation US20120041028A1 (en) 2006-03-22 2011-10-27 Benzimidazoles which have activity at m1 receptor and their uses in medicine

Publications (1)

Publication Number Publication Date
WO2007107565A1 true WO2007107565A1 (en) 2007-09-27

Family

ID=36383995

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/052638 WO2007107565A1 (en) 2006-03-22 2007-03-20 Benzimidazoles which have activity at m1 receptor and their uses in medicine

Country Status (22)

Country Link
US (3) US20100280071A1 (en)
EP (1) EP2004182B1 (en)
JP (1) JP5256187B2 (en)
KR (1) KR20090015027A (en)
CN (2) CN101448495B (en)
AR (1) AR059977A1 (en)
AU (1) AU2007228716A1 (en)
BR (1) BRPI0708999A2 (en)
CA (1) CA2646896A1 (en)
CR (1) CR10314A (en)
EA (1) EA200870360A1 (en)
GB (1) GB0605786D0 (en)
IL (1) IL194206A0 (en)
MA (1) MA30324B1 (en)
MX (1) MX2008012160A (en)
NO (1) NO20084048L (en)
NZ (1) NZ595738A (en)
PE (1) PE20080007A1 (en)
SG (1) SG170752A1 (en)
TW (1) TW200813004A (en)
WO (1) WO2007107565A1 (en)
ZA (1) ZA200807616B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119714A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2008119712A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Benzoimidazole derivatives which have activity at m1 receptor and their uses in medicine
WO2008119711A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Substituted benzimidazolone compounds which have activity at m1 receptor and their uses in medicine
WO2008119721A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2008119717A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2009037294A1 (en) * 2007-09-20 2009-03-26 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2009037296A1 (en) * 2007-09-20 2009-03-26 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2009124883A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel 1,3-dihydro-benzoimidazol-2-ones as m1 agonists
WO2010037723A1 (en) * 2008-10-01 2010-04-08 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
JP5990980B2 (en) * 2012-04-02 2016-09-14 大日本印刷株式会社 Method for producing olanzapine intermediate
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3009176A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
CN107129439A (en) * 2016-02-26 2017-09-05 中国科学院大连化学物理研究所 A kind of compound, muscarine m receptor antagonist, composition and application
JP2019510785A (en) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド How to treat cancer
CN116554168A (en) 2016-06-21 2023-08-08 X4 制药有限公司 CXCR4 inhibitors and uses thereof
CN109640988A (en) * 2016-06-21 2019-04-16 X4 制药有限公司 CXCR4 inhibitor and application thereof
JP6994767B2 (en) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド CXCR4 inhibitor and its use
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN113637001A (en) * 2021-08-09 2021-11-12 安康市农业科学研究院 Synthesis method of droperidol intermediate

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491212A1 (en) * 1990-12-17 1992-06-24 Leifeld GmbH &amp; Co. Roll-forming machine with at least one holder for a forming roller
WO1996013262A1 (en) * 1994-10-27 1996-05-09 Merck & Co., Inc. Muscarine antagonists
WO1997016186A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine agonists
WO2003105781A2 (en) * 2002-06-17 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2004054974A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
WO2007036711A1 (en) * 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10330377A (en) * 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd Piperidine derivative
PT1049689E (en) * 1998-01-19 2002-09-30 Pfizer COMPOUNDS OF 4- (2-CETO-1-BENZIMIDAZOLINYL) PIPERIDINE AS AGONISTS OF THE ORL1 RECEPTOR
JP2003524634A (en) * 1999-12-06 2003-08-19 ユーロ−セルティーク，エス．エイ． Benzimidazole compounds having nociceptin receptor affinity
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491212A1 (en) * 1990-12-17 1992-06-24 Leifeld GmbH &amp; Co. Roll-forming machine with at least one holder for a forming roller
WO1996013262A1 (en) * 1994-10-27 1996-05-09 Merck & Co., Inc. Muscarine antagonists
WO1997016186A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine agonists
WO2003105781A2 (en) * 2002-06-17 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2004054974A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
WO2007036711A1 (en) * 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119714A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2008119712A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Benzoimidazole derivatives which have activity at m1 receptor and their uses in medicine
WO2008119711A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Substituted benzimidazolone compounds which have activity at m1 receptor and their uses in medicine
WO2008119721A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2008119717A1 (en) * 2007-03-29 2008-10-09 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2009037296A1 (en) * 2007-09-20 2009-03-26 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2009037294A1 (en) * 2007-09-20 2009-03-26 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
US8278328B2 (en) 2007-09-20 2012-10-02 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
US8299257B2 (en) 2007-09-20 2012-10-30 Glaxo Group Limited Compounds which have activity at M1receptor and their uses in medicine
WO2009124883A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel 1,3-dihydro-benzoimidazol-2-ones as m1 agonists
WO2010037723A1 (en) * 2008-10-01 2010-04-08 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
US20110178131A1 (en) * 2008-10-01 2011-07-21 Dale James Johnson Compounds Which Have Activity At M1 Receptor And Their Uses In Medicine
JP2012504574A (en) * 2008-10-01 2012-02-23 グラクソ グループ リミテッド Compounds having activity at the M1 receptor and their use in medicine

Also Published As

Publication number Publication date
JP2009530347A (en) 2009-08-27
EP2004182A1 (en) 2008-12-24
AR059977A1 (en) 2008-05-14
BRPI0708999A2 (en) 2011-06-21
GB0605786D0 (en) 2006-05-03
AU2007228716A1 (en) 2007-09-27
CN103058990A (en) 2013-04-24
IL194206A0 (en) 2009-08-03
KR20090015027A (en) 2009-02-11
ZA200807616B (en) 2010-07-28
NZ595738A (en) 2012-11-30
CR10314A (en) 2008-12-01
US20120041028A1 (en) 2012-02-16
CN101448495B (en) 2013-05-08
CA2646896A1 (en) 2007-09-27
NO20084048L (en) 2008-10-20
CN101448495A (en) 2009-06-03
SG170752A1 (en) 2011-05-30
JP5256187B2 (en) 2013-08-07
MA30324B1 (en) 2009-04-01
PE20080007A1 (en) 2008-03-16
EA200870360A1 (en) 2009-02-27
MX2008012160A (en) 2008-10-03
EP2004182B1 (en) 2013-05-08
TW200813004A (en) 2008-03-16
US20120316202A1 (en) 2012-12-13
US20100280071A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
EP2004182B1 (en) Benzimidazoles which have activity at m1 receptor and their uses in medicine
EP1943230B1 (en) Compounds which have activity at m1 receptor and their uses in medicine
EP1960389B1 (en) Compounds which have activity at m1 receptor and their uses in medicine
EP1996188B1 (en) Benzimidazoles which have activity at m1 receptor and their uses in medicine
EP1937670A1 (en) Benzimidazolones which have activity at m1 receptor
EP1996189B1 (en) Benzimidazoles which have activity at m1 receptor and their uses in medicine
WO2009037296A1 (en) Compounds which have activity at m1 receptor and their uses in medicine
WO2008119720A1 (en) 1-(1-cyclobutyl-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
WO2008119713A1 (en) 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
WO2008119716A1 (en) 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
WO2008119718A1 (en) Compounds which have activity at m1 receptor and their uses in medicine
WO2008119721A1 (en) Compounds which have activity at m1 receptor and their uses in medicine
WO2008119717A1 (en) Compounds which have activity at m1 receptor and their uses in medicine
WO2008119712A1 (en) Benzoimidazole derivatives which have activity at m1 receptor and their uses in medicine
WO2008119711A1 (en) Substituted benzimidazolone compounds which have activity at m1 receptor and their uses in medicine
WO2008119719A1 (en) 1- (1-cyclohexyl-4-piperidinyl) -1, 3-dihydro-2h-benzimidazol-2-one derivatives which have activity on the m1 receptor and their use in medicine
EP2194982A1 (en) Compounds which have activity at m1 receptor and their uses in medicine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780018823.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07727115

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007228716

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12008502009

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 571241

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 7784/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 194206

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2646896

Country of ref document: CA

Ref document number: 12293625

Country of ref document: US

Ref document number: 08099632

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2008091561

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/012160

Country of ref document: MX

Ref document number: 2009500852

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: CR2008-010314

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2007228716

Country of ref document: AU

Date of ref document: 20070320

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007727115

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: DZP2008000606

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 1020087025705

Country of ref document: KR

Ref document number: 200870360

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0708999

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080919